Aryl or heteroaryl substituted glutarimide derivative and use thereof

Abstract

The present disclosure relates to a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof and a use of the compound. The present disclosure further relates to a pharmaceutical composition containing, as an active ingredient, the compound of formula (I) or the salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof and a use of the composition. A series of compounds designed and synthesized in the present disclosure can effectively prevent or treat celeblon protein-related diseases or disorders, comprising tumors or cancers.

Description

Aryl or heteroaryl substituted glutarimide derivatives and their applications Technical Field

[0001] The present disclosure relates to a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, polymorph thereof and uses thereof, in particular, uses thereof for preventing or treating diseases or conditions associated with cereblon protein including tumors or cancer. Background Art

[0002] Phthalimide immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide, are highly effective in treating multiple myeloma and autoimmune diseases. However, it wasn't until 2010 that their direct binding protein, the E3 ubiquitin ligase cereblon (CRBN), was identified. Subsequently, it was demonstrated that upon binding to CRBN, these drugs act as molecular glues to recruit substrate proteins (such as the transcription factors IKZF1 / 3), enabling protein-protein interactions between CRBN and substrate proteins and subsequently ubiquitination of these substrate proteins. Polyubiquitinated substrate proteins are then recognized and degraded by the proteasome, resulting in pharmacological effects including anti-tumor and immunomodulatory effects. Molecular glue protein degraders directly target and degrade target proteins, offering potential advantages such as targeting undruggable targets. Furthermore, molecular glue degraders typically have a small molecular weight and good drugability, making their development highly valued. Based on the CRBN E3 ubiquitin ligase and molecular glue degradation mechanism, a series of compounds have been developed, including the marketed pomalidomide, as well as CC-122, CC-220, CC-90009, CC-99282, and CC-92480 from Bristol-Myers Squibb (BMS), DKY709 from Novartis, and CFT7455 from C4 Therapeutics, all currently undergoing clinical trials. The degradation substrates of these molecular glues have also expanded from the initially discovered transcription factors IKZF1 / 3 to casein kinase 1α (CK1α), zinc finger protein 91 (ZFP91), and translation factor GSPT1. The degradation of these protein substrates enables the molecular glues to exert pharmacological activities such as immunomodulation, anti-inflammatory, and anti-tumor effects. The structural novelty of the molecular glue candidates discovered so far is very limited, and the design of diversified scaffolds and the development of more molecular glues have become research hotspots in this field.

[0003] Therefore, this patent application designs and develops a series of novel molecular glue degraders based on CRBN E3 ubiquitin ligase, which can be used to treat and / or prevent diseases or conditions mediated by or related to degraded proteins.

[0004] Summary of the Invention

[0005] In view of the above, the object of the present disclosure is to provide novel molecular glue-type protein degradation drugs based on an aromatic or heteroaromatic substituted glutarimide skeleton, their uses, and methods of using them.

[0006] To achieve the above-mentioned and other related purposes, in one aspect, the present disclosure provides a compound of formula (I) or its salt, stereoisomer (including enantiomer, diastereomer), solvate, or polymorph:

[0007] in

[0008] R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy;

[0009] Y represents CH or N;

[0010] X represents N(R1), wherein R1 represents hydrogen or C 1-4 Alkyl, or X represents a bond;

[0011] Ring A represents a 6- to 20-membered monocyclic, bicyclic or tricyclic divalent group having the following structural formula:

[0012] wherein Ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring, i.e., the ring atom W represents C or N, the dotted line represents the presence or absence of Ring C and / or Ring D, when Ring C is present, Ring C represents an optionally substituted heteroaromatic ring or an optionally substituted heterocyclic ring, and when Ring D is present, Ring D represents an optionally substituted aromatic ring, provided that: when both Ring C and Ring D are present or absent, Ring B represents an optionally substituted benzene ring; and when Ring A represents a bicyclic divalent group, Ring D is absent, Ring C represents an optionally substituted heteroaromatic ring or an optionally substituted heterocyclic ring, and W represents C or N; and the symbol * indicates the point of attachment of Ring A to X, and the symbol ** indicates the point of attachment of Ring A to R x connection points;

[0013] R x Indicates C(O)NH, NHC(O), -N(R2)-C 0-2 Alkylene-, -C 0-2Alkylene-N(R2)-, O, S, S(O), S(O)2, alkynylene, alkenylene, -C(R3R4)-, optionally substituted piperazinylene or optionally substituted piperidinylene, wherein each R2 independently represents hydrogen or C 1-4 Alkyl, each C 0-2 The alkylene group is optionally substituted, and R3 and R4 each independently represent hydrogen, halogen or hydroxy;

[0014] LIN means

[0015] where R L1 Connect R x , R L2 Connect R w ;

[0016] R L2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a5 ), where R a5 Indicates H or C 1-3 alkyl;

[0017] Each ring A 1 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 independently optionally be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20;

[0018] Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 independently optionally by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20;

[0019] Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20;

[0020] R L1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1- 20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: La 、R Lb and any combination thereof, each group R La Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R La When substituted, each group R La Not directly connected to each other; each group R Lbare each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof;

[0021] R w express:

[0022] NR w1 R w2 、C(O)NR w3 R w4 、N(R w5 )C(O)R w6 、NHC(O)NR w7 R w8 , OR w9 SR w10 、S(O)2NR w11 R w12 、N(R w13 )S(O)2R w14 、S(O)2R w15 or an optionally substituted linear or branched alkyl group, wherein R w1 、R w2 、R w3 、R w7 、R w9 、R w10 and R w11 Each independently represents H, an optionally substituted linear or branched alkyl group, -(CH2) m -cycloalkyl, -(CH2) m -aryl, -(CH2) m -heterocyclyl or -(CH2) m -heteroaryl, wherein R w4 、R w6 、R w8 、R w12 、R w14 and R w15 Each independently represents an optionally substituted straight or branched alkyl group, -(CH2) m -cycloalkyl, -(CH2) m -aryl, -(CH2) m -heterocyclyl or -(CH2) m -heteroaryl, and wherein R w5 and R w13 Each independently represents H or an optionally substituted linear or branched alkyl group, or wherein R w3 and R w4 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, or wherein R w11 and R w12Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, wherein each -(CH2) m -, cycloalkyl, aryl, heterocyclyl or heteroaryl are each independently optionally substituted, and m represents an integer of 0, 1 or 2; or

[0023] Ring A 4 represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, (R d1 ) n1 Represents Ring A 4 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20;

[0024] R e represents C(O)NH or NHC(O), or R e represents a key; and

[0025] Ring A 5 represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, m1 represents an integer of 0 or 1, (R d2 ) n2 Represents Ring A 5 Optionally n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer of 0-20.

[0026] In another aspect, the present disclosure provides a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier.

[0027] In another aspect, the present disclosure further provides a drug box or a test kit comprising: a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.

[0028] In another aspect, the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, prodrug or polymorph thereof, for use as a medicament.

[0029] In another aspect, the present disclosure provides the compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition described herein, for use in treating or preventing a disease or condition selected from the following: tumor or cancer, infectious disease, inflammatory disease, autoimmune disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

[0030] On the other hand, the present disclosure also provides the use of the compound of formula (I) or its pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph, or the pharmaceutical composition of the present disclosure, which is used to prepare a medicament for treating or preventing a disease or condition selected from the following: tumor or cancer, infectious disease, inflammatory disease, autoimmune disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

[0031] In another aspect, the present disclosure also provides a method for treating or preventing a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph thereof, or the pharmaceutical composition, wherein the disease or condition is selected from the group consisting of: tumor or cancer, infectious disease, inflammatory disease, autoimmune disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] FIG1 shows the Western Blot experimental results of the compounds of the present invention on the degradation of target substrate proteins in cells.

[0033] Detailed Description of the Invention

[0034] The following detailed description is provided as an exemplary embodiment to help those skilled in the art understand and implement the present disclosure. However, it should be understood that such description is not intended to limit the scope of the present disclosure. Without departing from the spirit and scope of the present disclosure, the specific embodiments described in the present disclosure may be subjected to various modifications and changes, and these changes and improvements all fall within the scope of the present disclosure as claimed.

[0035] I. Compounds

[0036] Compound of formula (I)

[0037] The present disclosure provides a compound of formula (I) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog, prodrug or polymorph:

[0038] Among them, ring A, R a1 、R a2 、R a3 、R a4 , Y, X, R x , LIN and R w As defined above for the compounds of formula (I) and its embodiments.

[0039] The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs provided herein have binding affinity for CRBN, help recruit substrate proteins, and can act as molecular glues to bind to CRBN E3 ubiquitin ligases. The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs disclosed herein can also degrade substrate proteins (e.g., IKZF1 / 2 / 3 / 4 proteins, WEE1 proteins, CK1α proteins, GSPT1 proteins, ZFP91 proteins, etc.). The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs disclosed herein have anti-tumor activity or excellent pharmacokinetic properties and can be used as therapeutic drugs for cancer patients.

[0040] In some embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 The same or different and each independently represents H, deuterium (ie, D), C 1-6 Alkyl (e.g. C 1-3 Alkyl, such as methyl, ethyl, or propyl), halo C 1-6 Alkyl (e.g. halo-C 1-4 alkyl, such as trifluoromethyl), deuterated C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy), deuterated C 1-6 Alkoxy or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 In some sub-embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 Each independently represents H.

[0041] In some embodiments of the present disclosure, Y represents CH or N.

[0042] In some embodiments of the present disclosure, X represents N(R1), wherein R1 represents hydrogen or C 1-4 Alkyl, or X represents a bond.

[0043] In some embodiments of the present disclosure, X represents NH or N(CH 3 ).

[0044] In some embodiments of the present disclosure, X represents a bond.

[0045] In some embodiments of the present disclosure, Y represents CH, and X represents N(R1), wherein R1 represents hydrogen or C 1-4 alkyl.

[0046] In some embodiments of the present disclosure, Y represents CH, and X represents a bond.

[0047] In some embodiments of the present disclosure, Y represents N, and X represents a bond.

[0048] In some embodiments of the present disclosure, Ring A represents a 6- to 20-membered monocyclic, bicyclic, or tricyclic divalent group having the following structural formula:

[0049] wherein ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring, i.e., ring atom W represents C or N, and the dotted line represents the presence or absence of ring C and / or ring D, and when ring C is present, ring C represents an optionally substituted heteroaromatic ring (e.g., a 4- to 14-membered heteroaromatic ring or a 4- to 16-membered heteroaromatic ring) or an optionally substituted heterocyclic ring (e.g., a 4- to 14-membered heterocyclic ring or a 4- to 16-membered heterocyclic ring), and when ring D is present, ring D represents an optionally substituted aromatic ring (e.g., C 5-10 aromatic ring), provided that: when both ring C and ring D are present or absent, ring B represents an optionally substituted benzene ring; and when ring A represents a bicyclic divalent group, ring D is absent, ring C represents an optionally substituted heteroaromatic ring or an optionally substituted heterocyclic ring, and W represents C or N; and

[0050] The symbol * indicates the connection point between the ring A and X, and the symbol ** indicates the connection point between the ring A and R x connection point.

[0051] In some embodiments of the present disclosure, ring B, ring C, and ring D in ring A are each independently optionally substituted with n substituents R d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4.

[0052] In some embodiments of the present disclosure, examples of heteroaromatic rings include, but are not limited to, furan, oxazole, isoxazole, oxadiazole, thiophene, thiazole, isothiazole, thiadiazole, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrimidine, pyridazine, pyrazine, tetrazole, and triazine.

[0053] In some embodiments of the present disclosure, examples of aromatic rings include, but are not limited to, benzene rings or naphthalene or fluorene.

[0054] In some embodiments of the present disclosure, examples of heterocycles include, but are not limited to, azetidine, oxetane, pyrrolidine, imidazolidine, pyrazolidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, oxazolidine, thiazolidine, piperidine, piperazine, morpholine, thiomorpholine, dioxane, azepane, azacyclooctane, diazepane (e.g., 1,4-diazacycloheptane), diazacyclooctane, 2-oxopyrrolidine, 2,5-dioxopyrrolidine, 2-oxopiperidine, and glutarimide.

[0055] In the embodiments of the present disclosure, the number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block.

[0056] In some embodiments of the present disclosure, both ring C and ring D are present. Ring atom W represents C, ring B represents an optionally substituted benzene ring, ring C represents an optionally substituted 4- to 14-membered heteroaryl ring or an optionally substituted 4- to 14-membered heterocyclic ring, and ring D represents an optionally substituted C 5-10 The aromatic ring, ie, Ring A, represents a 10- to 25-membered tricyclic divalent group having the following structural formula:

[0057] The symbol * indicates the connection point between the ring A and X, and the symbol ** indicates the connection point between the ring A and R x In some sub-embodiments of the present disclosure, the benzene ring, the 4- to 14-membered heteroaryl ring, the 4- to 14-membered heterocyclic ring and the C 5-10 Each aromatic ring is independently optionally substituted by n substituents R d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1- 3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1- 4-alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4.

[0058] In some sub-embodiments of the present disclosure, Ring A represents a divalent 11- to 21-membered tricyclic group having the following structural formula:

[0059] wherein Ring B and Ring D each independently represent an optionally substituted benzene ring, and Ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring. In some subembodiments of the present disclosure, the benzene ring, the 4- to 14-membered heteroaromatic ring, and the 4- to 14-membered heterocyclic ring each independently represent an optionally substituted benzene ring. d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4.

[0060] In some embodiments of the present disclosure, when both ring C and ring D are present, ring C in ring A is linked to X, and ring B or ring D in ring A is linked to Rx.

[0061] In some embodiments of the present disclosure, when both ring C and ring D are absent, ring B represents an optionally substituted benzene ring, ie, ring A represents the following optionally substituted phenylene:

[0062] The symbol * indicates the connection point between the ring A and X, and the symbol ** indicates the connection point between the ring A and R x In other words, when both ring C and ring D are absent, X is connected to R via ring B (i.e., phenylene). x In some sub-embodiments of the present disclosure, the benzene ring is optionally substituted with n substituents R d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4.

[0063] In some embodiments of the present disclosure, when ring A represents a bicyclic divalent group, ring D is absent, ring C represents an optionally substituted heteroaromatic ring (e.g., a 4- to 16-membered heteroaromatic ring or a 4- to 14-membered heteroaromatic ring) or an optionally substituted heterocyclic ring (e.g., a 4- to 16-membered heterocyclic ring or a 4- to 14-membered heterocyclic ring), and W represents C or N, i.e., ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring. In some sub-embodiments of the present disclosure, the benzene ring, pyridine ring, heteroaromatic ring, and heterocyclic ring are each independently optionally substituted with n substituents R d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1- 3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1- 4-alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4. In some subembodiments of the present disclosure, when ring A represents a bicyclic divalent group, ring D is absent, ring C in ring A is connected to X, and ring B in ring A is connected to Rx.

[0064] In some embodiments of the present disclosure, Ring A represents an 8- to 20-membered bicyclic divalent group having the following structural formula:

[0065] wherein Ring C represents an optionally substituted 4- to 16-membered heteroaromatic ring or an optionally substituted 4- to 16-membered heterocyclic ring, and Ring B represents an optionally substituted phenyl ring or an optionally substituted pyridine ring, i.e., W represents C or N. In some subembodiments of the present disclosure, the phenyl ring, the pyridine ring, the 4- to 16-membered heteroaromatic ring, and the 4- to 16-membered heterocyclic ring are each independently optionally substituted with n substituents R d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1- 4 alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4.

[0066] In some embodiments of the present disclosure, examples of Ring A include, but are not limited to, the following optionally further substituted groups:

[0067] Among them, each R c Each independently represents H or C 1-6 The symbol * indicates the connection point between the ring A and X, and the symbol ** indicates the connection point between the ring A and R x In some sub-embodiments of the present disclosure, each of the above groups is independently optionally further substituted with n substituents R d Substitution, each substituent R d the same or different and each independently selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (e.g., ethynyl), wherein n represents an integer of 0, 1, 2, 3, or 4. In some embodiments of the present disclosure, R x Indicates C(O)NH, NHC(O), -N(R2)-C 0- 2-alkylene-, -C 0-2Alkylene-N(R2)-, O, S, S(O), S(O)2, alkynylene (e.g. C 2-6 Alkyne), alkenylene (e.g. C 2-6 alkylene), -C(R3R4)-, optionally substituted piperazinylene or optionally substituted piperidinylene, wherein each R2 independently represents hydrogen or C 1-4 Alkyl, each C 0-2 The alkylene group is optionally substituted, and R3 and R4 each independently represent hydrogen, halogen or hydroxy.

[0068] R x represents O, S, S(O), S(O)2, alkenylene, alkynylene or N(R a6 ), where R a6 Indicates H or C 1-3 Alternatively, in some sub-embodiments of the present disclosure, R represents O, S, S(O), S(O)2, C 2-6 Alkenylene (e.g. vinylene), C 2-6 Alkyne (e.g., ethynylene), NH or N(CH3).

[0069] In some sub-embodiments of the present disclosure, examples of Rx include, but are not limited to, C(O)NH, NHC(O), N(R2), -N(R2)-methylene-, -N(R2)-ethylene-, -methylene-N(R2)-, -ethylene-N(R2)-, O, S, S(O), S(O)2, C 2-6 Alkenylene, C 2-6 Alkyne, -C(R3R4)-, optionally substituted piperazinyl or optionally substituted piperidinyl, wherein each R2 independently represents hydrogen or C 1-4 alkyl, each methylene and ethylene are each independently optionally substituted, and R3 and R4 each independently represent hydrogen, halogen or hydroxy. For example, R x Including C(O)NH, NHC(O), NH, N(CH3), -NHCH2-, -NHCH2CH2-, -N(CH3)CH2-, -N(CH3)CH2CH2-, -CH2NH-, -CH2CH2NH-, -CH2N(CH3)-, -CH2CH2N(CH3)-, O, S, S(O), S(O)2, C 2-4 Alkenylene, C 2-4 alkylene, -CH2-, optionally substituted piperazinylene or optionally substituted piperidinylene.

[0070] In some subembodiments of the present disclosure, the piperazinyl and piperidinyl groups are each independently optionally substituted with one or more (e.g., 0, 1, 2, 3, 4, 5, 6, 7, or 8) substituents, each of which is the same or different and is independently selected from deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl) and C 2-6 Alkynyl (eg, ethynyl).

[0071] In some sub-embodiments of the present disclosure, each C 0-2 The alkylene, methylene and ethylene groups are each independently optionally substituted with one or more (e.g., 0, 1, 2, 3, or 4) substituents, each substituent being the same or different and each independently selected from deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, mercapto, nitro, amino, and cyano.

[0072] In some embodiments of the present disclosure, LIN represents:

[0073] where R L1 Connect Rx , R L2 Connect R w ;

[0074] R L2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a5 ), where R a5 Indicates H or C 1-3 alkyl;

[0075] Each ring A 1 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 independently optionally be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20;

[0076] Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 independently optionally by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20;

[0077] Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; and

[0078] R L1 represents a bond, or represents an optionally substituted linear or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more (e.g., 1-15, 1-10, 1-6, 1-4, 2-6, or 1) methylene groups of the main carbon chain backbone of the alkylene group may be optionally replaced by one or more groups selected from the following: La 、R Lb and any combination thereof, each group R La Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R La When substituted, each group R La Not directly connected to each other; each group R Lb Each is independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof.

[0079] In some embodiments of the present disclosure, R L2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a5 ), where R a5 Indicates H or C 1-3 alkyl.

[0080] In some embodiments of the present disclosure, R L2 Indicates a key.

[0081] In some embodiments of the present disclosure, y1 represents an integer of 0, 1, 2 or 3, and each ring A 1 Each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3- 20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0082] In some embodiments of the present disclosure, y1 represents an integer of 0, 1, 2 or 3, and each ring A 1 Examples include, but are not limited to:

[0083] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazacycloheptanediylene, diazacyclooctanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene.

[0084] In some embodiments of the present disclosure, y1 represents an integer of 0, 1, 2, or 3. Examples of each ring A1 include, but are not limited to:

[0085] In some embodiments of the present disclosure, y1 represents an integer of 0, 1, 2 or 3, and each ring A 1 Each independently optionally represented by a1 R y1 Substituent substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a1 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y1 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 or alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0086] In some embodiments of the present disclosure, y2 represents an integer of 0, 1, 2 or 3, and each ring A 2 Each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3- 20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0087] In some embodiments of the present disclosure, y2 represents an integer of 0, 1, 2 or 3, and each ring A 2 Examples include, but are not limited to:

[0088] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazacycloheptanediylene, diazacyclooctanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene.

[0089] In some embodiments of the present disclosure, y2 represents an integer of 0, 1, 2 or 3, and each ring A 2 Examples include, but are not limited to:

[0090] In some embodiments of the present disclosure, y2 represents an integer of 0, 1, 2 or 3, and each ring A 2 Each independently optionally represented by a2 R y2Substituent substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a2 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y2 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 or alkoxy, for example, F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a2 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0091] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3- 20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0092] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Examples include, but are not limited to:

[0093] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazacycloheptanediylene, diazacyclooctanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene.

[0094] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A3 Examples include, but are not limited to:

[0095] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Each independently optionally represented by a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a3 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y3 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 or alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a3 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0096] In some embodiments of the present disclosure, in the general formula of LIN Partially indicates:

[0097] wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0098] In some embodiments of the present disclosure, R L1 Indicates a key.

[0099] In some embodiments of the present disclosure, R L1 represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) methylene groups of the main carbon chain backbone of the alkylene group are optionally replaced by one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) groups selected from the following: R La 、R Lb and any combination thereof, each group R La Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 Alkyl), and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R La When substituted, each group R La Not directly connected to each other; each group R Lb are each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkenylene, alkynylene, and any combination thereof. Lbare each independently selected from optionally substituted C 3-30 Cycloalkylene, optionally substituted C 5-30 arylene, an optionally substituted 4- to 30-membered heterocyclylene, an optionally substituted 5- to 30-membered heteroarylene, C 2-6 Alkenylene, C 2-6 In some subembodiments, each group R Lb are each independently selected from optionally substituted C 3-20 Cycloalkylene, optionally substituted C 5-20 arylene, an optionally substituted 4- to 20-membered heterocyclylene, an optionally substituted 5- to 20-membered heteroarylene, C 2-4 Alkenylene, C 2-4 In some subembodiments, each group R Lb are each independently selected from optionally substituted C 3-15 Cycloalkylene, optionally substituted C 5-15 arylene, an optionally substituted 4- to 15-membered heterocyclylene, an optionally substituted 5- to 15-membered heteroarylene, C 2-4 Alkenylene or C 2-4 In some sub-embodiments, the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1- 6 alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 In some subembodiments, the straight or branched C 1-20 The alkylene group may be optionally substituted with one or more (e.g., 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) groups independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3cD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0100] In some embodiments of the present disclosure, R L1 express:

[0101] -C 1-15 Alkylene-;

[0102] -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0103] -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R La (C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0104] -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R La (C(R Lc5 )(R Lc6 )) r3 ) s2 -(R La (C(R Lc7 )(R Lc8 )) r4 ) s3 -#;

[0105] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -#;

[0106] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1-((C(R Lc5 )(R Lc6 )) r3 R La ) s2 -#;

[0107] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -((C(R Lc5 )(R Lc6 )) r3 R La ) s2 -((C(R Lc7 )(R Lc8 )) 14 R La ) s3 -#;

[0108] -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0109] -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R Lb (C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0110] -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R L3 )(R Lc4 )) r2 ) s1 -(R Lb (C(R Lc5 )(R Lc6 )) r3 )s2 -(R Lb (C(R Lc7 )(R Lc8 )) r4 ) s3 -#;

[0111] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -#;

[0112] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -((C(R Lc5 )(R Lc6 )) r3 R Lb ) s2 -#;

[0113] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -((C(R Lc5 )(R Lc6 )) r3 R Lb ) s2 -((C(R Lc7 )(R Lc8 )) r 4R Lb ) s3 -#;

[0114] -(C(R Lc1 )(R Lc2 )) r1 -(R La -R Lb -(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0115] -(C(RLc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R Lb (C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0116] -(C(R Lc1 )(R Lc2 )) r1 -(R Lb -R La -(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0117] -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R La (C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0118] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -R La -R Lb ) s1 -#;

[0119] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -((C(R Lc5 )(R Lc6 )) r3 R Lb )s2 -#;

[0120] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -R Lb -R a ) s1 -#;or

[0121] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -((C(R Lc5 )(R Lc6 )) r3 R La ) s2 -#;

[0122] Among them, each group R La independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl; each group R Lb are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof;

[0123] R Lc1 、R Lc2 、R Lc3 、R Lc4 、R Lc5 、R Lc6 、R Lc7 and R Lc8 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, halo 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and

[0124] r1, r2, r3, r4, s1, s2, s3 each independently represent an integer 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0125] The symbol # indicates that the x connection points; and

[0126] The C 1-15 The alkylene group is optionally substituted with one or more (e.g., 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) substituents selected from the group consisting of deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, oxo, haloC 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl and any combination thereof. L1 The total number of carbon atoms in each general formula (excluding R La 、R LbThe number of carbon atoms in the group), that is, the sum of R1+R2*S1, the sum of R1+R2*S1+R3*S2, and the sum of R1+R2*S1+R3*S2+R4*S5, are all less than or equal to 20.

[0127] In some embodiments of the present disclosure, R L1 Indicates -C 1-15 Alkylene-, wherein the C 1-15 The alkylene group is optionally substituted with one or more (e.g., 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) substituents selected from the group consisting of deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, oxo, haloC 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0128] In some embodiments of the present disclosure, R L1 represents the following groups: -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2)12 -、-(CH2) 13 -、-(CH2) 14 -or-(CH2) 15 -; wherein the group is optionally further substituted by one or more substituents selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, halo C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0129] In some embodiments of the present disclosure, R L1 Represents the following structure:

[0130] -(C(R Lc1 )(R Lc2 )) r1 -(O(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0131] -(C(R Lc1 )(R Lc2 )) r1 -(O(C(R Lc3 )(R Lc4 )) r2 )s1 -(O(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0132] -(C(R Lc1 )(R Lc2 )) r1 -(O(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O(C(R Lc5 )(R Lc6 )) r3 ) s2 -(O(C(R Lc7 )(R Lc8 )) r4 ) s3 -#;

[0133] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 O) s1 -#;

[0134] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 O) s1 -(((C(R Lc5 )(R Lc6 )) r3 O) s2 -#;

[0135] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 O) s1 -((C(R Lc5 )(R Lc6 )) r3 O) s2 -((C(R Lc7 )(R Lc8 )) r4 O) s3 -#;

[0136] -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0137] -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )(C(R Lc3 )(R Lc4 )) r2 ) s1 -(N(R La1 )(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0138] -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )(C(R Lc3 )(R Lc4 )) r2 ) s1 -(N(R La1 )(C(R Lc5 )(R Lc6 )) r3 ) s2 -(N(R La1 )(C(R Lc7 )(R Lc8 )) r4 ) s3 -#;

[0139] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 N(R La1 )) s1 -#;

[0140] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 N(R La1 ))s1 -((C(R Lc5 )(R Lc6 )) r3 N(R La1 )) s2 -#;

[0141] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 N(R La1 )) s2 -((C(R Lc7 )(R Lc8 )) r4 N(R La1 )) s3 -#;

[0142] -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0143] -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(C(O)N(R La1 )-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0144] -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(C(O)N(RLa1 )-(C(R Lc5 )(R Lc6 )) r3 ) s2 -(C(O)N(R La1 )-(C(R Lc7 )(R Lc8 )) r4 ) s3 -#;

[0145] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -#;

[0146] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 -C(O)N(R La1 )) s2 -#;

[0147] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 -C(O)N(R La1 )) s2 -((C(R Lc7 )(R Lc8 )) r4 -C(O)N(R La1 )) s3 -#;

[0148] -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(RLa1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0149] -(C(R Lc1 )(R Lc2 )) r1 -C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 -(O(C(R Lc5 )(R Lc6 )) r3 ) s1 -#;

[0150] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 O) s2 -#;

[0151] -(C(R Lc1 )(R Lc2 )) r1 -(C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )-((C(R Lc5 )(R Lc6 )) r3 O) s1 -#;

[0152] -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0153] -(C(RLc1 )(R Lc2 )) r1 -(N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O-(C(R Lc5 )(R Lc6 ))) r3 ) s2 -#;

[0154] -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O-(C(R Lc5 )(R Lc6 )) r3 ) s2 -(O-(C(R Lc7 )(R Lc8 )) r4 ) s3 -#;

[0155] -(C(R Lc1 )(R Lc2 )) r1 -N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 -(O(C(R Lc5 )(R Lc6 )) r3 ) s1 -#;

[0156] -(C(R Lc1 )(R Lc2 )) r1 -N(R La1 )C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 .#;

[0157] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2-N(R La1 )(C(O)) s1 -#;

[0158] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -N(R La1 )(C(O)) s1 -((C(R Lc5 )(R Lc6 ))) r3 -O) s2 -#;

[0159] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -N(R La1 )(C(O)) s1 -((C(R Lc5 [[ID=5۲]])(R Lc6 ))) r3 O) s2 -((C(R Lc7 )(R Lc8 ) )) r4 O) s3 -#;

[0160] -(C(R Lc1 )(R Lc2 )) r1 -(C(R Lc3 )(R Lc4 )) r2 -N(R La1 )(C(O)-((C(R Lc5 )(R Lc6 ))) r3 O) s1 -#;

[0161] -(C(R Lc1 )(R Lc2 )) r1 -(Arylene-(C(R Lc3 )(R Lc4 ))) r2 ) s1 -#;

[0162] -(C(R Lc1 )(R Lc2 )) r1-(arylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -arylene-(C(R Lc5 )(R Lc6 )) r3 -#;

[0163] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -arylene) s1 -#;

[0164] -(C(R Lc1 )(R Lc2 )) r1 -((C(R L c3)(R Lc4 )) r2 -arylene) s1 -(C(R Lc5 )(R Lc6 )) r3 -arylene-#;

[0165] -(C(R Lc1 )(R Lc2 )) r1 -(Heterocyclylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0166] -(C(R Lc1 )(R Lc2 )) r1 -(Heterocyclylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(Heterocyclylene-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0167] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heterocyclylene) s1 -#;

[0168] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heterocyclylene) s1 -((C(R Lc5 )(R Lc6 )) r3 -heterocyclylene) s2 -#;

[0169] -(C(R Lc1 )(R Lc2 )) r1 -(heteroarylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0170] -(C(R Lc1 )(R Lc2 )) r1 -(heteroarylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(heteroarylene-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0171] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heteroarylene) s1 -#;

[0172] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heteroarylene) s1 -((C(R Lc5 )(R Lc6 )) r3 -heteroarylene) s2 -#;

[0173] -(C(R Lc1 )(R Lc2 )) r1-(cycloalkylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#;

[0174] -(C(R Lc1 )(R Lc2 )) r1 -(cycloalkylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(cycloalkylene-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#;

[0175] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -cycloalkylene) s1 -#;or

[0176] -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -cycloalkylene) s1 -((C(R Lc5 )(R Lc6 )) r3 -cycloalkylene) s2 -#;

[0177] Among them, each R La1 independently represents H or C 1-6 alkyl ；

[0178] The cycloalkylene group (eg C 3-20 Cycloalkylene), the arylene group (such as C 5-20 arylene), the heterocyclylene (e.g., 4- to 20-membered heterocyclylene) and the heteroarylene (e.g., 5- to 20-membered heteroarylene) are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof;

[0179] R Lc1 、R Lc2 、R Lc3 、R Lc4 、R Lc5 、R Lc6 、R Lc7 and R Lc8 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, halo C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and

[0180] r1, r2, r3, r4, s1, s2, s3 each independently represent an integer 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

[0181] The symbol # indicates that the x connection point.

[0182] In some embodiments, R L1 Examples of cycloalkylene in the above general structure include but are not limited to C 3-20 Cycloalkylene, C 3-15 Cycloalkylene and C 3-11 Cycloalkylene, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (for example, C 5-15 The cycloalkylene group is optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0183] In some embodiments, R L1 Examples of arylene groups in the above general structure include, but are not limited to, C 5-20 Arylene, C 6-20 Arylene, C 5-15 Arylene and C 6-15 Arylene, such as phenylene or naphthylene. Arylene is optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0184] In some embodiments, R L1 Examples of heterocyclylene groups in the above general structure include, but are not limited to, 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclylene groups, such as azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thio ... The heterocyclyl group may be selected from the group consisting of deuterium, hydroxy, amino, sulfhydryl, nitro, halogen, cyano, oxo, C- 1- 1- 2- aryl, thiol, cycloheptanyl, 2- 1- 1- aryl, oxo, 2- 1- aryl, 2- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 3- 1- aryl, 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0185] In some embodiments, R L1 Examples of heteroarylene groups in the above general structure represented by include, but are not limited to, 5- to 20-membered heteroarylene groups, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroarylene groups, such as oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, azoles, benzothiazolylidenes, benzisothiazolylidenes, benzotriazoles, benzo[2,1,3]oxadiazoles, benzo[2,1,3]thiadiazolylidenes, benzo[1,2,3]thiadiazolylidenes, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidenes, or imidazo[2,1.b]thiazolylidenes. Heteroarylene is optionally selected from deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0186] In some embodiments, R L1 Examples include, but are not limited to, the following groups:

[0187] -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10-、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O- (CH2) 10-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH 2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-( CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1- 、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-CH(CH3)-O-(CH2)9-、-CH(CH3)-O-(CH2) 10-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(CH2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2 )2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2- (O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-C H2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、 -(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(C H2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2 )3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4- (O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-( CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2 )2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R、 La1 )-(CH2)1-、-(CH2)1-N(R La1 )-(CH2)2-、-(CH2)1-N(R La1 )-(CH2)3-、-(CH2)1-N(R La1 )-(CH2)4-、-(CH2)1-N(R La1 )-(CH2)5-、-(CH2)1-N(R La1 )-(CH2)6-、-(CH2)1-N(R La1 )-(CH2)7-、-(CH2)1-N(R La1 )-(CH2)8-、-(CH2)1-N(R La1 )-(CH2)9-、-(CH2)1-N(R La1 )-(CH2) 10 -、-N(R La1 )-(CH2)1-、-N(R La1 )-(CH2)2-、-N(R La1 )-(CH2)3-、-N(R La1 )-(CH2)4-、-N(R La1 )-(CH2)5-、-N(R La1 )-(CH2)6-、-N(R La1 )-(CH2)7-、-N(R La1 )-(CH2)8-、-N(R La1 )-(CH2)9-、-N(R La1 )-(CH2) 10 -、-(CH2)2-N(R La1 )-(CH2)1-、-(CH2)2-N(R La1 )-(CH2)2-、-(CH2)2-N(R La1 )-(CH2)3-、-(CH2)2-N(RLa1 )-(CH2)4-、-(CH2)2-N(R La1 )-(CH2)5-、-(CH2)2-N(R La1 )-(CH2)6-、-(CH2)2-N(R La1 )-(CH2)7-、-(CH2)2-N(R La1 )-(CH2)8-、-(CH2)2-N(R La1 )-(CH2)9-、-(CH2)2-N(R La1 )-(CH2) 10 -、-(CH2)3-N(R La1 )-(CH2)1-、-(CH2)3-N(R La1 )-(CH2)2-、-(CH2)3-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)1-、-(CH2)4-N(R La1 )-(CH2)2-、-(CH2)4-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)1-、-(CH2)5-N(R La1 )-(CH2)2-、-(CH2)5-N(R La1 )-(CH2)3-、-(CH2)5-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)5-、-(CH2)6-N(R La1 )-(CH2)1-、-(CH2)6-N(R La1 )-(CH2)2-、-(CH2)6-N(R La1 )-(CH2)3-、-(CH2)7- N(R La1 )-(CH2)1-、-(CH2)7-N(R La1 )-(CH2)2-、-(CH2)7-N(R La1 )-(CH2)3-、-(CH2)8-N(R La1 )-(CH2)1-、-(CH2)8-N(R La1 )-(CH2)2-、-(CH2)8-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)1-、-CH(CH3)-N(RLa1 )-(CH2)2-、-CH(CH3)-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)4-、-CH(CH3)-N(R La1 )-(CH2)5-、-CH(CH3)-N(R La1 )-(CH2)6-、-CH(CH3)-N(R La1 )-(CH2)7-、-CH(CH3)-N(R La1 )-(CH2)8-、-CH(CH3)-N(R La1 )-(CH2)9-、-CH(CH3)-N(R La1 )-(CH2) 10 -、-(CH2)1-N(R La1 )-、-(CH2)2-N(R La1 )-、-(CH2)3-N(R La1 )-、-(CH2)4-N(R La1 )-、-(CH2)5-N(R La1 )-、-(CH2)6-N(R La1 )-、-(CH2)7-N(R La1 )-、-(CH2)8-N(R La1 )-、-(CH2)9-N(R La1 )-、-(CH2) 10 -N(R La1)-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)N H(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O )NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O) (CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)( CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC( O)(CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-, -(CH2)2-phenylene-, -(CH2)3-phenylene-, -(CH2)4-phenylene-, -(CH2)5-phenylene-, -(CH2)6-phenylene-, -(CH2)7-phenylene-, -(CH2)8-phenylene-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-,-CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH 2) 3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene-(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5- , -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, -(CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6- Phenylene-(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-,-(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-, -(CH2)8-phenylene-(CH2)7-, -N(R, La1 )-CH2-phenylene-CH2-、-N(R La1 )-CH2-phenylene-(CH2)2-, -N(R La1 )-CH2-phenylene-(CH2)3-、-N(R La1 )-CH2-phenylene-(CH2)4-、-N(R La1 )-CH2-phenylene-(CH2)5-、-N(R La1 )-CH2-phenylene-(CH2)6-、-N(R La1 )-CH2-phenylene-(CH2)7-、-N(R La1 )-CH2-phenylene-(CH2)8-, -CH2-N(R La1 )-CH2-phenylene-CH2-, -CH2-N(R La1 )-CH2-phenylene-(CH2)2-, -CH2-N(R La1 )-CH2-phenylene-(CH2)3-, -CH2-N(R La1 )-CH2-phenylene-(CH2)4-, -CH2-N(R La1 )-CH2-phenylene-(CH2)5-, -CH2-N(R La1 )-CH2-phenylene-(CH2)6-, -CH2-N(R La1 )-CH2-phenylene-(CH2)7-, -CH2-N(R La1 )-CH2-phenylene-(CH2)8-, -CH2-N(R La1 )-(CH2)2-phenylene-CH2-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)2-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)3-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)4-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)5-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)6-, -CH2-N(R La1)-(CH2)2-phenylene-(CH2)7-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)8-, -(CH2)2-N(R La1 )-CH2-phenylene-CH2-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)4-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)5-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)6-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)7-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)3-N(R La1 )-CH2-phenylene-CH2-, -(CH2)3-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)3-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)3-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)4-N(R La1 )-CH2-phenylene-CH2-, -(CH2)4-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)4-N(R La1 )-CH2-phenylene-(CH2)3-、-(CH2)4-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)5-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)5-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)6-N(R La1 )-CH2-phenylene-(CH2)3-、-(CH2)6-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)7-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R La1 )-CH2-phenylene-CH2-, -(CH2)8-N(R La1)-CH2-phenylene-(CH2)2-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)4-、-(CH2)8-N(R La1 )-CH2-phenylene-(CH2)5-, -(CH2)8-N(R La1)-CH2-phenylene-(CH2)6-, -thiazolylene-CH2-, -thiazolylene-(CH2)2-, -thiazolylene-(CH2)3-, -thiazolylene-(CH2)4-, -thiazolylene-(CH2)5-, -thiazolylene-(CH2)6-, -thiazolylene-(CH2)7-, -thiazolylene-(CH2)8-, -CH2-thiazolylene-, -(CH2)2-thiazolylene-, -(CH2)3-thiazolylene-, -(CH2)4-thiazolylene-, -(CH2)5-thiazolylene-, -CH2-thiazolylene-CH2-, -CH2-thiazolylene-(CH2)2-, -CH2-thiazolylene-(CH2)3-, -CH2-thiazolylene-(CH2)4-, -CH2-thiazolylene-(CH2)5-, -CH2-thiazolylene-(CH2)6-, -CH2-thiazolylene-(CH2)7-, -CH2-thiazolylene-(CH2)8-, -(CH2)2-thiazolylene-(CH2)1-, -(CH2)2-thiazolylene-(CH2)2-, -(CH2)2-thiazolylene-(CH2)3-, -(CH2)2-thiazolylene-(CH2)4-, -(CH2)2-thiazolylene-(CH2)5-, -(CH2)2-thiazolylene-(CH2)6-, -(CH2)2-thiazolylene-(CH2)7-, -(CH2)2- Thiazolylene-(CH2)8-, -(CH2)3-thiazolylene-CH2-, -(CH2)3-thiazolylene-(CH2)2-, -(CH2)3-thiazolylene-(CH2)3-, -(CH2)3-thiazolylene-(CH2)4-, -(CH2)3-thiazolylene-(CH2)5-, -(CH2)3-thiazolylene-(CH2)6-, -(CH2)3-thiazolylene-(CH2)7-, -(CH2)3-thiazolylene-(CH2)8-, -(CH2)4-thiazolylene-CH2-, -(CH2)4-thiazolylene-(CH2)2-, -(CH2)4-thiazolylene-(CH2)3-, -(CH2)4 -(CH2)4-thiazolylene-(CH2)5-, -(CH2)4-thiazolylene-(CH2)6-, -(CH2)4-thiazolylene-(CH2)7-, -(CH2)4-thiazolylene-(CH2)8-, -(CH2)5-thiazolylene-(CH2)1-, -(CH2)5-thiazolylene-(CH2)2-, -(CH2)5-thiazolylene-(CH2)3-, -(CH2)5-thiazolylene-(CH2)4-, -(CH2)5-thiazolylene-(CH2)5-, -(CH2)5-thiazolylene-(CH2)6-, -(CH2)5-thiazolylene-(CH2)7-,-(CH2)5-thiazolylene-(CH2)8-, -(CH2)6-thiazolylene-(CH2)1-, -(CH2)6-thiazolylene-(CH2)2-, -(CH2)6-thiazolylene-(CH2)3-, -(CH2)6-thiazolylene-(CH2)4-, -(CH2)6-thiazolylene-(CH2)5-, -(CH2)6-thiazolylene-(CH2)6-, -(CH2)6-thiazolylene-(CH2)7-, -(CH2)6-thiazolylene-(CH2)8-, -(CH2)7-thiazolylene-(CH2)1-, -(CH2)7-thiazolylene-(CH2)2-, -(CH2)7-thiazolylene-(CH2)3 -、-(CH2)7-thiazolylene-(CH2)4-、-(CH2)7-thiazolylene-(CH2)8-、-(CH2)8-thiazolylene-CH2-、-(CH2)8-thiazolylene-(CH2)2-、-(CH2)8-thiazolylene-(CH2)3-、-(CH2)8-thiazolylene-(CH2)4-、-(CH2)8-thiazolylene-(CH2)5-、-(CH2)8-thiazolylene-(CH2)6-、-(CH2)8-thiazolylene-(CH2)7-、-piperidinylene-CH2-、-piperidinylene-(CH2)2-、-piperidinylene-(CH2)3-、-piperidinylene-(CH2)4-、-piperidinylene-(CH 2)5-, -piperidinylene-(CH2)6-, -piperidinylene-(CH2)7-, -piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7-, -CH2-piperidinylene-(CH2)8-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3- , -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-(CH2)6-, -(CH2)3-piperidinylene-(CH2)7-,-(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2)4-piperidinylene-(CH2)8-, -(CH2)5- Piperidinylene-(CH2)1-, -(CH2)5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-(CH2)1-, -(CH2)6-piperidinylene- (CH2)2-, -(CH2)6-piperidinylene-(CH2)3-, -(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2) 3-, -(CH2)7-piperidinylene-(CH2)4-, -(CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R, La1 )-CH2-piperidinyl-CH2-、-N(R La1 )-CH2-piperidinyl-(CH2)2-、-N(R La1 )-CH2-piperidinyl-(CH2)3-、-N(R La1 )-CH2-piperidinyl-(CH2)4-、-N(R La1 )-CH2-piperidinyl-(CH2)5-、-N(R La1 )-CH2-piperidinyl-(CH2)6-、-N(R La1)-CH2-piperidinyl-(CH2)7-、-N(R La1 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R La1 )-CH2-piperidinyl-CH2-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)2-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)3-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)5-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)6-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)7-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R La1 )-(CH2)2-piperidinyl-CH2-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)2-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)3-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)4-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)5-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)6-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)7-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)8-, -(CH2)2-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)4-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)5-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)6-, -(CH2)2-N(R La1)-CH2-piperidinyl-(CH2)7-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)3-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)3-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)3-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)3-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)4-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)4-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)4-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)4-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)5-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)5-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)6-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)6-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)7-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)4-、-(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)5-, -(CH2)8-N(R La1)-CH2-piperidinylene-(CH2)6-, -piperazinylene-CH2-, -piperazinylene-(CH2)2-, -piperazinylene-(CH2)3-, -piperazinylene-(CH2)4-, -piperazinylene-(CH2)5-, -piperazinylene-(CH2)6-, -piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7 -, -CH2-piperazinylene-(CH2)8-, -(CH2)2-piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)6-, -(CH2)2-piperazinylene-(CH2)7-, -(CH2)2-piperazinylene-(CH2)8-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -( -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-(CH2)6-, -(CH2)3-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2) -(CH2)4-piperazinylene-(CH2)8-, -(CH2)5-piperazinylene-(CH2)1-, -(CH2)5-piperazinylene-(CH2)2-, -(CH2)5-piperazinylene-(CH2)3-, -(CH2)5-piperazinylene-(CH2)4-, -(CH2)5-piperazinylene-(CH2)5-, -(CH2)5-piperazinylene-(CH2)6-, -(CH2)5-piperazinylene-(CH2)7-, -(CH2)5-piperazinylene-(CH2)8-, -(CH2)6-piperazinylene-(CH2)1-, -(CH2)6-piperazinylene-(CH2)2-, -(CH2)6-piperazinylene-(CH2)3-,-(CH2)6-piperazinylene-(CH2)4-, -(CH2)6-piperazinylene-(CH2)5-, -(CH2)6-piperazinylene-(CH2)6-, -(CH2)6-piperazinylene-(CH2)7-, -(CH2)6-piperazinylene-(CH2)8-, -(CH2)7-piperazinylene-(CH2)1-, -(CH2)7-piperazinylene-(CH2)2-, -(CH2)7-piperazinylene -(CH2)3-, -(CH2)7-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-(CH2)5-, or -(CH2)8-piperazinylene-(CH2)6-;

[0188] Among them, each R La1 independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl, or isopropyl);

[0189] Each phenylene and thiazolylene group is independently optionally selected from deuterium, hydroxy, amino, mercapto, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3- 6-cycloalkyl, deuterated C 3-6 substituted with a cycloalkyl group, a 4- to 10-membered heterocyclic group, and any combination thereof; and

[0190] The piperazinyl and piperidinyl groups are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 In this article, unless otherwise specified, any end of the above groups can be connected to the R x , and the other end is connected to ring A 1 For example, the O in the group -O-CH2- can be connected to the Rx , and CH2 can be connected to ring A of the compound of formula (I) 1 ,vice versa.

[0191] In some embodiments, LIN represents a bond.

[0192] In some embodiments, examples of LIN include, but are not limited to, the following groups:

[0193] C(O), C(O)NH, NHC(O), NH, -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -;-O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10 -, -(CH2)1-O-, -(CH2)2-O-, -(CH2)3-O-, -(CH2)4-O-, -(CH2)5-O-, -(CH2)6-O-, -(CH2)7-O-, -(CH2)8-O-, -(CH2)9-O-, -(CH2) 10-O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-( CH2)1-O-(CH2)8-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2 )5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(C H2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、- (CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O -(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5 -、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、 -CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-CH2-(O(CH2)2)6-OCH 2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(C H2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2- (O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-CH2-O-(CH2)2-O -(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 La1 )-(CH2)1-、-(CH2)1-N(R La1 )-(CH2)2-、-(CH2)1-N(R La1 )-(CH2)3-、-(CH2)1-N(R La1 )-(CH2)4-、-(CH2)1-N(RLa1 )-(CH2)5-、-(CH2)1-N(R La1 )-(CH2)6-、-N(R La1 )- (CH2)1-、-N(R La1 )-(CH2)2-、-N(R La1 )-(CH2)3-、-N(R La1 )-(CH2)4-、-N(R La1 )-(CH2)5-、-N(R La1 )-(CH2)6-、-(CH2)2-N(R La1 )-(CH2)1-、-(CH2)2-N(R La1 )-(CH2)2-、-(CH2)2-N(R La1 )-(CH2)3-、-(CH2)2-N(R La1 )-(CH2)4-、-(CH2)2-N(R La1 )-(CH2)5-、-(CH2)2-N(R La1 )-(CH2)6-、-(CH2)3-N(R La1 )-(CH2)1-、-(CH2)3-N(R La1 )-(CH2)2-、-(CH2)3-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)1-、-(CH2)4-N(R La1 )-(CH2)2-、-(CH2)4-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)1-、-(CH2)5-N(R La1 )-(CH2)2-、-(CH2)5-N(R La1 )-(CH2)3-、-(CH2)5-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)5-、-(CH2)6-N(R La1 )-(CH2)1-、-(CH2)6-N(R La1 )-(CH2)2-、-(CH2)6-N(R La1 )-(CH2)3-、-(CH2)7-N(R La1 )-(CH2)1-、-(CH2)7-N(R La1)-(CH2)2-、-(CH2)7-N(R La1 )-(CH2)3-、-(CH2)8-N(R La1 )-(CH2)1-、-(CH2)8-N(R La1 )-(CH2)2-、-(CH2)8-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)1-、-CH(CH3)-N(R La1 )-(CH2)2-、-CH(CH3)-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)4-、-CH(CH3)-N(R La1 )-(CH2)5-、-CH(CH3)-N(R La1 )-(CH2)6-、-(CH2)1-N(R La1 )-、-(CH2)2-N(R La1 )-、-(CH2)3-N(R La1 )-、-(CH2)4-N(R La1 )-、-(CH2)5-N(R La1 )-、-(CH2)6-N(R La1 )-、-(CH2)7-N(R La1 )-、-(CH2)8-N(R La1 )-、-(CH2)9-N(R La1 )-、-(CH2) 10 -N(R La1)-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O) NH(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH 2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH 2)4-、-(CH2)4NHC(O)(CH2)4-、-(CH2)5NHC(O)(CH2)5-、-(CH2)2NHC(O)(CH2)2-O-(CH2)2-、-(CH2)4NHC(O)CH2-、-phenylene-CH2-、-phenylene-(CH2)2-、-phenylene-(CH2)3-、-phenylene-(CH2)4-、-phenylene-(CH2)5-、-phenylene-(CH2)6-、-phenylene-(CH2)7-、-phenylene-(CH2)8-、-CH2-phenylene-、-(CH2)2-phenylene-、-(CH2)3-phenylene-、-(CH2)4-phenylene-、-(C -(CH2)5-phenylene-, -(CH2)6-phenylene-, -(CH2)7-phenylene-, -(CH2)8-phenylene-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-,-(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -thiazolylene-CH2-, -thiazolylene-(CH2)2-, -thiazolylene-(CH2)3-, -thiazolylene-(CH2)4-, -thiazolylene-(CH2)5-, -thiazolylene-(CH2)6-, -thiazolylene-(CH2)7-, -thiazolylene-(CH2)8-, -CH2-thiazolylene-, -(CH2)2-thiazolylene-, -(CH2)3-thiazolylene-, -(CH2)4-thiazolylene-, -(CH2)5-thiazolylene-, -CH2-thiazolylene-CH2-, -CH2-thiazolylene-(CH2)2-, -CH2-thiazolylene-(CH2)3-, -CH2-thiazolylene-(CH2)4-, -CH2-thiazolylene-(CH2)5-, -CH2-thiazolylene-(CH2)6-, -CH2-thiazolylene-(CH2)7-, - CH2-thiazolylene-(CH2)8-, -(CH2)2-thiazolylene-(CH2)1-, -(CH2)2-thiazolylene-(CH2)2-, -(CH2)2-thiazolylene-(CH2)3-, -(CH2)2-thiazolylene-(CH2)4-, -(CH2)2-thiazolylene-(CH2)5-, -(CH2)2-thiazolylene-(CH2)6-, -(CH2)2-thiazolylene-(CH2)7-, -(CH2)2-thiazolylene-(CH2)8-, -(CH2)3-thiazolylene-CH2-, -(CH2)3-thiazolylene-(CH2)2-, -(CH2)3-thiazolylene-(CH2)3-, -( -(CH2)3-thiazolylene-(CH2)4-, -(CH2)3-thiazolylene-(CH2)5-, -(CH2)3-thiazolylene-(CH2)6-, -(CH2)3-thiazolylene-(CH2)7-, -(CH2)3-thiazolylene-(CH2)8-, -(CH2)4-thiazolylene-CH2-, -(CH2)4-thiazolylene-(CH2)2-, -(CH2)4-thiazolylene-(CH2)3-, -(CH2)4-thiazolylene-(CH2)4-, -(CH2)4-thiazolylene-(CH2)5-, -(CH2)4-thiazolylene-(CH2)6-, -(CH2)4-thiazolylene-(CH2)7-,-(CH2)4-thiazolylene-(CH2)8-, -(CH2)5-thiazolylene-(CH2)1-, -(CH2)5-thiazolylene-(CH2)2-, -(CH2)5-thiazolylene-(CH2)3-, -(CH2)5-thiazolylene-(CH2)4-, -(CH2)5-thiazolylene-(CH2)5-, -(CH2)5-thiazolylene-(CH2)6-, -(CH2)5-thiazolylene-(CH2)7-, -(CH2)5-thiazolylene-(CH2)8-, -(CH2)6-thiazolylene-(CH2)1-, -(CH2)6-thiazolylene-(CH2)2-, -(CH2)6-thiazolylene-(C -(CH2)3-, -(CH2)6-thiazolylene-(CH2)4-, -(CH2)6-thiazolylene-(CH2)5-, -(CH2)6-thiazolylene-(CH2)6-, -(CH2)6-thiazolylene-(CH2)7-, -(CH2)6-thiazolylene-(CH2)8-, -(CH2)7-thiazolylene-(CH2)1-, -(CH2)7-thiazolylene-(CH2)2-, -(CH2)7-thiazolylene-(CH2)3-, -(CH2)7-thiazolylene-(CH2)4-, -(CH2)7-thiazolylene-(CH2)8-, -(CH2)8-thiazolylene-CH2-, -(CH2)8-thiazolylene- (CH2)2-, -(CH2)8-thiazolylene-(CH2)3-, -(CH2)8-thiazolylene-(CH2)4-, -(CH2)8-thiazolylene-(CH2)5-, -(CH2)8-thiazolylene-(CH2)6-, -(CH2)8-thiazolylene-(CH2)7-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2- Piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-,-CH2-Piperazinylene-(CH2)5-, -(CH2)2-Piperazinylene-(CH2)1-, -(CH2)2-Piperazinylene-(CH2)2-, -(CH2)2-Piperazinylene-(CH2)3-, -(CH2)2-Piperazinylene-(CH2)4-, -(CH2)2-Piperazinylene-(CH2)5-, -(CH2)3-Piperazinylene-CH2-, -(CH2)3-Piperazinylene-(CH2)2-, -(CH2)3-Piperazinylene-(CH2)3-, -(CH2)3-Piperazinylene-(CH2)4-, -(CH2)3-Piperazinylene -(CH2)5-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, and -(CH2)8-piperazinylene-(CH2)5-;

[0194] Among them, each R La1 Each independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl, or isopropyl);

[0195] Each phenylene and thiazolylene group is independently optionally selected from deuterium, hydroxy, amino, mercapto, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3- 6-cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof;

[0196] The piperazinyl and piperidinyl groups are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0197] In some embodiments, examples of LIN include, but are not limited to, the following groups:

[0198] wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0199] In some embodiments of the present disclosure, R w express:

[0200] NR w1 R w2 、C(O)NR w3 R w4 、N(R w5 )C(O)R w6 、NHC(O)NR w7 R w8 , OR w9 SR w10 、S(O)2NR w11 R w12 、N(R w13 )S(O)2R w14 、S(O)2R w15 or an optionally substituted linear or branched alkyl group, wherein R w1 、R w2 、R w3 、R w7 、R w9 、R w10 and R w11 Each independently represents H, an optionally substituted linear or branched alkyl group (e.g., an optionally substituted linear or branched C 1-10 Alkyl, or optionally substituted linear or branched C 1-6 alkyl), -(CH2) m -cycloalkyl, -(CH2) m -aryl, -(CH2) m -heterocyclyl or -(CH2) m -heteroaryl, wherein R w4 、R w6 、R w8、R w12 、R w14 and R w15 Each independently represents an optionally substituted straight-chain or branched alkyl group (for example, an optionally substituted straight-chain or branched C 1-10 Alkyl, or optionally substituted linear or branched C 1-6 alkyl), -(CH2) m -cycloalkyl, -(CH2) m -aryl, -(CH2) m -heterocyclyl or -(CH2) m -heteroaryl, and wherein R w5 and R w13 Each independently represents H or an optionally substituted linear or branched alkyl group (e.g. an optionally substituted linear or branched C 1-10 Alkyl, or optionally substituted linear or branched C 1-6 alkyl), or wherein R w3 and R w4 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, or wherein R w11 and R w12 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, wherein each -(CH2) m -, cycloalkyl, aryl, heterocyclyl or heteroaryl are each independently optionally substituted, and m represents an integer of 0, 1 or 2.

[0201] In some embodiments of the present disclosure, examples of optionally substituted linear or branched alkyl groups include, but are not limited to, optionally substituted linear or branched C 1-10 Alkyl, and optionally substituted linear or branched C 1-6 In some embodiments of the present disclosure, the straight or branched alkyl group may be optionally substituted with one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) groups independently selected from halogen, amino, hydroxyl, thiol, cyano, oxo, nitro, and C 3-6 The cycloalkyl group is substituted with a substituent.

[0202] In some embodiments of the present disclosure, examples of optionally substituted linear or branched alkyl groups include, but are not limited to, CF2CF3, CF3, dicyclopropylmethyl, or cyclopropylethyl.

[0203] In some embodiments of the present disclosure, -(CH2) m Examples of -cycloalkyl groups include, but are not limited to, -(CH2) m -C 3-30 Cycloalkyl, such as -(CH2) m -C 3-20 Cycloalkyl, and -(CH2)m -C 3-15 Cycloalkyl, wherein each -(CH2) m - and cycloalkyl are each independently optionally substituted, and m represents an integer of 0, 1 or 2.

[0204] In some embodiments of the present disclosure, -(CH2) m Examples of -cycloalkyl groups include, but are not limited to, -(CH2) m -cyclopropyl, -(CH2) m -cyclobutyl, -(CH2) m -cyclopentyl, -(CH2) m -cyclopentenyl, -(CH2) m -cyclohexyl, -(CH2) m -cyclohexenyl, -(CH2) m -cycloheptyl, -(CH2) m -cyclooctyl, -(CH2) m -decalin, -(CH2) m -octahydropentadienyl, -(CH2) m -octahydro-1H-indenyl, -(CH2) m -spirocycloalkyl (e.g. -(CH2) m -C5-C 20 Spirocyclic groups, such as -(CH2) m -spiro[3.3]heptyl, -(CH2) m -spiro[2.5]octyl, -(CH2) m -spiro[3.5]nonyl, -(CH2) m -spiro[4.4]nonyl, -(CH2) m -spiro[4.5]decyl, -(CH2) m -spiro[5.5]undecyl), -(CH2) m -p-menthanyl, -(CH2) m -m-menthanyl, or -(CH2) m -bridged cycloalkyl (e.g. -(CH2) m -C6-C 20 Bridged ring groups, such as -(CH2) m -adamantyl, -(CH2) m -noradamantyl, -(CH2) m -bornyl, -(CH2) m -Norbornyl, -(CH2) m -bicyclo[2.2.1]heptyl, -(CH2) m -2-Oxobicyclo[2.2.1]heptyl or -(CH2) m-bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents, and m represents an integer of 0, 1 or 2.

[0205] In some embodiments of the present disclosure, -(CH2) m Examples of -aryl groups include, but are not limited to, -(CH2) m -C 5-30 Aryl, such as -(CH2) m -C 5-20 Aryl and -(CH2) m -C 5-15 Aryl, wherein each -(CH2) m - and aryl are each independently optionally substituted, and m represents an integer of 0, 1 or 2.

[0206] In some embodiments of the present disclosure, -(CH2) m Examples of -aryl groups include, but are not limited to, -(CH2) m -phenyl or -(CH2) m -naphthyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents, and m represents an integer of 0, 1 or 2.

[0207] In some embodiments of the present disclosure, -(CH2) m Examples of -heterocyclyl groups include, but are not limited to, -(CH2)m -4 to 30 membered heterocyclic group, for example -(CH2) m -4 to 20 membered heterocyclic group and -(CH2) m -4 to 15 membered heterocyclic group, wherein each -(CH2) m - and heterocyclyl are each independently optionally substituted, and m represents an integer of 0, 1 or 2.

[0208] In some embodiments of the present disclosure, -(CH2) m Examples of -heterocyclyl groups include, but are not limited to, -(CH2) m -azetidinyl, -(CH2) m -oxetanyl, -(CH2) m -pyrrolidinyl, -(CH2) m -imidazolidinyl, -(CH2) m -pyrazolidinyl, -(CH2) m -tetrahydrofuranyl, -(CH2) m -tetrahydropyranyl, -(CH2) m -tetrahydrothienyl, -(CH2) m -tetrahydrothiopyranyl, -(CH2) m -oxazolidinyl, -(CH2) m -thiazolidinyl, -(CH2) m -piperidinyl, -(CH2) m -piperazinyl, -(CH2) m -tetrahydropyridinyl, -(CH2) m -dihydroxypiperidinyl, -(CH2) m -difluoropiperidinyl, -(CH2) m -morpholinyl, -(CH2) m -thiomorpholinyl, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -dioxane, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -diazepanyl (e.g. -(CH2) m -1,4-diazepanyl, -(CH2) m -4,5-diazepanyl, -(CH2) m -1,3-diazepanyl), -(CH2) m -diazocanyl, -(CH2) m -bridged heterocyclic group (e.g. -(CH2) m-6 to 20 membered bridged heterocyclic group, such as -(CH2) m -6-azabicyclo[3.1.1]heptyl, -(CH2) m -2,5-diazabicyclo[2.2.1]heptyl, -(CH2) m -3,6-diazabicyclo[3.1.1]heptyl, -(CH2) m -3-azabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -2,5-diazabicyclo[2.2.2]octyl and -(CH2) m -quinuclidinyl), and -(CH2) m -azaspirocyclic group (e.g. -(CH2) m -5 to 20 membered azaspirocyclic group, such as -(CH2) m -2,6-diazaspiro[3.3]heptyl, -(CH2) m -2,7-diazaspiro[3.5]nonyl, -(CH2) m -2,8-diazaspiro[4.5]decyl, -(CH2) m -3,9-diazaspiro[5.5]undecyl, -(CH2) m -3-azaspiro[5.5]undecyl and -(CH2) m -7-azaspiro[3.5]nonyl), or -(CH2) m -octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents, and m represents an integer of 0, 1 or 2.

[0209] In some embodiments of the present disclosure, -(CH2) m Examples of -heteroaryl groups include, but are not limited to, -(CH2) m-5 to 30 membered heteroaryl, for example -(CH2) m -5 to 20 membered heteroaryl and -(CH2) m -5 to 15 membered heteroaryl, wherein each -(CH2) m - and heteroaryl are each independently optionally substituted, and m represents an integer of 0, 1 or 2.

[0210] In some embodiments of the present disclosure, -(CH2) m Examples of -heteroaryl groups include, but are not limited to, -(CH2) m -furyl, -(CH2) m -oxazolyl, -(CH2) m -isoxazolyl, -(CH2) m -oxadiazolyl, -(CH2) m -thienyl, -(CH2) m -thiazolyl, -(CH2) m -isothiazolyl, -(CH2) m -thiadiazolyl, -(CH2) m -pyrrolyl, -(CH2) m -imidazolyl, -(CH2) m -pyrazolyl, -(CH2) m -triazolyl, -(CH2) m -pyridyl, -(CH2) m -pyrimidinyl, -(CH2) m -pyridazinyl, -(CH2) m -pyrazinyl, -(CH2) m -triazine, -(CH2) m -indolyl, -(CH2) m -isoindolyl, -(CH2) m -indolinyl, -(CH2) m -Benzofuryl, -(CH2) m -chromanyl, -(CH2) m -isobenzofuranyl, -(CH2) m -Benzothienyl, -(CH2) m -indazolyl, -(CH2) m -benzimidazole, -(CH2) m -Benzoxazolyl, -(CH2) m -Benzisoxazolyl, -(CH2) m -Benzothiazolyl, -(CH2) m -Benzisothiazolyl, -(CH2) m -Benzotriazolyl, -(CH2) m-Benzo[2,1,3]oxadiazolyl, -(CH2) m -Benzo[2,1,3]thiadiazolyl, -(CH2) m -Benzo[1,2,3]thiadiazolyl, -(CH2) m -2-Oxo-2,3-dihydro-1H-benzo[d]imidazolyl, -(CH2) m -Benzo[b][1,4]oxazinyl, -(CH2) m -3,4-dihydro-2H-benzo[b][1,4]oxazinyl, -(CH2) m -quinolinyl, -(CH2) m -isoquinolinyl, -(CH2) m -1,2,3,4-tetrahydroquinolinyl, -(CH2) m -naphthyridinyl, -(CH2) m -cinnolinyl, -(CH2) m -quinazolinyl, -(CH2) m -quinoxalinyl, -(CH2) m -1,2,3,4-tetrahydroquinoxalinyl, -(CH2) m -phthalazinyl, -(CH2) m -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, -(CH2) m -4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, -(CH2) m -5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, -(CH2) m -thieno[2,3-d]pyrimidinyl, -(CH2) m -thieno[3,2-d]pyrimidinyl, -(CH2) m -isoxazolo[4,5-c]pyridinyl, -(CH2) m -isoxazolo[4,5-c]pyrimidinyl, -(CH2) m -isoxazolo[4,5-d]pyrimidinyl, -(CH2) m -pyrazolo[1,5-a]pyridinyl, -(CH2) m -pyrazolo[1,5-a]pyrimidinyl, -(CH2) m -imidazo[1,2-a]pyridinyl, -(CH2) m -1H-pyrrolo[3,2-b]pyridinyl, -(CH2) m -1H-pyrrolo[2,3-b]pyridinyl, -(CH2) m -pyrrolo[2,1-b]thiazolyl, -(CH2) m-imidazo[2,1-b]thiazolyl, -(CH2) m -5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or -(CH2) m -6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents, and m represents an integer of 0, 1 or 2.

[0211] In some embodiments of the present disclosure, examples of 4- to 20-membered nitrogen-containing heterocyclic groups include, but are not limited to, 4- to 15-membered nitrogen-containing heterocyclic groups, 5- to 20-membered nitrogen-containing heterocyclic groups, and 5- to 15-membered nitrogen-containing heterocyclic groups. In some embodiments of the present disclosure, 4- to 20-membered nitrogen-containing heterocyclic groups are optionally substituted.

[0212] In some embodiments of the present disclosure, examples of 4- to 20-membered nitrogen-containing heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazacycloheptyl, diazacyclooctanyl, nitrogen-bridged heterocyclic groups (e.g., 6- to 20-membered nitrogen-bridged heterocyclic groups, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.2]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1 .1]heptyl, 3-azabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), or a nitrogen-containing spiroheterocyclic group (e.g., a 5- to 20-membered nitrogen-containing spiroheterocyclic group, such as a 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro [4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0213] In some embodiments of the present disclosure, R w1 、R w2 、R w3 、R w7 、R w9 、R w10 and R w11 Each independently represents: H;

[0214] Optionally substituted linear or branched C 1-10 Alkyl (e.g., optionally substituted with one or more (e.g., 1-10, 1-6, 1-4,

[0215] 2-6 or 1) are each independently selected from halogen, amino, hydroxy, mercapto, cyano, oxo, nitro and C 3-6 The cycloalkyl substituents are linear or branched C 1-10 alkyl);

[0216] -(CH2) m -cyclopropyl, -(CH2) m -cyclobutyl, -(CH2) m -cyclopentyl, -(CH2) m -cyclopentenyl, -(CH2) m -cyclohexyl, -(CH2) m -cyclohexenyl, -(CH2) m -cycloheptyl, -(CH2) m -cyclooctyl, -(CH2) m -decalin, -(CH2) m -octahydropentadienyl, -(CH2) m -octahydro-1H-indenyl, -(CH2) m -spirocycloalkyl (e.g. -(CH2) m -C5-C 20 Spirocyclic groups, such as -(CH2) m -spiro[3.3]heptyl, -(CH2) m -spiro[2.5]octyl, -(CH2) m -spiro[3.5]nonyl, -(CH2) m -spiro[4.4]nonyl, -(CH2) m -spiro[4.5]decyl, -(CH2) m -spiro[5.5]undecyl), -(CH2) m -p-menthanyl, -(CH2) m -m-menthanyl, or -(CH2) m -bridged cycloalkyl (e.g. -(CH2) m -C6-C 20 Bridged ring groups, such as -(CH2) m -adamantyl, -(CH2) m -noradamantyl, -(CH2) m -bornyl, -(CH2) m -Norbornyl, -(CH2) m -bicyclo[2.2.1]heptyl, -(CH2) m -2-Oxobicyclo[2.2.1]heptyl or -(CH2) m-bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C2-6 alkynyl and any combination thereof;

[0217] -(CH2) m -azetidinyl, -(CH2) m -oxetanyl, -(CH2) m -pyrrolidinyl, -(CH2) m -imidazolidinyl, -(CH2) m -pyrazolidinyl, -(CH2) m -tetrahydrofuranyl, -(CH2) m -tetrahydropyranyl, -(CH2) m -tetrahydrothienyl, -(CH2) m -tetrahydrothiopyranyl, -(CH2) m -oxazolidinyl, -(CH2) m -thiazolidinyl, -(CH2) m -piperidinyl, -(CH2) m -piperazinyl, -(CH2) m -tetrahydropyridinyl, -(CH2) m -dihydroxypiperidinyl, -(CH2) m -difluoropiperidinyl, -(CH2) m -morpholinyl, -(CH2) m -thiomorpholinyl, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -dioxane, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -diazepanyl (e.g. -(CH2) m -1,4-diazepanyl, -(CH2) m -4,5-diazepanyl, -(CH2) m-1,3-diazepanyl), -(CH2) m -diazocanyl, -(CH2) m -bridged heterocyclic group (e.g. -(CH2) m -6 to 20 membered bridged heterocyclic group, such as -(CH2) m -6-azabicyclo[3.1.1]heptyl, -(CH2) m -2,5-diazabicyclo[2.2.1]heptyl, -(CH2) m -3,6-diazabicyclo[3.1.1]heptyl, -(CH2) m -3-azabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -2,5-diazabicyclo[2.2.2]octyl and -(CH2) m -quinuclidinyl), and -(CH2) m -azaspirocyclic group (e.g. -(CH2) m -5 to 20 membered azaspirocyclic group, such as -(CH2) m -2,6-diazaspiro[3.3]heptyl, -(CH2) m -2,7-diazaspiro[3.5]nonyl, -(CH2) m -2,8-diazaspiro[4.5]decyl, -(CH2) m -3,9-diazaspiro[5.5]undecyl, -(CH2) m -3-azaspiro[5.5]undecyl and -(CH2) m -7-azaspiro[3.5]nonyl), or -(CH2) m -octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof;

[0218] -(CH2) m -phenyl or -(CH2) m -naphthyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or

[0219] -(CH2) m -furyl, -(CH2) m -oxazolyl, -(CH2) m -isoxazolyl, -(CH2) m -oxadiazolyl, -(CH2) m -thienyl, -(CH2) m -thiazolyl, -(CH2) m -isothiazolyl, -(CH2) m -thiadiazolyl, -(CH2) m -pyrrolyl, -(CH2) m -imidazolyl, -(CH2) m -pyrazolyl, -(CH2) m -triazolyl, -(CH2) m -pyridyl, -(CH2) m -pyrimidinyl, -(CH2) m -pyridazinyl, -(CH2) m -pyrazinyl, -(CH2) m -triazine, -(CH2) m -indolyl, -(CH2) m -isoindolyl, -(CH2) m -indolinyl, -(CH2) m -Benzofuryl, -(CH2) m -chromanyl, -(CH2) m -isobenzofuranyl, -(CH2) m -Benzothienyl, -(CH2) m -indazolyl, -(CH2) m -benzimidazole, -(CH2)m -Benzoxazolyl, -(CH2) m -Benzisoxazolyl, -(CH2) m -Benzothiazolyl, -(CH2) m -Benzisothiazolyl, -(CH2) m -Benzotriazolyl, -(CH2) m -Benzo[2,1,3]oxadiazolyl, -(CH2) m -Benzo[2,1,3]thiadiazolyl, -(CH2) m -Benzo[1,2,3]thiadiazolyl, -(CH2) m -2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, -(CH2) m -Benzo[b][1,4]oxazinyl, -(CH2) m -3,4-dihydro-2H-benzo[b][1,4]oxazinyl, -(CH2) m -quinolinyl, -(CH2) m -isoquinolinyl, -(CH2) m -1,2,3,4-tetrahydroquinolinyl, -(CH2) m -naphthyridinyl, -(CH2) m -cinnolinyl, -(CH2) m -quinazolinyl, -(CH2) m -quinoxalinyl, -(CH2) m -1,2,3,4-tetrahydroquinoxalinyl, -(CH2) m -phthalazinyl, -(CH2) m -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, -(CH2) m -4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, -(CH2) m -5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, -(CH2) m -thieno[2,3-d]pyrimidinyl, -(CH2) m -thieno[3,2-d]pyrimidinyl, -(CH2) m -isoxazolo[4,5-c]pyridinyl, -(CH2) m -isoxazolo[4,5-c]pyrimidinyl, -(CH2) m -isoxazolo[4,5-d]pyrimidinyl, -(CH2) m -pyrazolo[1,5-a]pyridinyl, -(CH2) m -pyrazolo[1,5-a]pyrimidinyl, -(CH2) m-imidazo[1,2-a]pyridinyl, -(CH2) m -1H-pyrrolo[3,2-b]pyridinyl, -(CH2) m -1H-pyrrolo[2,3-b]pyridinyl, -(CH2) m -pyrrolo[2,1-b]thiazolyl, -(CH2) m -imidazo[2,1-b]thiazolyl, -(CH2) m -5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or -(CH2) m -6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1- 6-alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0220] In some embodiments of the present disclosure, R w4 、R w6 、R w8 、R w12 、R w14 and R w15 Each independently represents:

[0221] Optionally substituted linear or branched C 1-10 Alkyl (e.g., optionally substituted with one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) groups each independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, nitro and C 3-6 The cycloalkyl substituents are linear or branched C 1-10 alkyl);

[0222] -(CH2) m -cyclopropyl, -(CH2) m -cyclobutyl, -(CH2) m -cyclopentyl, -(CH2) m -cyclopentenyl, -(CH2) m -cyclohexyl, -(CH2) m-cyclohexenyl, -(CH2) m -cycloheptyl, -(CH2) m -cyclooctyl, -(CH2) m -decalin, -(CH2) m -octahydropentadienyl, -(CH2) m -octahydro-1H-indenyl, -(CH2) m -spirocycloalkyl (e.g. -(CH2) m -C5-C 20 Spirocyclic groups, such as -(CH2) m -spiro[3.3]heptyl, -(CH2) m -spiro[2.5]octyl, -(CH2) m -spiro[3.5]nonyl, -(CH2) m -spiro[4.4]nonyl, -(CH2) m -spiro[4.5]decyl, -(CH2) m -spiro[5.5]undecyl), -(CH2) m -p-menthanyl, -(CH2) m -m-menthanyl, or -(CH2) m -bridged cycloalkyl (e.g. -(CH2) m -C6-C 20 Bridged ring groups, such as -(CH2) m -adamantyl, -(CH2) m -noradamantyl, -(CH2) m -bornyl, -(CH2) m -Norbornyl, -(CH2) m -bicyclo[2.2.1]heptyl, -(CH2) m -2-Oxobicyclo[2.2.1]heptyl or -(CH2) m -bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof;

[0223] -(CH2) m -azetidinyl, -(CH2) m -oxetanyl, -(CH2) m -pyrrolidinyl, -(CH2) m -imidazolidinyl, -(CH2) m -pyrazolidinyl, -(CH2) m -tetrahydrofuranyl, -(CH2) m -tetrahydropyranyl, -(CH2) m -tetrahydrothienyl, -(CH2) m -tetrahydrothiopyranyl, -(CH2) m -oxazolidinyl, -(CH2) m -thiazolidinyl, -(CH2) m -piperidinyl, -(CH2) m -piperazinyl, -(CH2) m -tetrahydropyridinyl, -(CH2) m -dihydroxypiperidinyl, -(CH2) m -difluoropiperidinyl, -(CH2) m -morpholinyl, -(CH2) m -thiomorpholinyl, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -dioxane, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -diazepanyl (e.g. -(CH2) m -1,4-diazepanyl, -(CH2) m -4,5-diazepanyl, -(CH2) m -1,3-diazepanyl), -(CH2) m -diazocanyl, -(CH2) m -bridged heterocyclic group (e.g. -(CH2) m -6 to 20 membered bridged heterocyclic group, such as -(CH2) m -6-azabicyclo[3.1.1]heptyl, -(CH2) m -2,5-diazabicyclo[2.2.1]heptyl, -(CH2) m -3,6-diazabicyclo[3.1.1]heptyl, -(CH2) m -3-azabicyclo[3.2.1]octyl, -(CH2) m-3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -2,5-diazabicyclo[2.2.2]octyl and -(CH2) m -quinuclidinyl), and -(CH2) m -azaspirocyclic group (e.g. -(CH2) m -5 to 20 membered azaspirocyclic group, such as -(CH2) m -2,6-diazaspiro[3.3]heptyl, -(CH2) m -2,7-diazaspiro[3.5]nonyl, -(CH2) m -2,8-diazaspiro[4.5]decyl, -(CH2) m -3,9-diazaspiro[5.5]undecyl, -(CH2) m -3-azaspiro[5.5]undecyl and -(CH2) m -7-azaspiro[3.5]nonyl), or -(CH2) m -octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof;

[0224] -(CH2) m -phenyl or -(CH2) m -naphthyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C2-6 Alkynyl and any combination thereof; or

[0225] -(CH2) m -furyl, -(CH2) m -oxazolyl, -(CH2) m -isoxazolyl, -(CH2) m -oxadiazolyl, -(CH2) m -thienyl, -(CH2) m -thiazolyl, -(CH2) m -isothiazolyl, -(CH2) m -thiadiazolyl, -(CH2) m -pyrrolyl, -(CH2) m -imidazolyl, -(CH2) m -pyrazolyl, -(CH2) m -triazolyl, -(CH2) m -pyridyl, -(CH2) m -pyrimidinyl, -(CH2) m -pyridazinyl, pyrazinyl, triazinyl, -(CH2) m -indolyl, -(CH2) m -isoindolyl, -(CH2) m -indolinyl, -(CH2) m -Benzofuryl, -(CH2) m -chromanyl, -(CH2) m -isobenzofuranyl, -(CH2) m -Benzothienyl, -(CH2) m -indazolyl, -(CH2) m -benzimidazole, -(CH2) m -Benzoxazolyl, -(CH2) m -Benzisoxazolyl, -(CH2) m -Benzothiazolyl, -(CH2) m -Benzisothiazolyl, -(CH2) m -Benzotriazolyl, -(CH2) m -Benzo[2,1,3]oxadiazolyl, -(CH2) m -Benzo[2,1,3]thiadiazolyl, -(CH2) m -Benzo[1,2,3]thiadiazolyl, -(CH2) m -2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, -(CH2) m -Benzo[b][1,4]oxazinyl, -(CH2) m-3,4-dihydro-2H-benzo[b][1,4]oxazinyl, -(CH2) m -quinolinyl, -(CH2) m -isoquinolinyl, -(CH2) m -1,2,3,4-tetrahydroquinolinyl, -(CH2) m -naphthyridinyl, -(CH2) m -cinnolinyl, -(CH2) m -quinazolinyl, -(CH2) m -quinoxalinyl, -(CH2) m -1,2,3,4-tetrahydroquinoxalinyl, -(CH2) m -phthalazinyl, -(CH2) m -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, -(CH2) m -4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, -(CH2) m -5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, -(CH2) m -thieno[2,3-d]pyrimidinyl, -(CH2) m -thieno[3,2-d]pyrimidinyl, -(CH2) m -isoxazolo[4,5-c]pyridinyl, -(CH2) m -isoxazolo[4,5-c]pyrimidinyl, -(CH2) m -isoxazolo[4,5-d]pyrimidinyl, -(CH2) m -pyrazolo[1,5-a]pyridinyl, -(CH2) m -pyrazolo[1,5-a]pyrimidinyl, -(CH2) m -imidazo[1,2-a]pyridinyl, -(CH2) m -1H-pyrrolo[3,2-b]pyridinyl, -(CH2) m -1H-pyrrolo[2,3-b]pyridinyl, -(CH2) m -pyrrolo[2,1-b]thiazolyl, -(CH2) m -imidazo[2,1-b]thiazolyl, -(CH2) m -5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or -(CH2) m -6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6-alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted

[0226] In some embodiments of the present disclosure, R w represents C(O)NR w3 R w4 , where R w3 and R w4 Together with the nitrogen atoms to which they are attached, they form:

[0227] azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazacycloheptyl, diazacyclooctanyl, nitrogen-bridged heterocyclic groups (e.g., 6- to 20-membered nitrogen-bridged heterocyclic groups, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.2]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2 .1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), or a nitrogen-containing spiroheterocyclyl (e.g., a 5- to 20-membered nitrogen-containing spiroheterocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or an octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1- 6 alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0228] In some embodiments of the present disclosure, R w Represents S(O)2NR w11 R w12 , where R w11 and R w12 Together with the nitrogen atoms to which they are attached, they form:

[0229] azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazacycloheptyl, diazacyclooctanyl, nitrogen-bridged heterocyclic groups (e.g., 6- to 20-membered nitrogen-bridged heterocyclic groups, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.2]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2 .1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), or a nitrogen-containing spiroheterocyclyl (e.g., a 5- to 20-membered nitrogen-containing spiroheterocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or an octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1- 6 alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0230] In some embodiments of the present disclosure, R w express:

[0231] Ring A 4 represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, (R d1 ) n1 Represents Ring A 4 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20;

[0232] R e represents C(O)NH or NHC(O), or R e represents a key; and

[0233] Ring A 5 represents a heterocyclic group, a cycloalkyl group, an aryl group or a heteroaryl group, m1 represents an integer of 0 or 1, (R d2 ) n2 Represents Ring A 5 Optionally n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer of 0-20.

[0234] In some embodiments of the present disclosure, Ring A 4represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), C 3-30 Cycloalkylene (e.g. C 3-20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 In some embodiments, ring A 4 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), hydroxy-substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy or C 1-3 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy or halogenated C 1-3 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, oxo, nitro, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl (e.g., ethynyl) or C2-6 an alkenyl group (e.g., a vinyl group), and n1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0235] In some embodiments of the present disclosure, Ring A 4 Indicates C 3-30 Cycloalkylene (e.g. C 3-20 Cycloalkylene, or C 3-15 In some embodiments, C 3-30 Examples of cycloalkylene include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, spirocycloalkylene (e.g., C5-C 20 Spirocycloalkylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, spiro[5.5]undecanylene), p-menthanylene, m-menthanylene, or bridged cycloalkylene (e.g., C6-C 20 In some embodiments, the C3-30 cycloalkylene group is optionally substituted by one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl, C 2-6 The alkenyl group and any combination thereof are substituted with substituents.

[0236] In some embodiments of the present disclosure, Ring A 4represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group). In some embodiments, examples of 4- to 30-membered heterocyclylene groups include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, tetrahydropyridinylene, dihydroxypiperidinylene, difluoropiperidinylene, morpholinylene, thiopyranylene, morpholinyl, azepanyl, azepanyl, dioxanyl, azepanyl, azepanyl, diazepanyl, diazepanylidene (e.g., 1,4-diazepanylidene, 4,5-diazepanylidene, 1,3-diazepanylidene), diazepanylidene, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptane subunit, 2,5-diazabicyclo[2.2.1]heptane subunit, 3,6-diazabicyclo[3.1.1]heptane subunit, 3-azabicyclo[3.2.1]octanyl subunit, 3,8-diazabicyclo[3.2.1]octanyl subunit, 3,8-diazabicyclo[3.2.1]octanyl subunit, 2,5-diazabicyclo[2.2.2]octanyl subunit and quinuclidinyl subunit), azaspirocyclic subunit (e.g., 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecanyl, 3-azaspiro[5.5]undecanyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrroleyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl, C 2-6 The alkenyl group and any combination thereof are substituted with substituents.

[0237] In some embodiments of the present disclosure, Ring A 4 Indicates C 5-30 Arylene (e.g. C 5-20Arylene, or C 5-15 In some embodiments, C 5-30 Examples of arylene groups include, but are not limited to, phenylene or naphthylene. 5-30 The arylene group may be optionally substituted with one or more (eg, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, C 1- 6-alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl, C 2-6 The alkenyl group and any combination thereof are substituted with substituents.

[0238] In some embodiments of the present disclosure, Ring A 4represents a 5- to 30-membered heteroarylene group (e.g., a 5- to 20-membered heteroarylene group, or a 5- to 15-membered heteroarylene group). In some embodiments, examples of 5- to 30-membered heteroarylene groups include, but are not limited to, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, triazinylene, indolylene, isoindolylene, indolinylene, benzofuranylene, chromanylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, Benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolylene, benzo[b][1,4]oxazinylene, 3,4-dihydro-2H-benzo[b][1,4]oxazinylene, quinolinylene yl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinylidene, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydro Thieno[3,2-d]pyrimidine subunit, thieno[2,3-d]pyrimidine subunit, thieno[3,2-d]pyrimidine subunit, isoxazolo[4,5-c]pyrimidine subunit, isoxazolo[4,5-c]pyrimidine subunit, isoxazolo[4,5-d]pyrimidine subunit, pyrazolo[1,5-a]pyrimidine subunit, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridine In some embodiments, the 5- to 30-membered heteroarylene group is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl, C 2-6 The alkenyl group and any combination thereof are substituted with substituents.

[0239] In some embodiments of the present disclosure, Ring A 5 represents a 4- to 30-membered heterocyclic group (e.g., a 4- to 20-membered heterocyclic group, or a 4- to 15-membered heterocyclic group), C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkyl, or C 3-15 Cycloalkyl), C 5-30 Aryl (e.g. C 5-20 Aryl, or C 5-15 In some embodiments, m1 represents an integer of 0 or 1. In some embodiments, (R d2 ) n2 Represents Ring A 5 Optionally n2 R d2 Group substitution, each R d2 Deuterium, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), hydroxy-substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy or C 1-3 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy or halogenated C 1-3 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, oxo, nitro, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl (e.g., ethynyl) or C 2-6 an alkenyl group (e.g., a vinyl group), and n2 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0240] In some embodiments of the present disclosure, Ring A 5 Indicates C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkyl, or C 3-15 In some embodiments, C 3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl2-4 Alkenyl, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0241] In some embodiments of the present disclosure, Ring A 5 represents a 4- to 30-membered heterocyclic group (e.g., a 4- to 20-membered heterocyclic group, or a 4- to 15-membered heterocyclic group). In some embodiments, examples of 4- to 30-membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazacyclooctanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[3.1.1]heptanyl, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1- 6 alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0242] In some embodiments of the present disclosure, Ring A 5 Indicates C5- 30 Aryl (e.g. C 5-20 Aryl, or C 5-15 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30 The aryl group may be optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0243] In some embodiments of the present disclosure, Ring A 5represents a 5- to 30-membered heteroaryl group (e.g., a 5- to 20-membered heteroaryl group, or a 5- to 15-membered heteroaryl group). In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole [1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl group is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 alkyl)phosphono, C 1-6 Alkylsulfonyloxy, C1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0244] In some embodiments of the present disclosure, R e represents C(O)NH or NHC(O). In some embodiments, R e Indicates a key.

[0245] In some embodiments of the present disclosure, R e represents a key, and m1 represents an integer 0, R w express:

[0246] Ring A 4 and (R d1 ) n1 As defined herein for the compounds of formula (I) and embodiments thereof.

[0247] In some embodiments of the present disclosure, R w Examples include, but are not limited to:

[0248] Piperidine-1-carbonyl, N,N-diisopropylcarbamoyl, NHC(O)CH3, OH, adamantyl-O-, norbornyl-O-, 1,7,7-trimethyl-bicyclo[2.2.1]heptanyl-O-, 2-isopropyl-5-methylcyclohexyl-O-, SH, adamantyl-NHC(O)-, 3,5-dimethyladamantan-1-yl-NHC(O)-, cyclopropyl, cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptan-2-yl, adamantyl, 2,3-dihydro-1H-indenyl, 4-cyano-2,3-dihydro-1H-indenyl, 3,5-dimethyladamantan-1-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, Phenyl, 4-fluorophenyl, 4-chlorophenyl, 3,5-difluorophenyl, 4-(bromomethyl)-2-fluorophenyl, 3,4,5-trifluorophenyl, (2-bromovinyl)phenyl, morpholinyl, piperidinyl, 2-oxopiperidin-1-yl, piperazinyl, N-methylpiperazinyl, 4-(methylsulfonyl)piperazin-1-yl, 4-(ethylsulfonyl)piperazin-1-yl, 3,5-dimethylpiperazinyl, 1,4-diazepan-1-yl, 4-methyl-1,4-diazepan-1-yl, 1-methyl-1,4-diazepan-1-yl, 8-methyl-3,8-diazabicyclo[3.2.1]octane-3 -yl, 1,4-diazabicyclo[3.2.1]octan-4-yl, 5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl, 8,8-difluoro-2-azabicyclo[3.2.1]octan-2-yl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 3-fluoro-4-hydroxypyrrolidin-1-yl, 3-methyl-4-(trifluoromethyl)pyrrolidin-1-yl, 2,6-dioxopiperidin-3-yl, 4,4-dimethylpiperidin-1-yl, 3,5-dimethylpiperidin-1-yl, 4,4-difluoropiperidin-2-yl, 4-methylpiperazin-1-yl, tetrahydro-2H-pyran-2 -yl, pyrrolidinyl, 3-cyanoazetidinyl, 3-hydroxyazetidinyl, 3-hydroxy-3-methylazetidinyl, 3-hydroxy-2-methylazetidin-1-yl, 3-(trifluoromethoxy)azetidin-1-yl, azepan-1-yl, azocan-1-yl, 7-fluoro-5-azaspiro[2.4]heptane-5-yl, 1,1-difluoro-5-azaspiro[2.4]heptane-5-yl, 1,1-difluoro-6-azaspiro[2.5]octan-6-yl, 6-azaspiro[2.5]octan-6-yl, 2-oxa-7-azaspiro[3.5]nonane-7-yl, 3-azabicyclo [3.1.0]hexan-3-yl, 6-(difluoromethyl)-3-azabicyclo[4.1.0]heptan-3-yl, pyridinyl, pyrimidinyl, thiazolyl, quinolinyl, 6,7-difluoroquinazolin-4-yl, 3-cyano-quinolinyl, indolyl, isoindol-2-yl, 1-methyl-1H-indol-7-yl, benzothienyl, benzofuranyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, 3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl, 3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl, or thiomorpholino;

[0249] In some embodiments, R w Indicates NR w1 R w2 ,in

[0250] R w1represents H, methyl, ethyl, isopropyl, cyclohexyl or phenyl, and

[0251] R w2 represents methyl, ethyl, isopropyl, tert-butyl, 2,4-dimethylpentan-3-yl, dicyclopropylmethyl, 1-cyclopropylethyl, 2,6-dichloro-3-fluorophenylethyl, 2,4-dimethylpentan-3-yl, pyrimidinyl, pyridinyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, indolyl, 1-methyl-1H-indol-7-yl, benzothienyl, benzofuranyl, 3-cyano-quinolin-4-yl, quinolyl, thiazolyl, oxazolyl, 2,3-dihydro-1H-indenyl , 5-methyloxazol-2-yl, 4-cyano-2,3-dihydro-1H-inden-1-yl, phenyl, 3-chloro-4-methylphenyl, 4-fluorophenyl, 3,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-(dimethylphosphonyl)phenyl, 2-(isopropylsulfonyl)phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, dimethylcyclohexyl, 4,4-dimethylcyclohexyl, adamantyl, 3,5-dimethyladamantyl, 3-hydroxyadamantyl, 3-chloroadamantane-1-yl , 4-chloroadamantan-1-yl, 2-chloroadamantan-1-yl, spiro[5.5]undecane-3-yl, spiro[3.3]heptyl, noradamantanyl, norbornyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.2]octyl, 4,4-dimethylcyclohexyl, 1,7,7-trimethylbicyclo[2.2.1]heptyl, 7,7-dimethylbicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptyl, 2-methoxycyclopropyl, 3-fluorocyclobutyl, 3,3 -difluorocyclobutyl, 3,3-difluorocyclopentyl, 3-hydroxycyclohexyl, 3-cyano-bicyclo[1.1.1]pentan-1-yl, bicyclo[2.2.2]octan-1-yl, 4-hydroxybicyclo[2.2.2]octan-1-yl, 2-isopropyl-5-methylcyclohexyl, quinuclidin-3-yl, 7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl, hexahydro-2,5-methanopental-3a(1H)-yl, bicyclo[2.2.1]heptan-1-yl, pyrrolidinyl, azepanyl, azocanyl, piperidinyl, dimethylpiperidinyl, oxetanyl or quinuclidinyl.

[0252] In some embodiments, R w NHC(O)NR w7 R w8 , where R w7 represents H, and R w8 represents an adamantyl group, a 3,5-dimethyladamantan-1-yl group, a phenyl group, or a 3-chloro-4-methylphenyl group.

[0253] In some embodiments, R wrepresents optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6 or 1) groups independently selected from halogen, amino, hydroxy, thiol, cyano, oxo, nitro and C 3-6 The cycloalkyl substituents are linear or branched C 1-10 alkyl.

[0254] In some embodiments, R w Examples include, but are not limited to:

[0255] CF2CF3, CF3, dicyclopropylmethyl, cyclopropylethyl, NHCH3, N(CH3)2, N(CH2CH3)2, N(CH(CH3)2)2,

[0256] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (IA):

[0257] wherein Ring B represents an optionally substituted benzene ring, Ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring, and Ring D represents an optionally substituted C 5-10 Aromatic ring, and group R a1 、R a2 、R a3 、R a4 、R x , LIN and R w As defined above for compounds of formula (I) and embodiments thereof. Ring B, Ring C and Ring D are also as defined above for the embodiments of compounds of formula (I) in which both Ring C and Ring D are present.

[0258] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (IA-1):

[0259] wherein Ring B and Ring D each independently represent an optionally substituted benzene ring, Ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring, and the group R a1 、R a2 、R a3 、R a4 、R x , LIN and R w As defined above for compounds of formula (I) and embodiments thereof. Ring B, Ring C and Ring D are also as defined above for the embodiments of compounds of formula (I) in which both Ring C and Ring D are present.

[0260] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (IB):

[0261] wherein ring C represents an optionally substituted 4- to 16-membered heteroaromatic ring or an optionally substituted 4- to 16-membered heterocyclic ring, and ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring, i.e. W represents C or N, and the group R a1 、R a2 、R a3 、R a4 、R x , LIN and R w As defined above for the compounds of formula (I) and the embodiments thereof. Ring B and Ring C are also as defined above for the compounds of formula (I) in which Ring A represents a bicyclic divalent group.

[0262] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (IC):

[0263] wherein the phenylene group in the formula (IC) is optionally further substituted by 1, 2, 3 or 4 identical or different groups independently selected from deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Substituents of the alkynyl group, and the group R a1 、R a2 、R a3 、R a4 、R x , LIN and R w As defined above for the compounds of formula (I) and its embodiments.

[0264] In some embodiments of the present disclosure, the compound of formula (I) is also of the structure of the following formula:

[0265] Among them, (R d ) n represents n substituents R d , wherein n represents an integer of 0, 1, 2 or 3, each substituent R dThe same or different and each independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl, and R a1 、R a2 、R a3 、R a4 、R x , LIN and R w As defined above for the compounds of formula (I) and its embodiments.

[0266] Particularly preferred are the compounds of the present invention in Table 1 and their salts (especially pharmaceutically acceptable salts, such as their hydrochlorides), enantiomers, diastereomers, solvates, or polymorphs:

[0267] Table 1 Compounds of the present invention

[0268] II. Other Forms of the Compound (including Salts, Enantiomers, Stereoisomers, Solvates, Isotopically Enriched Analogs, Prodrugs, or Polymorphs of the Compound)

[0269] The compounds of the present disclosure have the structure of any one of Formula (I), (IA), (IA-1), (IB), (IC), (IA-11), (IA-12), (IB-11), (IB-12), (IB-13), (IB-14), (IB-15), (IB-16), (IC-11), (IC-12), or (IC-13). Unless otherwise indicated, reference to the compounds of the present disclosure refers to compounds including any one of Formula (I), (IA), (IA-1), (IB), (IC), (IA-11), (IA-12), (IB-11), (IB-12), (IB-13), (IB-14), (IB-15), (IB-16), (IC-11), (IC-12), or (IC-13), as well as specific compounds that fall within the scope of these general formulas.

[0270] It will be appreciated that the compounds of the present disclosure (including compounds of Formula (I)-7, (IA)-8, (IA-1), (IB)-9, (IC)-11, (IA-12), (IB-11), (IB-12), (IB-13), (IB-14), (IB-15), (IB-16), (IC-11), (IC-12), or (IC-13)) may have stereo configurations and, therefore, may exist as more than one stereoisomer. The present disclosure also relates to compounds having stereo configurations that are optically enriched, such as about greater than 90% ee, such as about 95% ee or 97% ee, or greater than 99% ee, and mixtures thereof, including racemic mixtures. As used herein, "optically enriched" means that a mixture of enantiomers is composed of a significantly greater proportion of one enantiomer and can be described by enantiomeric excess (ee%). Purification of isomers and separation of isomeric mixtures can be achieved by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, asymmetric synthesis (e.g., by using chiral intermediates) and / or chiral resolution, etc.).

[0271] In some embodiments, polymorphic forms of compounds of the present disclosure or salts of compounds of the present disclosure are also provided. The salts of compounds of the present disclosure can be pharmaceutically acceptable salts, including but not limited to hydrohalides (including hydrochlorides, hydrobromides), sulfates, maleates, sulfonates, citrates / citrate, lactates, lactobionates, L-tartrates, fumarates, L-malates, L-lactates, α-ketoglutarate, hippurates, D-glucuronates, D-gluconates, α-D-glucoheptonates, glycolates, mucates, L-ascorbic acid salts, orotates, picrates, glycinates, alanine salts, arginine salts, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2-dichloroacetate, trimethylacetate, propionate, pentanoate, thiazolinone ... The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. In some embodiments, the compounds of the present disclosure can be prepared as prodrugs or prodrugs. Prodrugs can be converted into parent drugs in the body and exert their effects. In some embodiments, isotope-labeled compounds of the present disclosure are also provided. Examples of isotopes include deuterium (D or 2 H).

[0272] III. Pharmaceutical Compositions / Formulations

[0273] In some embodiments, the present disclosure provides a pharmaceutical composition comprising as an active ingredient a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof, and at least one pharmaceutically acceptable carrier.

[0274] In some embodiments, pharmaceutically acceptable carriers include, but are not limited to, fillers, stabilizers, dispersants, suspending agents, diluents, excipients, thickeners, colorants, solvents, or encapsulating materials. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compounds useful in the present disclosure) and is not harmful to the patient. Some examples of materials that are pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline surfactants; polyoxyethylene, polyvinyl pyrrolidone, polyacrylamide, poloxamer; and other nontoxic compatible substances used in pharmaceutical formulations.

[0275] The pharmaceutical composition of the present disclosure further includes at least one second therapeutic agent, such as an anticancer agent. The second therapeutic agent can be combined with the compound of formula (I) described herein to treat the disease or condition described herein. The second therapeutic agent includes, but is not limited to, a chemotherapeutic agent, an immunotherapeutic agent, a gene therapy agent, and the like.

[0276] The pharmaceutical composition of the present disclosure comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared into a suitable dosage form according to a suitable administration route (including but not limited to nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration and intravenous administration), such as spray preparations, patches, tablets (such as conventional tablets, dispersible tablets, orally disintegrating tablets), capsules (such as soft capsules, hard capsules, enteric-coated capsules), dragees, lozenges, powders, granules, powder injections, suppositories, or liquid preparations (such as suspensions (such as aqueous or oily suspensions), solutions, emulsions or syrups), or conventional injection forms such as injectable solutions (such as sterile injection solutions prepared according to methods known in the art using water, Ringer's solution or isotonic sodium chloride solution as a carrier or solvent) or lyophilized compositions. Those skilled in the art can also prepare the compound of formula (I) into conventional, dispersible, chewable, orally rapidly disintegrating or rapidly dissolving preparations, or sustained-release capsules or controlled-release capsules as needed.

[0277] As the active ingredient, the compound of formula (I) as described in the present disclosure is contained in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to the subject a therapeutically effective amount for the indication to be treated without causing serious toxic effects in the treated subject. The dosage of the active compound for all diseases or conditions mentioned herein is, for example, from about 5 ng / kg subject weight / day to 500 mg / kg subject weight / day, from about 10 ng / kg subject weight / day to 300 mg / kg subject weight / day, for example, from 0.1 to 100 mg / kg subject weight / day, or from 0.5 to about 25 mg / kg subject weight / day.

[0278] The compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure can be conveniently administered in any suitable dosage form, and the specifications of the suitable dosage form include but are not limited to less than 1 mg, 1 mg to 3000 mg, 5 mg to 1000 mg, for example, 5 to 500 mg, 25 to 250 mg of active ingredient per unit dosage form.

[0279] IV.Kits / Packaging Products

[0280] The compound of formula (I) described in the present disclosure, or its pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers, is used as a medicament. The medicament of the present disclosure or the pharmaceutical composition of the present disclosure may be present in a medicine box / packaged product. The medicine box / packaged product may include packaging or container. The packaging or container includes but is not limited to ampoules, blister packs, pharmaceutical plastic bottles, vials, pharmaceutical glass bottles, containers, syringes, laminated flexible packaging, co-extruded film infusion containers, test tubes and dispensing devices, etc. The medicine box / packaged product may include product instructions for use.

[0281] V. Treatment Methods and Uses

[0282] The compounds of formula (I) described in the present disclosure, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof, can also be used as medicaments. In particular, the compounds of formula (I) described in the present disclosure, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof can be used to prepare drugs for preventing and / or treating diseases or conditions. The diseases or conditions include diseases or conditions associated with cereblon protein. In some embodiments, the diseases or conditions include: tumors or cancers, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes. In some embodiments, the disease or condition includes, but is not limited to: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute myeloid leukemia (AML), monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, C D20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory Treatment options include: primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; glioblastoma; astrocytoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and Cowden's disease; pancreatic cancer; central nervous system cancers; and neuroblastoma.Glioma; peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; Richter syndrome (Richter syndrome) sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, and bronchitis; cerebral malaria; infectious diseases, These include viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

[0283] The present disclosure provides a method for preventing and / or treating a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) as an active ingredient or a pharmaceutically acceptable salt thereof as described herein. In some embodiments, the disease or condition includes a disease or condition associated with cereblon protein. In some embodiments, the disease or condition includes: tumors or cancer, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes. In some embodiments, the disease or condition includes, but is not limited to, myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and leukemia. B-cell leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, small cell lung cancer carcinoma; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; glioblastoma; astrocytoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden's disease; pancreatic cancer; central nervous system cancer; neuroblastoma; glioma; peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer;Brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, These include viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

[0284] In the method for preventing and / or treating the disease or condition, a therapeutically effective amount of a compound of formula (I) described herein, or a pharmaceutical composition comprising a compound of formula (I) as an active ingredient described herein, is administered to the subject by at least one administration route selected from nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural space administration, intrathecal administration, and intravenous administration.

[0285] The term "treatment" or "treating" refers to administering to a subject a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, to slow (mitigate) the development of an undesirable disease or condition (e.g., a tumor). Beneficial or desired clinical outcomes of the present disclosure include, but are not limited to, alleviating symptoms, reducing the severity of the disease, stabilizing the state of the disease, delaying or slowing the progression of the disease, improving or alleviating the condition, and alleviating the disease.

[0286] A "therapeutically effective amount" of a compound of the present disclosure depends on a variety of factors, including the activity of the particular compound used, the metabolic stability and duration of action of the compound, the age, sex, and weight of the patient, the patient's overall medical condition, the route and timing of administration, the rate of excretion, concomitant medications, and the progression of the disease or condition being treated in the patient. One skilled in the art will be able to determine an appropriate dosage based on these and other factors.

[0287] It should be understood that the choice of using one or more active compounds and / or compositions and their dosages depends on the individual's basic conditions (generally, the individual's conditions should be optimized). Administration and dosing regimens should be within the capabilities of those skilled in the art, and appropriate dosages depend on many factors including the knowledge and ability level of the ordinary skilled physician, veterinarian, or researcher (see, for example, Li Jun, ed., "Clinical Pharmacology," 4th edition, People's Medical Publishing House (2008)).

[0288] The patients or subjects for treatment mentioned above refer to animals, such as mammals, including but not limited to primates (such as humans), cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice, etc.

[0289] VII. Definitions

[0290] Unless otherwise specified, the following words, phrases and symbols used in this specification generally have the meanings described below.

[0291] In general, the nomenclature used herein (including IUPAC nomenclature) and the laboratory procedures described below (including for cell culture, organic chemistry, analytical chemistry and pharmacology, etc.) are those well known and commonly used in the art. Unless otherwise defined, all scientific and technical terms used herein in conjunction with the present disclosure described herein have the same meaning as commonly understood by those skilled in the art. In addition, in the claims and / or the specification, when the term "one" or "an" is used in conjunction with the term "comprising" or a noun, its meaning may be "one", but is also consistent with the meaning of "one or more", "at least one" and "one or more than one". Similarly, the term "another" or "other" can mean at least a second or more.

[0292] It should be understood that whenever various aspects are described herein using the terms "including" or "comprising," other similar aspects described by "consisting of" and / or "consisting essentially of" are also provided.

[0293] The term "about," used alone or in combination, is used herein to mean approximately, roughly, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​recited. Generally, the term "about" can modify a numerical value above and below the recited value by a variation, for example, 10%, 5%, 2%, or 1%, above or below the recited value.

[0294] As used herein, the phrase "... represents a bond" used alone or in combination means that it is a bond linker (i.e., it does not exist). For example, the phrase "X represents a bond" means that X is a bond linker. In other words, when X is a bond, Y of the structure of formula (I) is directly connected to ring A in the structure of formula (I). For example, the phrase "R L2 "Represents a key" means R L2 is a bond linker. In other words, when R L2 When the ring A in the group LIN is a bond, 3 Direct connection to R w .

[0295] As used herein, the term "optionally substituted" used alone or in combination means that the indicated group may be unsubstituted or substituted with one or more substituents as defined herein. The terms "optionally substituted with" and "unsubstituted or substituted" are used interchangeably herein. The term "substituted" generally means that one or more hydrogen atoms in the structure being referred to are replaced with the same or different specific substituents. The number of substituents is not subject to any limitation in principle, or is automatically limited by the size of the building block (i.e., the total number of hydrogen atoms of the building block that can be replaced), or as explicitly defined herein.

[0296] In this document, a bond broken by a wavy line shows the point of attachment of the depicted group to the rest of the molecule. For example, the monovalent group R w

[0297] Represents the group R w Ring A 4 is connected to the group LIN of the structure of formula (I). In this document, unless otherwise explicitly stated, the two bonds of a divalent group that are interrupted by a wavy line represent the two points of connection of the depicted group to the rest of the molecule. For example, in the structure of the group LIN depicted below: As defined herein, R L1 Connect R x , R L2 Connect R w For example, R L1 The group -O-CH2- represented by any end can be connected to R x , and the other end is connected to ring A1 In other words, the O in the group -O-CH2- can connect to the R x , and CH2 can be connected to ring A of the compound of formula (I) 1 ,vice versa.

[0298] As used herein, the expression "straight-chain or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: La 、R Lb and any combination thereof” has the meaning known in the art, that is, it can refer to one or more groups R La 、R Lb or the group R La With R Lb C can be optionally replaced by any combination of 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group. In this article, examples of the above terms may include but are not limited to C 1-20 Any one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) methylene groups of the alkylene main carbon chain backbone are optionally replaced by one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups R as defined herein. La and / or one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups R Lb and / or one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups R La With R Lb The main chain groups formed by the above-mentioned straight or branched C 1-20 The two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R La When substituted, each group R La When the straight or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by one or more groups R La and / or one or more groups R Lb and / or one or more groups R La With R LbWhen any combination of the above is replaced, the main chain group formed may contain one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) of the following fragments, such as but not limited to "-(CH2) 0-5 -R L a -(CH2) 0-5 -"fragment,"-R La -(CH2) 1-5 -R La -" fragment, "-(CH2) 0-5 -(R Lb ) 0-5 -(CH2) 0-5 -" fragment, "-(R Lb ) 0-5 -(CH2) 1-5 -(R Lb ) 0-5 -" fragment, "-(CH2) 0-5 -R L a -(R Lb ) 0-5 -(CH2) 0-5 -" fragment, "-R La -(CH2) 0-5 -(R L b) 0-5 -(CH2) 0-5 -" fragment, "-(CH2) 0-5 -R La -(CH2) 0-5 -(R Lb ) 0-5- ” fragments, etc., in which each R La Same or different, each R Lb the same or different, and as defined herein.

[0299] As used herein, the term "deuterated," alone or in combination, means that one or more hydrogens of the referenced group are replaced by a deuterium atom.

[0300] As used herein, the term "oxo" or "oxo" refers to =0.

[0301] As used herein, the term "carbonyl," alone or in combination, refers to C(O) or C(=O).

[0302] As used herein, the term "halogen atom" or "halogen" alone or in combination refers to fluorine, chlorine, bromine or iodine.

[0303] As used herein, the term "alkyl" used alone or in combination refers to a straight chain or branched chain alkyl group. x -C y Alkyl" or "C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms. The term "C1-C 10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms. The term "C1-C 10 Examples of "alkyl" include C 1-9 Alkyl, C 1-8 Alkyl, C 2-8 Alkyl, C 1-7 Alkyl, C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Representative examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl. The term "C1-C3 alkyl" in this disclosure refers to a group consisting of a C1-C2 alkyl group and a C1-C2 alkyl group. 1-3 "C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms, representative examples of which include methyl, ethyl, n-propyl and isopropyl. In the present disclosure, the "alkyl" is optionally substituted, and the substituents are optionally one or more selected from halogen, hydroxyl, cyano, C 1-3 Alkyl, C 1- 3 alkoxy, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkyl (e.g. trifluoromethyl), C 3-6 a cycloalkyl group, a 4-membered to 7-membered heterocyclic group, or a combination thereof.

[0304] As used herein, the term "haloalkyl" alone or in combination refers to a linear or branched alkyl group substituted with one or more halogens, wherein one or more hydrogen atoms in the alkyl group are replaced with halogens. x -C y Alkyl" or "halogenated C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms substituted by one or more halogens. The term "halogenated C 1-10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms substituted by one or more halogens. 1-10 Examples of alkyl groups include halo-C 1-9 Alkyl groups, such as halogenated C 1-8 Alkyl, halogenated C 2-8 Alkyl, halogenated C 1-7 Alkyl, halogenated C 1-6 Alkyl, halogenated C1-5 Alkyl, or halogenated C 1-4 Representative examples include halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, halogenated sec-butyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated neopentyl, halogenated tert-pentyl, halogenated hexyl, halogenated heptyl, halogenated octyl, halogenated nonyl and halogenated decyl. The term "halogenated C 1-3 "Alkyl" or "halogenated C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms substituted by one or more halogens, representative examples of which include halomethyl (e.g., trifluoromethyl), haloethyl, halo-n-propyl, and halo-isopropyl.

[0305] As used herein, the term "deuterated alkyl" alone or in combination refers to a straight or branched chain alkyl group substituted with one or more deuterium atoms, wherein one or more hydrogen atoms in the alkyl group are replaced with deuterium atoms. x -C y Alkyl" or "deuterated C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms substituted by one or more deuterium atoms. The term "deuterated C 1-10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms substituted by one or more deuterium atoms. 1-10 Examples of alkyl groups include deuterated C 1-9 Alkyl groups, such as deuterated C 1-8 Alkyl, deuterated C 2-8 Alkyl, deuterated C 1-7 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-5 Alkyl, or deuterated C 1-4 Representative examples include perdeuterated methyl (CD3), perdeuterated ethyl (CD3CD2), perdeuterated n-propyl, perdeuterated isopropyl, perdeuterated n-butyl, perdeuterated isobutyl, perdeuterated sec-butyl, perdeuterated tert-butyl, perdeuterated pentyl, perdeuterated isopentyl, perdeuterated neopentyl, perdeuterated tert-pentyl, and perdeuterated hexyl. The term "deuterated C 1-3 "Alkyl" or "deuterated C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms substituted by one or more deuterium atoms, representative examples of which include perdeuterated methyl (CD3-) and perdeuterated ethyl (CD3CD2).

[0306] As used herein, the term "alkylene" (which is used interchangeably with "alkylene chain"), used alone or in combination, refers to a straight or branched divalent saturated hydrocarbon group consisting of carbon and hydrogen, which is a divalent radical form of a straight or branched alkyl group. x -C y "Alkylene" or "Cx-y "alkylene" (x and y are each an integer) refers to a straight or branched chain alkylene containing x to y carbon atoms. The term "C1-C 20 "Alkylene" refers to a straight or branched chain alkylene group containing 1 to 20 carbon atoms, examples of which include but are not limited to C1-C 20 Alkylene, C1-C 15 Alkylene, C1-C 14 Alkylene, C1-C 13 Alkylene, C1-C 12 Alkylene, C1-C 11 Alkylene, C1-C 10 C1-C9 alkylene, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene, and C1-C2 alkylene. Representative examples include, but are not limited to, methylene (i.e., -CH2-), ethylene (e.g., -CH2CH2-), propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, pentylene, isopentylene, neopentylene, tert-pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, tetradecylene, and pentadecylene. In the present disclosure, the "alkylene" is optionally substituted, and the substituents are optionally one or more selected from C1-C3 alkyl, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene, and C1-C2 alkylene. 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0307] As used herein, the term "alkoxy" used alone or in combination refers to a straight or branched chain alkoxy group having the formula alkyl-O-. Optionally, the alkyl portion of the alkoxy group may contain 1-10 (e.g., 1-6, 1-4, or 1-3) carbon atoms. Representative examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, and the like. The term "C1-C3 alkoxy" or "C 1-3 "Alkoxy" refers to a straight or branched chain alkoxy group containing 1 to 3 carbon atoms. 1- Representative examples of 3-alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, and isopropoxy.

[0308] As used herein, the term "haloalkoxy" alone or in combination refers to an alkoxy group substituted with one or more halogens. Optionally, the alkyl portion of the alkoxy group may contain 1-10 (e.g., 1-6, 1-4, or 1-3) carbon atoms. Examples of "haloalkoxy" include halogenated C 1-6 Alkoxy and halogenated C 1-4 Representative examples include, but are not limited to, F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0309] In the present invention, the term "heteroaryl" used alone or in combination refers to a 5- to 30-membered (optionally 5- to 20-membered, 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 6- to 15-membered, 6- to 9-membered, or 6- to 20-membered) monocyclic or bicyclic or polycyclic hydrocarbon group containing at least one aromatic ring having 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur. Bicyclic or polycyclic heteroaryl groups include bicyclic, tricyclic, or tetracyclic heteroaryl groups, one of which is an aromatic ring having one or more heteroatoms independently selected from O, S, and N, and the other rings may be saturated, partially unsaturated, or aromatic and may be carbocyclic or contain one or more heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, isoindolinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, oxazolopyridinyl, furopyridinyl, pteridinyl, purinyl, pyridopyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, chromanyl and 6,7-dihydrothieno[3,2-d]pyrimidinyl. Examples of tricyclic or polycyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, xanthenyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. The heteroaryl groups may be unsubstituted or substituted. Substituted heteroaryl refers to heteroaryl groups substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) with substituents, wherein the substituents are optionally selected from C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0310] In the present invention, the term "heteroarylene" used alone or in combination refers to a 5- to 30-membered (optionally 5- to 20-membered, 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 6- to 15-membered, 6- to 9-membered, or 6- to 20-membered) monocyclic or bicyclic or polycyclic hydrocarbon divalent group containing at least one aromatic ring having 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur. Bicyclic or polycyclic heteroarylene groups include bicyclic, tricyclic, or tetracyclic heteroarylene groups, one of which is an aromatic ring having one or more heteroatoms independently selected from O, S, and N, and the other rings may be saturated, partially unsaturated, or aromatic and may be carbocyclic or contain one or more heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroarylene groups include, but are not limited to, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, tetrazolylene, and triazinylene. Examples of bicyclic heteroarylene groups include, but are not limited to, indolylene, isoindolylene, isoindolylene, benzofurylene, isobenzofurylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoline oxalinyl, phthalazinyl, oxazolopyridylene, furopyridylene, pteridylene, purinylene, pyridopyridylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, imidazo[2,1-b]thiazolylene, chromanylene and 6,7-dihydrothieno[3,2-d]pyrimidinylene. Examples of tricyclic or polycyclic heteroarylene groups include, but are not limited to, acridinylene, benzindolylene, carbazolylene, dibenzofuranylene, xanthenylene, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinylene, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinylene. The heteroarylene groups may be unsubstituted or substituted. Substituted heteroarylene refers to heteroarylene groups that are substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) with substituents, wherein the substituents are optionally selected from C1-C3 alkyl, C 3-6Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0311] As used herein, the term "aryl" alone or in combination refers to a monovalent aromatic hydrocarbon group comprising 5 to 30 (e.g., 5-20, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-9, or 6-20) carbon atoms and optionally comprising one or more fused rings, such as phenyl, naphthyl, or fluorenyl. In the present disclosure, the "aryl" is an optionally substituted aryl. A substituted aryl refers to an aryl substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) by a substituent, for example, an aryl group is monosubstituted, disubstituted, trisubstituted, or polysubstituted by a substituent, wherein the substituent is optionally selected, for example, from C1-C3 alkyl, ... 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0312] In the present disclosure, the term "arylene", used alone or in combination, refers to a divalent aromatic hydrocarbon group containing 5 to 30 (e.g., 5-20, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-9, or 6-20) carbon atoms and optionally containing one or more fused rings, such as phenylene (e.g., ) or naphthylene or fluorenylene. In the present disclosure, the "arylene" is an optionally substituted arylene. Substituted arylene refers to an arylene substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) by a substituent, for example, the arylene is monosubstituted, disubstituted, trisubstituted, or polysubstituted by a substituent, wherein the substituent is optionally selected from, for example, C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0313] The term "cycloalkyl" as used herein, alone or in combination, refers to a saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) monocyclic, bicyclic, tricyclic, or polycyclic hydrocarbon radical having, in some embodiments, 3 to 30 carbon atoms (i.e., C 3-30 cycloalkyl), or 3 to 25 carbon atoms (i.e., C 3-25 cycloalkyl), or 3 to 20 carbon atoms (i.e., C 3-20 cycloalkyl), or 3 to 15 carbon atoms (i.e., C 3-15 Cycloalkyl), 3 to 12 carbon atoms (i.e., C 3- 12 cycloalkyl), or 3 to 11 carbon atoms (i.e., C 3-11 cycloalkyl), or 3 to 10 carbon atoms (i.e., C 3-10 cycloalkyl), or 3 to 8 carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 7 carbon atoms (i.e., C 3-7 cycloalkyl), or 3 to 6 carbon atoms (i.e., C 3-6 cycloalkyl), or 4 to 20 carbon atoms (i.e., C 4-20 cycloalkyl), or 4 to 15 carbon atoms (i.e., C 4-15 cycloalkyl), or 4 to 12 carbon atoms (i.e., C 4-12 cycloalkyl), or 4 to 10 carbon atoms (i.e., C 4-10 The term "cycloalkyl" includes monocyclic, bicyclic, tricyclic and polycyclic cycloalkyl groups having 3 to 30 carbon atoms. Examples of the term "cycloalkyl" include, but are not limited to, monocyclic cycloalkyl groups, bridged cycloalkyl groups (e.g., C 5-30 Bridged cycloalkyl or C 5-20 Bridged cycloalkyl or C 5-15 Bridged cycloalkyl or C 7-15 Bridged cycloalkyl), fused cycloalkyl (e.g. C 5-30 Condensed cycloalkyl, C 5-20 Condensed cycloalkyl, C 5-15 Condensed cycloalkyl, C 6-30 Condensed cycloalkyl, C 6-20 Condensed cycloalkyl, C 6-15 Condensed cycloalkyl, C 7-30 Condensed cycloalkyl, C 7-20 Condensed cycloalkyl, C 7-15 Condensed cycloalkyl, and C 8-15 fused cycloalkyl) and spirocycloalkyl (e.g. C 5-30 Spiroalkyl, C 5-20 Spiroalkyl, C 5-15 Spiroalkyl, C 6-30 Spiroalkyl, C 6-20 Spiroalkyl, C 6-15 Spiroalkyl, C 7-30 Spiroalkyl, C7-20 Spiroalkyl, C 7-15 Spiroalkyl, and C 8-15 Representative examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Examples of fused cycloalkyl groups, spirocycloalkyl groups, and bridged cycloalkyl groups include, but are not limited to, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, C 5-20 Spiroalkyl, C 5-15 Spirocycloalkyl, adamantyl, noradamantyl, bornyl and norbornyl (IUPAC system named bicyclo[2.2.1]heptyl). Herein, the "cycloalkyl" is optionally monosubstituted or polysubstituted, for example but not limited to, 2,2-, 2,3-, 2,4-, 2,5-, or 2,6-disubstituted cyclohexyl. The substituents of the substituted "cycloalkyl" are optionally one or more (e.g., 1-5, 1-4, 1-3, 1-2, or 1) selected from C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 Alkyl-C(O)NH-, cyano or any combination thereof. The term "C 3-6 Examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, and cyclohexyl.

[0314] In this document, the term “C x-y Spirocycloalkyl" (x and y are each an integer) refers to a spirocycloalkyl group containing x to y carbon atoms. The term "C 5-30 Spiroalkyl" refers to a spiroalkyl group containing 5 to 30 (for example, but not limited to, 5-20, 5-15, 7-20, 7-15, 5-11, 5-10, and 7-9) carbon atoms. The term "C 5-30 Spirocyclyl" includes "C 5-20 Spirocyclyl", "C 5-15 Spirocyclyl", "C 7-15 Spirocycloalkyl" and "C 7-20 Spirocycloalkyl”, representative examples of which include but are not limited to spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl or spiro[5.5]undecyl. The “C 5-30 The spirocycloalkyl group is optionally further selected from C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3Alkoxy, deuterated C 1-3 Alkoxy, C 1-3 The alkylamino group is substituted with one or more of alkylamino, amino, oxo, halogen, hydroxyl, cyano, or any combination thereof.

[0315] In this document, the term “C x-y "bridged cycloalkyl" (x and y are each an integer) refers to a bridged cycloalkyl group containing x to y carbon atoms. The term "C 5-30 The term "bridged cycloalkyl" refers to a bridged cycloalkyl group containing 5 to 30 (for example, but not limited to, 5-20, 6-20, 7-20, 5-15, 7-15, 5-11, 5-10, and 7-9) carbon atoms. 5-30 "Bridged cycloalkyl" includes "C5-C 20 Bridged ring group", "C6-C 20 Bridged ring group", "C7-C 20 Bridged ring group", "C 5-15 Bridged cycloalkyl", and "C7-C 15 "bridged ring group", representative examples of which include but are not limited to adamantyl, noradamantyl, bornyl, norbornyl (systematically named bicyclo[2.2.1]heptyl), 2-oxobicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl and cubanyl. The "C 5-30 The bridged cycloalkyl group is optionally substituted with 1 to 10 substituents selected from the group consisting of: 1-3 Alkyl, deuterated C 1-3 Alkyl, C 1-3 Alkoxy, halogen, halogenated C 1-3 Alkyl, C 1-3 alkylamino, amino, hydroxy, cyano, oxo, or any combination thereof.

[0316] In the present invention, the term "cycloalkylene" used alone or in combination refers to a saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) monocyclic or bicyclic or tricyclic or polycyclic hydrocarbon divalent group, which in some embodiments has 3 to 30 carbon atoms (i.e., C 3-30 cycloalkyl), or 3 to 25 carbon atoms (i.e., C 3-25 cycloalkyl), or 3 to 20 carbon atoms (i.e., C 3-20 cycloalkylene), or 3 to 15 carbon atoms (i.e., C 3-15 Cycloalkylene), 3 to 12 carbon atoms (i.e., C 3-12 cycloalkylene), or 3 to 11 carbon atoms (i.e., C 3-11 cycloalkylene), or 3 to 10 carbon atoms (i.e., C 3-10cycloalkylene), or 3 to 8 carbon atoms (i.e., C 3-8 cycloalkylene), or 3 to 7 carbon atoms (i.e., C 3-7 cycloalkylene), or 3 to 6 carbon atoms (i.e., C 3-6 cycloalkylene), or 4 to 20 carbon atoms (i.e., C 4-20 cycloalkylene), or 4 to 15 carbon atoms (ie, C 4-15 cycloalkylene), or 4 to 12 carbon atoms (i.e., C 4- 12 cycloalkylene), or 4 to 10 carbon atoms (i.e., C 4-10 The term "cycloalkylene" includes monocyclic, bicyclic, tricyclic and polycyclic hydrocarbon divalent groups having 3 to 30 carbon atoms. Examples of the term "cycloalkylene" include, but are not limited to, monocyclic cycloalkylene, bridged cycloalkylene (e.g., C 5-30 Cycloalkylene bridged, C 5-20 Cycloalkylene bridged, C 5-15 Cycloalkylene or C 7-15 bridged cycloalkylene), fused cycloalkylene (e.g. C 5-30 Fused cycloalkylene, C 5-20 Fused cycloalkylene, C 5-15 Fused cycloalkylene, C 6-30 Fused cycloalkylene, C 6-20 Fused cycloalkylene, C 6-15 Fused cycloalkylene, C 7-30 Fused cycloalkylene, C 7-20 Fused cycloalkylene, C 7-15 fused cycloalkylene, and C 8-15 fused cycloalkylene) and spirocycloalkylene (e.g. C 5-30 Spirocycloalkylene, C 5-20 Spirocycloalkylene, C 5- 15 Spirocycloalkylene, C 6-30 Spirocycloalkylene, C 6-20 Spirocycloalkylene, C 6-15 Spirocycloalkylene, C 7-30 Spirocycloalkylene, C 7-20 Spirocycloalkylene, C 7-15 Spirocycloalkylene, and C 8-15 Representative examples of monocyclic cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, and cyclooctylene. Examples of fused cycloalkylene groups, spirocycloalkylene groups, and bridged cycloalkylene groups include, but are not limited to, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-20 Spirocyclylene (e.g. C 5-15cyclohexyl, ... 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0317] In this document, the term “C x-y Spirocycloalkylene" or "C x-y Spirocyclylene" (x and y are each an integer) refers to a spirocycloalkylene group containing x to y carbon atoms. The term "C 5-30 Spirocycloalkylene refers to a spirocycloalkylene group containing 5 to 30 (e.g., 5-20, 5-15, 7-20, 7-15, 5-11, 5-10, 7-9) carbon atoms. The term "C 5-30 Spirocycloalkylene" includes "C 5-20 Spirocycloalkylene", "C 5-15 Spirocycloalkylene", "C 7-15 Spirocycloalkylene" and "C 7-20 Spirocycloalkylene”, representative examples of which include but are not limited to spiro[3.3]heptanediyl, spiro[2.5]octandiyl, spiro[3.5]nonanediyl, spiro[4.4]nonanediyl, spiro[4.5]decanediyl and spiro[5.5]undecanediyl. The “C 5-30 The spirocycloalkylene group is optionally further substituted with one or more C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 The group is substituted with alkyl-C(O)NH-, cyano or any combination thereof.

[0318] In this document, the term “C x-y "C-bridged cycloalkyl" or "C x-y"C-bridged cycloalkyl" (x and y are each an integer) refers to a bridged cycloalkyl group containing x to y carbon atoms. The term "C-bridged cycloalkyl" used alone or in combination in the present invention refers to a bridged cycloalkyl group containing x to y carbon atoms. 5-30 "Cycloalkylene" refers to a cycloalkylene group containing from 5 to 30 (for example, but not limited to, 5-20, 6-20, 7-20, 5-15, 7-15, 5-11, 5-10, and 7-9) carbon atoms. The term "C 5-30 "Cycloalkylene bridged" includes "C 5-20 Sub-bridged cycloalkyl", "C 6-20 Sub-bridged cycloalkyl", "C 7-20 Sub-bridged cycloalkyl", "C 5-15 "Cycloalkylene", and "C 7-15 "C-bridged cycloalkylene", representative examples of which include, but are not limited to, adamantylene, noradamantylene, bornylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[2.2.1]heptanylene, bicyclo[2.2.1]heptenylene and cubanylene. The "C-bridged cycloalkylene" is a cycloalkylene radical having a cycloalkylene radical, ... 5-30 The "bridged cycloalkyl" may be further substituted with one or more C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 The group is substituted with alkyl-C(O)NH-, cyano or any combination thereof.

[0319] As used herein, the term "heterocyclyl" or "heterocycloalkyl," alone or in combination, refers to a 4- to 30-membered (alternatively 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term "heterocyclyl" include, but are not limited to, monocyclic heterocyclyl (e.g., 4- to 30-membered monocyclic heterocyclyl, and 4- to 20-membered monocyclic heterocyclyl), bridged heterocyclyl (e.g., 5- to 30-membered bridged heterocyclyl, 5- to 20-membered bridged heterocyclyl, 7- to 20-membered bridged heterocyclyl, and 7- to 15-membered bridged heterocyclyl), fused heterocyclyl (e.g., 5- to 30-membered fused heterocyclyl, and 5- to 20-membered fused heterocyclyl), spiro heterocyclyl (e.g., 5- to 30-membered spiro heterocyclyl, and 5- to 20-membered spiro heterocyclyl), cyclic ester (i.e., lactone, e.g., 10-membered, 4-15-membered, 4-14-membered, 4-13-membered, 4-12-membered, 4-11-membered, 4-10-membered, 4-9-membered, 4-8-membered, 5-15-membered, 5-10-membered, 5-8-membered, 6-15-membered, or 6-10-membered cyclic ester groups) and cyclic amide groups (i.e., lactams, such as 4-15-membered, 4-14-membered, 4-13-membered, 4-12-membered, 4-11-membered, 4-10-membered, 4-9-membered, 4-8-membered, 5-15-membered, 5-10-membered, 5-8-membered, 6-15-membered, or 6-10-membered cyclic amide groups). Representative examples of monocyclic heterocyclyl groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), diazacanyl, 2-oxopyrrolidinyl, 2,5-dioxopyrrolidinyl, 2-oxopiperidinyl, and glutarimido.Examples of bridged heterocyclic groups, fused heterocyclic groups, and spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 3,6-diazabicyclo[3.1.1]heptan-3-yl, 3-azabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, azabicyclo[2.2.2]octan-2-yl, octahydro-1H-indolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl, 2-oxobenzo[d]oxazol-3(2H)-yl, 2-oxobenzo[cd]indol-1(2H)-yl, 1H-benzo[de]isoquinoline-1,3(2H)-dione and azaspirocyclyl (e.g., 5- to 20-membered azaspirocyclyl, e.g., 3-azaspiro[5.5]undec-3-yl). The heterocyclyl may be unsubstituted or substituted as defined (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, optionally deuterated C. 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH- or any combination thereof.

[0320] As used herein, the term "nitrogen-containing heterocyclyl" or "nitrogen-containing heterocycloalkyl", alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one nitrogen atom and optionally containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “nitrogen-containing heterocyclic group” include, but are not limited to, nitrogen-containing monocyclic heterocyclic groups (e.g., 4- to 30-membered nitrogen-containing monocyclic heterocyclic groups and 4- to 20-membered nitrogen-containing monocyclic heterocyclic groups), nitrogen-containing bridged heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing bridged heterocyclic groups, 5- to 20-membered nitrogen-containing bridged heterocyclic groups, 5- to 15-membered nitrogen-containing bridged heterocyclic groups, 7- to 20-membered nitrogen-containing bridged heterocyclic groups, or 7- to 15-membered nitrogen-containing bridged heterocyclic groups), nitrogen-containing fused heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing fused heterocyclic groups and 5- to 20-membered nitrogen-containing fused heterocyclic groups), and nitrogen-containing spiro heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing spiro heterocyclic groups and 5- to 20-membered nitrogen-containing spiro heterocyclic groups). Representative examples of nitrogen-containing monocyclic heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), and diazacyclooctanyl. Examples of nitrogen-containing bridged heterocyclic groups, nitrogen-containing fused heterocyclic groups, and nitrogen-containing spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 3,6-diazabicyclo[3.1.1]heptan-3-yl, 3-azabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.2]octan-2-yl, octahydro-1H-indolyl, and azaspirocyclic groups (e.g., a 5- to 20-membered azaspirocyclic group, such as 3-azaspiro[5.5]undec-3-yl). The nitrogen-containing heterocyclic group may be unsubstituted or substituted as defined (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH- or any combination thereof.

[0321] As used herein, the term "heterocyclylene" or "heterocycloalkylene," alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon radical containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term "heterocyclylene" include, but are not limited to, monocyclic heterocyclylene (e.g., 4 to 30-membered monocyclic heterocyclylene, and 4 to 20-membered monocyclic heterocyclylene), bridged heterocyclylene (e.g., 5 to 30-membered bridged heterocyclylene, 5 to 20-membered bridged heterocyclylene, 7 to 20-membered bridged heterocyclylene, or 7 to 15-membered bridged heterocyclylene), fused heterocyclylene (e.g., 5 to 30-membered fused heterocyclylene, and 5 to 20-membered fused heterocyclylene), spiro heterocyclylene (e.g., 5 to 30-membered spiro heterocyclylene, and 5 to 20-membered spiro heterocyclylene), cyclic ester substituents (i.e., lactones, ne), e.g., a 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 5- to 15-membered, 5- to 10-membered, 5- to 8-membered, 6- to 15-membered, or 6- to 10-membered cyclic ester subunit) and a cyclic amide subunit (i.e., a lactam, e.g., a 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 5- to 15-membered, 5- to 10-membered, 5- to 8-membered, 6- to 15-membered, or 6- to 10-membered cyclic amide subunit). Representative examples of monocyclic heterocyclylene groups include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azoctanylene, dioxanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), and diazaoctanylene.Examples of bridged, fused, and spiro heterocyclylene groups include, but are not limited to, 6-azabicyclo[3.1.1]heptanylidene, 2,5-diazabicyclo[2.2.1]heptanylidene, 3,6-diazabicyclo[3.1.1]heptanylidene, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene, octahydro-1H-indolylidene, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolylidene, and azaspiroylidene (e.g., a 5- to 20-membered azaspiroylidene, such as 3-azaspiro[5.5]undecylidene). The heterocyclylene group may be unsubstituted or substituted as explicitly defined (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents may be optionally selected from deuterium, hydroxy, amino, mercapto, nitro, halogen, cyano, optionally deuterated C. 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH- or any combination thereof.

[0322] As used herein, the term “nitrogen-containing heterocyclylene” or “nitrogen-containing heterocycloalkylene”, alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one nitrogen atom and optionally containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “nitrogen-containing heterocyclylene” include, but are not limited to, nitrogen-containing monocyclic heterocyclylene (e.g., a 4- to 30-membered nitrogen-containing monocyclic heterocyclylene, and a 4- to 20-membered nitrogen-containing monocyclic heterocyclylene), nitrogen-containing bridged heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing bridged heterocyclyl, a 5- to 20-membered nitrogen-containing bridged heterocyclyl, a 7- to 20-membered nitrogen-containing bridged heterocyclyl, or a 7- to 15-membered nitrogen-containing bridged heterocyclyl), nitrogen-containing fused heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing fused heterocyclyl and a 5- to 20-membered nitrogen-containing fused heterocyclyl), and nitrogen-containing spiro heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing spiro heterocyclyl and a 5- to 20-membered nitrogen-containing spiro heterocyclyl). Representative examples of nitrogen-containing monocyclic heterocyclylene groups include, but are not limited to, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), and diazepanylene. Examples of nitrogen-containing bridged heterocyclic groups, nitrogen-containing fused heterocyclic groups, and nitrogen-containing spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptanylidene, 2,5-diazabicyclo[2.2.1]heptanylidene, 3,6-diazabicyclo[3.1.1]heptanylidene, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene, octahydro-1H-indolylidene, and azaspiroylidene (e.g., a 5- to 20-membered azaspiroylidene, such as 3-azaspiro[5.5]undecanylidene). The nitrogen-containing heterocyclylene group may be unsubstituted or substituted as defined above (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH- or any combination thereof.

[0323] As used herein, the term "alkynylene" alone or in combination refers to a straight or branched divalent hydrocarbon group containing 2 to 8 (e.g., 2 to 6, 2 to 5, 2 to 4, more preferably 2) carbon atoms and having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon triple bonds. Examples of alkynylene groups include C 2-8 Alkynylidene, C 2-6 Alkynylidene or C 2-4 Alkynylenyl, representative examples of which include, but are not limited to, ethynylene, 1-propynylene, 1-butynylene, and 1,3-diynylene.

[0324] As used herein, the term "alkynyl" alone or in combination refers to a straight or branched monovalent hydrocarbon group containing 2 to 8 (e.g., 2 to 6, 2 to 5, 2 to 4, more preferably 2) carbon atoms and having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon triple bonds. Examples of "alkynyl" include C 2-8 Alkynyl, C 2-6 Alkynyl or C 2-4 Alkynyl, representative examples of which include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and 1,3-diynyl.

[0325] As used herein, the term "alkenylene," alone or in combination, refers to a straight or branched chain divalent hydrocarbon radical containing 2 to 8 carbon atoms (e.g., 2 to 6, 2 to 5 carbon atoms, or 2 to 4, 2 to 3, or 2 carbon atoms) having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon double bonds. Examples of alkenylene include C 2-8 Alkenylene, C 2-6 Alkenylene or C 2-4 Representative examples of alkenylene groups include, but are not limited to, vinylene (e.g., —CH═CH—), 1-propenylene, allylene, 1-butenylene, 2-butenylene, 3-butenylene, isobutenylene, pentenylene, n-penta-2,4-dienylene, 1-methyl-but-1-enylene, 2-methyl-but-1-enylene, 3-methyl-but-1-enylene, 1-methyl-but-2-enylene, 2-methyl-but-2-enylene, 3-methyl-but-2-enylene, 1-methyl-but-3-enylene, 2-methyl-but-3-enylene, 3-methyl-but-3-enylene, and hexenylene.

[0326] As used herein, the term "alkenyl" alone or in combination refers to a straight or branched monovalent hydrocarbon group containing 2 to 8 carbon atoms (e.g., 2 to 6, 2 to 5 carbon atoms, or 2 to 4, 2 to 3 or 2 carbon atoms) having one or more (e.g., 1 to 3, 1 to 2 or 1) carbon-carbon double bonds. Examples of "alkenyl" include C 2-8 Alkenyl, C 2-6 Alkenyl or C 2- Representative examples of the group include, but are not limited to, vinyl (e.g., CH2=CH-), 1-propenyl, allyl, 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, pentenyl, n-penta-2,4-dienyl, 1-methyl-but-1-enyl, 2-methyl-but-1-enyl, 3-methyl-but-1-enyl, 1-methyl-but-2-ylidene, 2-methyl-but-2-ylidene, 3-methyl-but-2-ylidene, 1-methyl-but-3-enyl, 2-methyl-but-3-enyl, 3-methyl-but-3-enyl, and hexenyl.

[0327] As used herein, the term "bornyl" or "bornane" (also known as 1,7,7-trimethylbicyclo[2.2.1]heptane; camphane; bomylane) has the definition known to those skilled in the art. As used herein, the term "bornyl" or "bornyl" refers to a monovalent radical of bornane, i.e., the radical remaining after any one of the hydrogen atoms in bornane is removed. Representative examples of "bornyl" include, but are not limited to, 1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-3-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-4-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-5-yl, or 1,7,7-trimethylbicyclo[2.2.1]heptane-6-yl,

[0328] As used herein, the term "bicyclo[2.2.1]heptane" (also known as bicyclo[2.2.1]heptane) or "norbornane" has the meaning known to those skilled in the art. As used herein, "bicyclo[2.2.1]heptane" or "norbornane" refers to a monovalent radical of bicyclo[2.2.1]heptane, i.e., the radical remaining after any one of the hydrogen atoms in bicyclo[2.2.1]heptane is removed. Representative examples of "bicyclo[2.2.1]heptane" include, but are not limited to, bicyclo[2.2.1]heptane-2-yl, bicyclo[2.2.1]heptane-3-yl, bicyclo[2.2.1]heptane-4-yl, bicyclo[2.2.1]heptane-5-yl, or bicyclo[2.2.1]heptane-6-yl.

[0329] As used herein, the term "bicyclo[2.2.1]heptene" (also known as bicyclo[2.2.1]heptene) has a definition known to those skilled in the art. As used herein, "bicyclo[2.2.1]heptenyl" refers to a monovalent radical of bicyclo[2.2.1]heptene, i.e., the radical remaining after any one of the hydrogen atoms in bicyclo[2.2.1]heptene is removed. Representative examples of "bicyclo[2.2.1]heptenyl" include, but are not limited to, bicyclo[2.2.1]hept-5-en-2-yl, bicyclo[2.2.1]hept-5-en-3-yl, or bicyclo[2.2.1]hept-5-en-7-yl.

[0330] In this article, the term "adamantane" (also known as Tricyclo[3.3.1.1 3，7 ]decane) has a definition known to those skilled in the art, and its structural formula is shown below, for example: As used herein, "adamantyl" refers to a monovalent radical of adamantane, i.e., the radical remaining after any hydrogen atom in adamantane is removed. Representative examples of "adamantyl" include, but are not limited to, 1-adamantyl, 2-adamantyl, 3-adamantyl, 4-adamantyl, 5-adamantyl, 6-adamantyl, 7-adamantyl, 8-adamantyl, 9-adamantyl, and 10-adamantyl.

[0331] As used herein, the term "noradamantane" (also known as noradamantane or octahydro-2,5-methanopentalene) has the definition known to those skilled in the art, and its structural formula is shown below, for example: As used herein, "noradamantyl" refers to a monovalent radical of noradamantane, i.e., the radical remaining after any hydrogen atom in noradamantane is removed. Representative examples of "noradamantyl" include, but are not limited to, 1-noradamantyl, 2-noradamantyl, 3-noradamantyl, 4-noradamantyl, 5-noradamantyl, 6-noradamantyl, 7-noradamantyl, 8-noradamantyl, and 9-noradamantyl.

[0332] As used herein, the term "adamantanamine" has the meaning known to those skilled in the art, i.e., refers to an adamantane having an amino substituent, wherein the amino group can replace a hydrogen on any carbon position of the adamantane. An example of an "adamantanamine" can be adamantane-1-amine (also known as adamantane-1-amine or Tricyclo[3.3.1.1 3，7 ]decan-1-amine; CAS: 768-94-5), having the following structural formula

[0333] The salts or pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, and polymorphs of the compounds of formula (I) described in the present disclosure are also encompassed within the scope of the present disclosure.

[0334] In all embodiments of the present disclosure, the salt or pharmaceutically acceptable salt of the compound of formula (I) refers to a non-toxic inorganic or organic acid and / or base addition salt. Examples include: sulfate, hydrohalide (including hydrochloride, hydrobromide), maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2-dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecylenate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, glycolate or p-toluenesulfonate, etc.

[0335] "Pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, such as a filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, that carries or transports a compound useful in the present disclosure into or to a patient so that it can perform its intended function. Typically, such a construct carries or transports a compound from one organ or part of the body to another. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compound useful in the present disclosure) and is not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline as a surfactant; and other nontoxic, compatible substances used in pharmaceutical formulations.

[0336] The term "room temperature" of the present disclosure refers to ambient temperature, for example, a temperature of 20-30°C.

[0337] As used herein, "stereoisomers" refer to compounds that have identical chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0338] As used herein, the term "solvate" refers to an association or complex of one or more solvent molecules and a compound of the present invention. Examples of solvents include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0339] As used herein, the term "chiral" refers to a molecule that is non-superimposable on its mirror image, whereas "achiral" refers to a molecule that is superimposable on its mirror image.

[0340] As used herein, the term "enantiomers" refers to two non-superimposable isomers of a compound that are mirror images of each other.

[0341] As used herein, the term "diastereoisomer" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high-resolution analytical procedures such as electrophoresis and chromatography, for example, HPLC.

[0342] In this document, "p-menthane" (also known as p-methane) has a definition known to those skilled in the art, and its structural formula is shown below: In this article, "p-menthanyl" refers to a monovalent group of p-menthane, that is, the group remaining after any hydrogen on any carbon position of p-menthane is removed. Representative examples include but are not limited to

[0343] In this document, "m-menthane" (also known as m-methane) has a definition known to those skilled in the art, and its structural formula is shown below: In this article, "m-menthanyl" refers to a monovalent group of m-menthane, that is, the group remaining after any hydrogen on any carbon position of m-menthane is removed. Representative examples include but are not limited to

[0344] In this document, “quinuclidine” (also known as Quinuclidine), whose chemical name is 1-azabicyclo[2.2.2]octane, has the definition known to those skilled in the art, and its structural formula is shown below: In this article, "quinuclidine" refers to a monovalent group of quinuclidine, that is, the group remaining after any hydrogen on any carbon position of quinuclidine is removed. Representative examples include but are not limited to Example

[0345] In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The present invention may be practiced without some or all of these specific details. In other cases, well-known process operations are not described in detail in order to avoid unnecessary obfuscation of the present invention. Although the present invention will be described in conjunction with specific embodiments, it should be understood that this is not intended to limit the invention to these embodiments.

[0346] The following abbreviations are used throughout the specification and examples: AcOH acetic acid NaOAc sodium acetate AIBN azobisisobutyronitrile Boc tert-butoxycarbonyl Con. Con. DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCM dichloromethane DIEA or DIPEA N,N-diisopropylethylamine DMF N,N-dimethylformamide

[0347] DMSO dimethyl sulfoxide

[0348] EA Ethyl acetate

[0349] ESI electrospray ionization

[0350] equiv equivalent

[0351] EtOH

[0352] EtOAc

[0353] HPLC high performance liquid chromatography

[0354] HRMS High Resolution Mass Spectrometry

[0355] LC-MS liquid chromatography-mass spectrometry

[0356] LRMS low-resolution mass spectrometry

[0357] LC liquid chromatography

[0358] Me methyl

[0359] MeCN Acetonitrile

[0360] MeOH methanol

[0361] MS

[0362] MsO- methanesulfonyloxy

[0363] 1 H NMR nuclear magnetic resonance spectroscopy

[0364] MeO-methoxy

[0365] NBS N-bromosuccinimide

[0366] NMP N-Methylpyrrolidone

[0367] ONs o-nitrobenzenesulfonyl

[0368] rt room temperature

[0369] tBu tert-butyl

[0370] TEA triethylamine

[0371] TFA trifluoroacetic acid

[0372] T f O-trifluoromethanesulfonyloxy

[0373] TLC thin layer chromatography

[0374] TMS trimethylsilyl

[0375] TsO- p-Toluenesulfonyloxy

[0376] Xantphos 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene

[0377] X-Phos 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl

[0378] In the present invention, 1H NMR spectra were measured using a Bruker-500 MHz nuclear magnetic resonance instrument, using CD3OD (δ = 3.31 ppm) containing 0.1% TMS (as an internal standard) as the solvent; CDCl3 (δ = 7.26 ppm) containing 0.1% TMS (as an internal standard) as the solvent; or DMSO-d6 (δ = 2.50 ppm) containing 0.03% TMS (as an internal standard) as the solvent. LC-MS spectra were measured on a Sciex API 2000 mass spectrometer equipped with an Agilent 1100 binary pump, DAD, and ELSD, or on an Agilent 1260-6125B single quadrupole liquid chromatography-mass spectrometer equipped with an Agilent 1260 quaternary pump, DAD, and ELSD. HPLC preparations were measured on a SHIMADZU LC-20AP instrument, and HPLC purity was measured on a SHIMADZU LC-30AP or Waters 1525 instrument. All reactions were carried out under air atmosphere unless otherwise specified; the reactions were monitored by TLC or LC-MS.

[0379] Solvent and reagent treatment was as follows: the reaction solvents DCM, DMF, anhydrous EtOH, and anhydrous MeOH were purchased from Sinopharm Group; preparative-grade CH3CN and deionized water were used for HPLC preparation; other reaction substrates, reagents, and drugs, unless otherwise specified, were directly purchased from commercial channels or synthesized using or according to methods known in the art.

[0380] Unless otherwise specified, the materials and reagents used in the following examples can be purchased from commercial sources and used directly, or can be synthesized using or according to methods known in the art.

[0381] General synthetic method

[0382] The compounds and / or pharmaceutically acceptable salts thereof disclosed herein can be synthesized using commercially available raw materials by synthetic techniques known in the art. The synthetic schemes described below illustrate the preparation methods of most compounds. The starting materials or reagents used in each scheme can be purchased from commercial sources or prepared by methods known to those skilled in the art. Salts, racemates, enantiomers, phosphates, sulfates, hydrochlorides and prodrug forms of the compounds of formula (I) disclosed herein can be prepared by those skilled in the art according to conventional techniques in the art.

[0383] General synthetic scheme

[0384] in,

[0385] (1) LE1 represents a group that can undergo amine alkylation reaction with an amino group, such as Br, Cl, I, OTs, OMs, or ONs, and substrate 2 represents NHRwa R wb , R w Indicates NR wa R wb , wherein (a) group R wa For example, the group R of the compound of formula (I) w1 and as defined in its various sub-embodiments, the group R wb For example, the group R of the compound of formula (I) w2 and as defined in its various sub-embodiments; or (b) a group R wa and group R wb Together with the nitrogen atom to which they are attached, they form the substituent and n1 R d1 Group-substituted nitrogen-containing heterocyclic ring A a : The nitrogen-containing heterocyclic ring A a For example, ring A of the compound of formula (I) 4 and its sub-embodiments, n1, R d1 、R e Ring A 5 , m1 and (R d2 ) n2 As defined in the compounds of formula (I) and its various subembodiments disclosed herein; or

[0386] (2) LE1 represents COOH, and substrate 2 represents NHR w3 R w4 , R w represents C(O)NR w3 R w4 , where the group R w3 and R w4 As defined in the compounds of formula (I) and its various subembodiments; or

[0387] (3)LE1 represents NHR w5 , substrate 2 represents R w6 COOH, R w Indicates N(R w5 )C(O)R w6 , where the group R w5 and R w6 As defined in the compounds of formula (I) and its various subembodiments; or

[0388] (4) LE1 represents Br, Cl or I, and substrate 2 represents R w9 OH, R w Indicates OR w9 , where the group R w9 As defined in the compounds of formula (I) and its various subembodiments.

[0389] Synthesis Scheme 1:

[0390] Solution 1

[0391] In Scheme 1, the dashed lines indicate the presence or absence of ring C and / or ring D, and the group R a1 、R a2 、R a3 、R a4 , X, Y, Ring B, Ring C, Ring D and W are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein. In some embodiments, the step 3 substrate amine NHR wa R wb The group R wa For example, the group R of the compound of formula (I) w1 and as defined in its various sub-embodiments, the group R wb For example, the group R of the compound of formula (I) w2 In some embodiments, the substrate amine NHR wa R wb The group R wa and group R wb Together with the nitrogen atom to which they are attached, they form the substituent and n1 R d1 Group-substituted nitrogen-containing heterocyclic ring A a : The nitrogen-containing heterocyclic ring A a For example, ring A of the compound of formula (I) 4 and its sub-embodiments, n1, R d1 、R e Ring A 5 , m1 and (R d2 ) n2 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0392] The Sonogashira coupling reaction in step 1 of Scheme 1 can be carried out, for example, in the presence of Pd(PPh3)2Cl2, cuprous iodide, TEA, and DMF at room temperature to 100°C (e.g., room temperature to 90°C, room temperature to 60°C, room temperature to 40°C, room temperature to 35°C, or room temperature to 30°C). The molar ratio of the bromo substrate to the alkynol substrate can be, for example, 1:1-4, 1:1.1-3, 1:1.1-2, or 1:1.2-1.5, etc.

[0393] The sulfonation in step 2 of Scheme 1 can be carried out, for example, in the presence of MsCl, DIEA (or TEA), and DCM at room temperature to 40° C. (e.g., room temperature to 35° C. or room temperature to 30° C.). The molar ratio of the hydroxyl substrate to MsCl can be, for example, 1:1-4, 1:1.1-3, 1:1.1-2, or 1:1.2-1.5.

[0394] The amine alkylation reaction in step 3 of Scheme 1 can be carried out, for example, in the presence of DIEA and sodium iodide, or triethylamine and sodium iodide, at room temperature to 100°C (e.g., 40°C to 90°C, 40°C to 80°C, 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). wa R wb The molar ratio of can be, for example, 1:1-4, 1:1.1-3, 1:1.1-1.2, or 1:1.2-2.

[0395] Synthesis Scheme 2:

[0396] Option 2

[0397] In Scheme 2, the dashed lines indicate the presence or absence of ring C and / or ring D, and the group R a1 、R a2 、R a3 、R a4 , X, Y, Ring B, Ring C, Ring D, W, R x and LIN are as defined in the compounds of formula (I) and various subembodiments thereof disclosed herein. In some embodiments, the substrate amine NHR wa R wb The group R wa For example, the group R of the compound of formula (I) w1 and as defined in its various sub-embodiments, the group R wb For example, the group R of the compound of formula (I) w2 In some embodiments, the substrate amine NHR wa R wb The group R wa and group R wb Together with the nitrogen atom to which they are attached, they form the substituent and n1 R d1 Group-substituted nitrogen-containing heterocyclic ring A a : The nitrogen-containing heterocyclic ring A a For example, ring A of the compound of formula (I) 4 and its sub-embodiments, n1, R d1 、R e Ring A 5 , m1 and (Rd2 ) n2 As defined in the compounds of formula (I) and its various subembodiments of the present disclosure. In some embodiments, the OMs group in the sulfonate substrate can also be replaced by other groups that can undergo amine alkylation reaction with amino groups, such as Br, Cl, I, OTs, or ONs.

[0398] The amine alkylation reaction in Scheme 2 can be carried out, for example, in the presence of DIEA and sodium iodide, or triethylamine and sodium iodide, at room temperature to 100°C (e.g., 40°C to 90°C, 40°C to 80°C, 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). wa R wb The molar ratio of can be, for example, 1:1-4, 1:1.1-3, 1:1.1-1.2, or 1:1.2-2.

[0399] Synthesis Scheme 3:

[0400] Option 3

[0401] In Scheme 3, the dashed lines indicate the presence or absence of ring C and / or ring D, and the group R a1 、R a2 、R a3 、R a4 , X, Y, Ring B, Ring C, Ring D, W, R x and LIN are as defined in the compounds of formula (I) and various subembodiments thereof disclosed herein. In some embodiments, the substrate amine NHR wa R wb The group R wa For example, the group R of the compound of formula (I) w1 and as defined in its various sub-embodiments, the group R wb For example, the group R of the compound of formula (I) w2 In some embodiments, the substrate amine NHR wa R wb The group R wa and group R wb Together with the nitrogen atom to which they are attached, they form the substituent and n1 R d1 Group-substituted nitrogen-containing heterocyclic ring A a : The nitrogen-containing heterocyclic ring A a For example, ring A of the compound of formula (I) 4 and its sub-embodiments, n1, R d1 、R e Ring A 5 , m1 and (R d2) n2 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0402] The amide condensation reaction in Scheme 3 can be carried out by conventional techniques and methods well known to those skilled in the art. For example, the amide condensation reaction can be carried out in the presence of HATU, DIEA and DMF, or HOAt, EDCI, TEA and DCM at room temperature to 80°C.

[0403] For example, the operation of scheme 3 can be as follows:

[0404] The substrate acid (1.05 eq.) and the substrate NHR wa R wb (1.0 eq.) was dissolved in DMF, followed by the addition of HATU (1.5 eq.) and triethylamine (3.0 eq.). The reaction mixture was stirred at 50°C for 1-24 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered, and the filtrate was isolated and purified by preparative HPLC to obtain the title compound.

[0405] Synthesis Scheme 4:

[0406] Option 4

[0407] In Scheme 4, the dashed lines indicate the presence or absence of ring C and / or ring D, and the group R a1 、R a2 、R a3 、R a4 , X, Y, Ring B, Ring C, Ring D, W, R x 、R w9 and LIN are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein. In some embodiments, the bromine in the brominated substrate can also be replaced by other groups that can undergo etherification reaction with the hydroxyl group, such as Cl or I.

[0408] The etherification reaction in Scheme 4 can be carried out by conventional techniques and methods well known to those skilled in the art. For example, the etherification reaction can be carried out in the presence of K2CO3, NaI and DMF at room temperature to 100°C.

[0409] For example, the operation of scheme 4 can be as follows:

[0410] The bromosubstrate (1.0 eq.) and the substrate alcohol (2.0 eq.) were dissolved in DMF. KCO (2.0 eq.) and NaI (1.0 eq.) were then added to the solution. The reaction mixture was allowed to react at 40°C for 1 hour and then heated to 80°C overnight. LCMS confirmed the reaction was complete. The reaction mixture was filtered, and the filtrate was isolated and purified using preparative HPLC to obtain the target compound.

[0411] Synthesis Scheme 5:

[0412] Option 5

[0413] In Scheme 5, the dashed lines indicate the presence or absence of ring C and / or ring D, and the group R a1 、R a2 、R a3 、R a4 , X, Y, Ring B, Ring C, Ring D, W, R x 、R w9 and LIN are as defined in the compounds of formula (I) and its various subembodiments disclosed herein. In some embodiments, the group -NR wa R wb The group R wa For example, the group R of the compound of formula (I) w1 and as defined in its various sub-embodiments, the group R wb For example, the group R of the compound of formula (I) w2 In some embodiments, the group -NHR of the substrate alkyne wa R wb The group R wa and group R wb Together with the nitrogen atom to which they are attached, they form the substituent and n1 R d1 Group-substituted nitrogen-containing heterocyclic ring A a : The nitrogen-containing heterocyclic ring A a For example, ring A of the compound of formula (I) 4 and its sub-embodiments, n1, R d1 、R e Ring A 5 , m1 and (R d2 ) n2 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0414] The hydrogenation reaction in Scheme 5 can be carried out using conventional techniques and methods well known to those skilled in the art.

[0415] For example, the operation of scheme 5 can be as follows:

[0416] The substrate alkyne (1.0 eq.) was dissolved in THF at room temperature, and palladium / barium sulfate (0.1 eq.) was added. The reaction mixture was replaced with hydrogen three times and stirred under a hydrogen atmosphere (15 psi) for 1 hour. LCMS confirmed the reaction was complete. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by C18 reverse-phase column to obtain the desired final product.

[0417] Depending on the target compound, the above schemes and their reaction substrates, reaction conditions (including reaction amount, temperature, time, etc.), post-treatment, etc. can be appropriately modified and adjusted by techniques and methods well known to those skilled in the art to obtain the desired target compound, and the obtained target compound can be further modified by substituents, etc. according to methods well known to those skilled in the art to obtain other target compounds.

[0418] Example

[0419] Example 1: Preparation of 3-(5-(8-((adamantan-1-yl)amino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (GT-03263)

[0420] The target compound GT-03263 was prepared according to the method of Scheme 1.

[0421] Step 1: To a 50 mL reaction flask, 3-(5-bromobenzofuran-3-yl)piperidine-2,6-dione (100 mg, 0.325 mmol, 1 eq), Pd(PPh3)2Cl2 (22.78 mg, 0.1 eq), and cuprous iodide (61.81 mg, 1 eq) were added. DMF (3 mL), TEA (0.3 mL), and oct-7-yn-1-ol (123.05 mg, 3 eq) were then added under nitrogen. After complete addition, the mixture was heated to 90°C and stirred for 16 h. After completion of the reaction, the reaction mixture was concentrated and purified by column chromatography to yield 3-(5-(8-hydroxyoct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (pale yellow solid, 70 mg, 60.94% yield). LCMS (ESI) m / z: C 21 H 24 NO4 + [M+H] + , calculated value 354.17; measured value 354.2.

[0422] Step 2: To a 50 mL reaction bottle, 3-(5-(8-hydroxyoctan-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (70 mg, 0.198 mmol, 1 eq) and DCM (15 mL) were added. TEA (60.13 mg, 3 eq) and MsCl (45.38 mg, 2 eq) were then added under nitrogen at room temperature. The mixture was stirred at room temperature for 1 h. After completion of the reaction, the reaction mixture was washed twice with saturated sodium bicarbonate solution and once with brine, dried over anhydrous sodium sulfate, and concentrated to give 8-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)oct-7-yn-1-yl methanesulfonate (pale yellow solid, 550 mg, yield 58.50%). LCMS (ESI) m / z: C22 H 26 NO6S + [M+H] + , calculated value 432.15; measured value 432.2.

[0423] Step 3: To a 10 mL reaction vial, 8-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)oct-7-yn-1-yl methanesulfonate (30 mg, 0.07 mmol, 1 eq) and adamantaneamine (21.03 mg, 2 eq) were added, followed by NMP (1.5 mL). Then, under nitrogen, sodium iodide (15.63 mg, 1.5 eq) and DIPEA (0.034 mL, 3 eq) were added. The mixture was stirred at 90°C for 16 h. After completion of the reaction, the reaction mixture was purified by LCMS on a C18 reverse-phase column to yield the desired product, GT-03263 (white solid, 7 mg, 19.25% yield). 1 H NMR (400MHz, MeOD) δ7.66 (s, 1H), 7.48 (s, 1H), 7.33 (d, J=8.4Hz, 1H), 7.20 (d d, J=8.6, 1.6Hz, 1H), 4.02 (dd, J=11.7, 5.1Hz, 1H), 2.91-2.82 (m, 2H), 2.74-2 .57(m, 2H), 2.38-2.31(m, 2H), 2.29-2.15(m, 2H), 2.07(s, 3H), 1.78(d, J=2. 2Hz, 6H), 1.64 (dd, J=37.0, 11.1Hz, 10H), 1.52-1.39 (m, 4H). LCMS (ESI) m / z: C 31 H 39 N2O3 + [M+H] + , calculated value 487.30; measured value 487.3.

[0424] Example 2: Preparation of 3-(5-(3-((adamantan-1-yl)amino)prop-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (GT-03207)

[0425] The target compound GT-03207 (light yellow solid, 5.0 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1H NMR (400MHz, MeOD) δ7.72 (d, J=7.0Hz, 1H), 7.64 (d, J=3.7Hz, 1H), 7.43 (d, J=8.5Hz, 1H), 7.34 (dd, J=8.6, 1.5Hz, 1H), 4.10-3.99 (m, 3 H), 2.68 (ddd, J=21.7, 14.5, 9.4Hz, 2H), 2.32-2.20 (m, 2H), 2.14 (s, 3H), 1.85 (dd, J=18.8, 5.4Hz, 6H), 1.74-1.64 (m, 6H). LCMS (ESI) C 26 H 29 N2O3 + [M+H] + : Calculated value, 417.22, measured value, 417.30.

[0426] Example 3: Preparation of 3-(5-(5-((adamantan-1-yl)amino)pent-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (GT-03034)

[0427] The target compound GT-03034 (white solid, 10 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1 H NMR (400MHz, MeOD) δ7.77 (s, 1H), 7.60 (s, 1H), 7.45 (d, J=8.5Hz, 1H), 7.33 (dd, J=8.5, 1.5Hz, 1H), 4.12 (dd, J=11.6, 5.2Hz, 1H), 3.21-3.0 8 (m, 2H), 2.86-2.67 (m, 2H), 2.62 (t, J=6.9Hz, 2H), 2.43-2.26 (m, 2H), 2.22 (s, 3H), 1.95 (t, J=7.6Hz, 8H), 1.83-1.71 (m, 6H). LCMS (ESI) C 28 H 33 N2O3 + [M+H] + : Calculated value, 445.25, measured value, 445.30.

[0428] Example 4: Preparation of 3-(5-(7-((adamantan-1-yl)amino)hept-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (GT-03206)

[0429] The target compound GT-03206 (light yellow solid, 5 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1H NMR (400MHz, MeOD) δ7.66 (s, 1H), 7.48 (s, 1H), 7.33 (d, J=8.5Hz, 1H), 7.21 (dd, J=8.5, 1.5Hz, 1H), 4.02 (dd, J=11.5, 5.2Hz, 1H), 2.89 (d , J=7.8Hz, 2H), 2.72-2.58 (m, 2H), 2.38 (t, J=6.5Hz, 2H), 2.29-2.19 (m, 2H), 2.10 (s, 3H), 1.81 (s, 6H), 1.71-1.61 (m, 12H).LCMS (ESI) C 30 H 37 N2O3 + [M+H] + : Calculated value, 473.28, measured value, 473.30.

[0430] Example 5: Preparation of 3-(5-(7-((adamantan-1-yl)(methyl)amino)hept-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (GT-03381)

[0431] The target compound GT-03381 (white solid, 20 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1 H NMR (400MHz, MeOD) δ7.66 (s, 1H), 7.49 (s, 1H), 7.33 (d, J=8.6Hz, 1H), 7.22 (d, J=8.6Hz, 1H), 4.02 (dd, J=11.5, 5.1Hz, 1H), 3.44-3.30 (m, 2 H), 2.72-2.58 (m, 6H), 2.39 (t, J=6.5Hz, 2H), 2.26 (dd, J=9.7, 6.6Hz, 1H), 2.14 (s, 3H), 1.98-1.80 (m, 8H), 1.59-1.50 (m, 10H). LCMS (ESI) C 31 H 39 N2O3 + [M+H] + : Calculated value, 487.30, measured value, 487.30.

[0432] Example 6: Preparation of 3-(5-(7-((3-hydroxyadamantan-1-yl)amino)hept-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione (GT-04350)

[0433] The target compound GT-04350 (white solid, 80 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1H NMR (400MHz, MeOD) δ7.78 (s, 1H), 7.60 (d, J=1.2Hz, 1H), 7.45 (dd, J=8.5, 0.5Hz, 1H), 7.33 (dd, J=8.5, 1.6Hz, 1H), 4.14 (dd, J=11.3, 5.0Hz, 1H), 3.50-3.46 (m, 2H), 3.06-2.98 (m, 2H) , 2.86 (s, 4H), 2.84-2.73 (m, 1H), 2.50 (t, J=6.5Hz, 2H), 2.42-2.38 (m, 4H), 2.09-2.02 (m, 2 H), 1.85 (s, 6H), 1.79-1.72 (m, 6H), 1.72-1.65 (m, 4H), 1.64-1.61 (m, 2H). LCMS (ESI) m / z: C 30 H 37 N2O4 + [M+H] + , calculated value 489.27; measured value, 489.3.

[0434] Example 7: Preparation of 3-(5-(7-((3-hydroxyadamantan-1-yl)amino)heptyl)benzofuran-3-yl)piperidine-2,6-dione (GT-04373)

[0435] The target compound GT-04373 (white solid, 20 mg) was prepared by the method of Reference Scheme 5. 1 H NMR (400MHz, MeOD) δ7.59 (s, 1H), 7.31-7.23 (m, 2H), 7.04 (dd, J=8.5, 1.5Hz, 1H), 4.02 (dd, J=11.2, 5.0Hz, 1H), 2.89-2.79 (m, 2H), 2.68 (dd, J=11. 3, 5.5Hz, 1H), 2.65-2.57(m, 3H), 2.33-2.24(m, 3H), 2.21-2.14(m, 1H), 1 .70(s, 6H), 1.65-1.55(m, 6H), 1.52(s, 4H), 1.30(s, 6H).LCMS(ESI)m / z: C 30 H 41 N2O4 + [M+H] + , calculated value 493.31; measured value, 493.3.

[0436] Example 8: Preparation of 3-(5-(7-((adamantan-1-yl)amino)heptyl)benzofuran-3-yl)piperidine-2,6-dione (GT-04375)

[0437] The target compound GT-04375 (white solid, 20 mg) was prepared by the method of reference scheme 5. 1 H NMR (400MHz, MeOD) δ7.58 (s, 1H), 7.31-7.23 (m, 2H), 7.04 (dd, J=8.4, 1.7Hz, 1H), 4.02 (dd, J=11.3, 5.1Hz, 1H), 2.85-2.78 (m, 2H), 2.72- 2.66 (m, 1H), 2.62 (t, J=6.3Hz, 2H), 2.10 (s, 4H), 1.84-1.75 (m, 8H), 1.74-1.60 (m, 8H), 1.53-1.49 (m, 2H), 1.30 (s, 6H). LCMS (ESI) m / z: C 30 H 41 N2O3 + [M+H] + , calculated value 477.31; measured value 477.3.

[0438] Example 9: Preparation of 1-(6-(5-((adamantan-1-yl)amino)pent-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (GT-02878)

[0439] The target compound GT-02878 (white solid, 7 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1 H NMR (400MHz, DMSO) δ10.67 (s, 1H), 8.74 (s, 3H), 7.87 (s, 1H), 7.70 (d, J = 9.3Hz, 1H), 7.51 (d, J = 9.6Hz, 1H), 3.76 (t, J = 6.4Hz, 2H), 2.93 (s, 2H), 2.78 (s, 2H), 2.57 (t, J=7.1Hz, 2H), 2.06 (s, 3H), 1.93-1.86 (m, 2H), 1.82 (s, 6H), 1.60-1.53 ​​(m, 6H). LCMS (ESI) m / z: C 26 H 32 N5O2 + [M+H] + , calculated value 446.26; measured value, 446.3.

[0440] Example 10: Preparation of 1-(6-(7-((adamantan-1-yl)amino)hept-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (GT-03286)

[0441] The target compound GT-03286 (white solid, 13 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1 H NMR (400MHz, MeOD) δ8.67 (s, 1H), 8.04 (s, 1H), 7.87-7.73 (m, 2H), 3.87 (t, J=6.7Hz, 2H), 2.95-2.80 (m, 4H), 2.45 (t, J =6.9Hz, 2H), 2.11 (s, 3H), 1.83 (d, J = 2.4Hz, 6H), 1.64 (dd, J = 20.7, 13.3Hz, 10H), 1.55-1.48 (m, 2H). LCMS (ESI) m / z: C 28 H 36 N5O2 + [M+H] + , calculated value 474.29; measured value, 474.3.

[0442] Example 11: Preparation of 1-(6-(7-((adamantan-1-yl)(methyl)amino)hept-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (GT-03307)

[0443] The target compound GT-03307 (white solid, 14 mg) was prepared by referring to Scheme 1 and Example 1. 1 H NMR (400MHz, MeOD) δ8.62 (s, 1H), 7.99 (s, 1H), 7.75 (s, 2H), 3.87 (t, J=6.6Hz, 2H), 3.44-3.34 (m, 1H), 2.87 (s, 2H), 2.75-2 .63 (m, 4H), 2.46 (dd, J=14.5, 7.6Hz, 2H), 2.16 (s, 3H), 1.91 (dd, J=27.8, 11.4Hz, 6H), 1.72-1.46 (m, 12H). LCMS (ESI) m / z: C 29 H 38 N5O2 + [M+H] + , calculated value 488.30; measured value, 488.3.

[0444] Example 12: Preparation of 1-(6-(8-((adamantan-1-yl)amino)oct-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (GT-02936)

[0445] The target compound GT-02936 (white solid, 8 mg) was prepared by referring to the method of Scheme 1 and Example 1.1 H NMR (400MHz, MeOD) δ8.83 (s, 1H), 8.20 (s, 1H), 8.03-7.87 (m, 2H), 3.99 (t, J=6.6Hz, 2H), 3.03-2.92 (m, 4H), 2.5 5 (t, J=7.1Hz, 2H), 2.22 (s, 3H), 1.94 (d, J=2.5Hz, 6H), 1.85-1.68 (m, 10H), 1.62-1.49 (m, 4H). LCMS (ESI) m / z: C 29 H 38 N5O2 + [M+H] + , calculated value 488.30; measured value, 488.3.

[0446] Example 13: Preparation of 1-(6-(8-((adamantan-1-yl)amino)octyl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (GT-02937)

[0447] The target compound GT-02937 (white solid, 12 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1 H NMR (400MHz, MeOD) δ8.58 (s, 1H), 8.17 (d, J=4.4Hz, 1H), 7.96 (qd, J=9.3, 2.5Hz, 2H), 4.01 (t, J=6.5Hz, 2H), 2.97 (dd, J=1 6.6, 8.7Hz, 4H), 2.89-2.78 (m, 2H), 2.23 (s, 3H), 1.94 (t, J=5.6Hz, 6H), 1.85-1.65 (m, 10H), 1.43 (s, 8H). LCMS (ESI) m / z: C 29 H 42 N5O2 + [M+H] + , calculated value 492.33; measured value, 492.4.

[0448] Example 14: Preparation of 1-(6-(7-(4-(adamantan-1-yl)piperazin-1-yl)hept-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (GT-03288)

[0449] The target compound GT-03288 (white solid, 7 mg) was prepared by referring to the method of Scheme 1 and Example 1. 1H NMR (400MHz, MeOD) δ8.81 (s, 1H), 8.08 (s, 1H), 7.84 (dt, J=23.2, 8.7Hz, 2H), 3.89 (t, J=6.6Hz, 2H), 3.84-3.65 (m, 4H), 3.43 (d, J=36.4Hz, 4H) , 3.13 (d, J=7.4Hz, 2H), 2.90 (s, 2H), 2.47 (t, J=6.8Hz, 2H), 2.19 (s, 3H), 1.98 (s, 6H), 1.79-1.63 (m, 10H), 1.57-1.50 (m, 2H). LCMS (ESI) m / z: C 32 H 43 N6O2 + [M+H] + , calculated value 543.34; measured value, 543.4.

[0450] Biological activity detection experiment

[0451] Experimental reagents and materials:

[0452] Experimental methods:

[0453] Cell culture

[0454] The tumor cells used in this disclosure were cultured in RPMI 1640 medium in a 37°C incubator containing 5% CO2. RPMI 1640 cell culture medium was supplemented with 10% fetal bovine serum and a final concentration of 100 U / mL penicillin and 100 μg / mL streptomycin. All cells were authenticated by STR and tested negative for mycoplasma using a mycoplasma detection kit prior to the experiment.

[0455] I. Half inhibitory concentration (IC) of the compound on tumor cells 50 ) determination

[0456] IC values ​​of the compounds disclosed herein (including compounds in Table 1 and example compounds) 50The assay was performed using the CellTiter-Meiluncell luminescence cell viability detection kit from Meilun Biotechnology. The specific steps are as follows: tumor cells were seeded in 96-well cell culture plates at the inoculation density shown in Table 2. The next day, the disclosed test compounds (including compounds in Table 1 and example compounds) were diluted 5-fold from a maximum concentration of 2000 μM, with a total of 9 concentrations (2000, 400, 80, 16, 3.2, 0.64, 0.128, 0.0256, 0.00512 μM) set from high to low. Subsequently, 0.5 μL of the disclosed test compound was drawn and added to a 96-well plate containing cells to be tested, each well containing 100 μL of cell culture medium. The final test concentrations of the test compound in each well reached 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064, 0.000128, and 0.0000256 μM, respectively. Take 0.5 μL of the diluted compounds of the present invention (including the compounds in Table 1 and the example compounds) and add them to 100 μL of the inoculated cells. After the cells are treated with the compounds of the present invention for a period of time (the treatment time is shown in Table 2), the cell activity detection reagent is added to the culture medium according to the operating instructions of the CellTiter-Meiluncell luminescent cell viability detection kit to measure the cell activity. The negative control is DMSO, and the control drug is the corresponding commercial immunomodulatory drug (including lenalidomide and pomalidomide), and the cells are treated in the same manner as the compounds of the present invention. The inhibition of cell growth by the compounds of the present invention is plotted by Prism Graphpad software and the IC of the compounds of the present invention is calculated therefrom. 50 .

[0457] Table 2 Tumor cell inoculation procedure and treatment time

[0458] The results of inhibiting tumor cell proliferation are listed in Table I-1.

[0459] Table I-1 Inhibitory activity of the disclosed compounds on tumor cell proliferation (IC 50 , nM)

[0460] Note: In Table I-1, the symbols A++, A+, A, B, C, D, E, F, and G indicate as follows: 0 nM < A++ ≤ 5 nM; 5 nM < A+ ≤ 10 nM; 10 nM < A ≤ 50 nM; 50 nM < B ≤ 100 nM; 100 nM < C ≤ 500 nM; 500 nM < D ≤ 1000 nM; 1000 nM < E ≤ 5000 nM; 5000 nM < F ≤ 10000 nM; 10000 nM < G. The symbol “-” indicates not tested.

[0461] The results showed that the disclosed compounds had a significant inhibitory effect on the proliferation of MM.1S cells (human multiple myeloma cells), MM.1R cells (human multiple myeloma cells-dexamethasone-resistant), JEKO-1 cells (human mantle cell lymphoma cells), Daudi cells (human Burkitt's lymphoma cells), TMD8 cells (human diffuse large B lymphoma cells), Ramos cells (human B lymphoma cells), SR cells (human large cell immunoblastic lymphoma cells), SU-DHL-6 cells (human diffuse large B lymphoma cells) and CCRF-CEM cells (human acute lymphoblastic leukemia T lymphocytes) (as shown in Table I-1), and the inhibitory effect was better than that of the corresponding positive control drugs.

[0462] II. Western Blot Assay

[0463] Conventional Western Blot was used to detect the effects of the disclosed compounds on the expression of target proteins in cells.

[0464] (1) Cell seeding and protein collection: The cell density is 1×10 6 hPBMC cells of 1000 cells / mL were revived according to the PBMC cell resuscitation operating instructions (Miaoshun (Shanghai) Biotechnology Co., Ltd.), and then treated with the compounds of the present invention (including the compounds in Table 1 and the compounds of each embodiment) at a concentration of 500nM and 50nM. A negative control group (DMSO) and a positive control group were also set up: the corresponding commercial immunomodulatory drugs (lenalidomide) were used, and the cells were treated in the same manner as the compounds of the present invention. After the cells were treated with the compounds for 24 hours, the cells were collected, RIPA protein lysis buffer containing protease inhibitors was added to lyse the cells, and the cells were placed on ice for 30 minutes and centrifuged. The supernatant was collected, and the resulting supernatant was the extracted total cell protein. The protein concentration of the supernatant was determined by conventional BCA method (Bicinchoninc acid procedure).

[0465] (2) Add 5X SDS loading buffer to the collected supernatant, denature at 95°C for 5 minutes, perform polyacrylamide gel SDS-PAGE electrophoresis, and then transfer to a nitrocellulose membrane (0.45 μM NC membrane). Block with blocking solution at room temperature for 1 hour, and then perform antibody incubation and development according to the antibody instructions of Cell Signaling Technology.

[0466] Half degradation concentration (drug concentration corresponding to 50% protein degradation, i.e., DC 50 ) Reading method: Compare the grayscale value of the Western blotting band after drug treatment with the grayscale value of the Western blotting band after blank DMSO treatment, and read the drug concentration range at which the grayscale value is half of the grayscale value of the Western blotting band after blank DMSO treatment.

[0467] DC 50 The values ​​can be calculated by reading the grayscale values ​​of the corresponding Western blotting bands after drug treatment using ImageJ software. The relationship curve between drug concentration and grayscale value is fitted to estimate the drug concentration corresponding to half the grayscale value.

[0468] The % protein remaining refers to the amount of target protein remaining in the cells after the cells are treated with a protein degrader compound.

[0469] Calculation of the % remaining protein content: Use Image J software to read the grayscale value of the corresponding Western blotting band after drug (protein degrader) treatment. Divide the grayscale value of the Western blotting band corresponding to the drug treatment by the grayscale value of the Western blotting band corresponding to the internal reference protein. Normalize the resulting quotient to obtain the relative % remaining content of the target protein after protein degrader treatment.

[0470] Target protein degradation rate % = 1-target protein remaining content %

[0471] The effects of the compounds disclosed herein (including the compounds in Table 1 and the compounds in the Examples) on the expression of substrate proteins in cells are listed in the following Table II-1.

[0472] Table II-1 Degradation results of the disclosed compounds on substrate proteins WEE1, IKZF1, IKZF2, IKZF3, CK1α and GSPT1

[0473] Note: In Table II-1, A means 0% ≤ residual substrate protein content ≤ 80%, and B means 80% < residual substrate protein content ≤ 100%.

[0474] The degradation effects of the compounds of the present invention on target substrate proteins are shown in Table II-1 and Figure 1. As can be seen from the experimental results in Table II-1 and Figure 1, the compounds of the present invention can significantly degrade substrate proteins (e.g., WEE1 protein, IKZF1 / 2 / 3 protein, CK1α protein, GSPT1 protein, ZFP91 protein, etc.). Compared to lenalidomide, the compounds of the present invention have significantly improved the efficiency of inducing substrate protein degradation and can also selectively induce the degradation of substrate proteins, thereby being used to treat indications related to substrate proteins.

[0475] III. Binding affinity test of compounds to CRBN:

[0476] The CRBN binding ability of the test compound was determined by HTRF (homogeneous time-resolved fluorescence) using the CEREBLON BINDING KITS kit (10,000 tests; Catalog No. 64BDCRBNPEH; supplier: CISBIO). The specific method is as follows:

[0477] 1. According to the instructions of the CEREBLON BINDING KITS kit, the test compounds of the present disclosure and lenalidomide were serially diluted with diluent #9 (1X) solution, specifically using diluent #9 (1X) solution as the diluent, and multiple concentration gradients were set. The dilution operation was as follows: the test compounds of the present disclosure (including the compounds in Table 1 and the compounds of each example) were diluted 5-fold starting from the highest concentration of 40 μM, and a total of 7 concentrations were set from high to low (40, 8, 1.6, 0.32, 0.064, 0.0128, 0.00256 μM). Subsequently, the diluted test compounds of the present disclosure and the corresponding detection reagents were added to each well of a 96-well plate, and the final test concentrations of the test compounds in each well reached 10, 2, 0.4, 0.08, 0.016, 0.0032, and 0.00064 μM, respectively. The experimental operation is described below using a diluted 40 μM test compound and lenalidomide solution as an example.

[0478] 2. Add 2.5 μL of the diluted 40 μM test compound and lenalidomide solutions and the same volume of diluent #9 (1X) solution (solvent control, Std0) to each well of a 96-well plate. Then, add 2.5 μL of human Cereblon WT GST-tagged protein solution to each well. Finally, add 5 μL of the mixed Thalidomide-Red reagent and GST Eu antibody working solution to each well. The final concentration of the test compound and lenalidomide in each well is 10 μM.

[0479] 3. Add 2.5 μL of diluent #9 (1X) solution, 2.5 μL of PROTAC binding buffer solution, and 5 μL of evenly mixed Thalidomide-Red reagent and GST Eu antibody working solution to the blank control wells in sequence.

[0480] 4. After the solutions in the above wells were sealed and incubated at room temperature for 3 hours, the absorbance values ​​of each well at emission wavelengths of 620 nm and 665 nm were detected using the HTRF method of Spark microplate reader (V3.1 SP1).

[0481] The corresponding CRBN binding inhibition rate was calculated using the following method:

[0482] R 化合物 =OD 665nm 化合物 / OD 620nm 化合物 -OD 665nm 对照 / OD 620nm 对照

[0483] R Std0 =OD 665nm Std0 / OD 620nm Std0 -OD 665nm 对照 / OD 620nm 对照

[0484] Inhibition rate (%) = (1-R 化合物 / R Std0 )*100

[0485] Note: OD 665nm 化合物 is the absorbance value of each well of the test compound at an emission wavelength of 665 nm

[0486] OD 620nm 化合物 is the absorbance value of each well of the test compound at an emission wavelength of 620 nm

[0487] OD 665nm 对照is the absorbance value of the blank control well at an emission wavelength of 665 nm

[0488] OD 620nm 对照 is the absorbance value of the blank control well at an emission wavelength of 620 nm

[0489] OD 665nm Std0 is the absorbance value of the solvent control well at an emission wavelength of 665 nm

[0490] OD 620nm Std0 is the absorbance value of the solvent control well at an emission wavelength of 620 nm

[0491] The results are shown in Table III-1 below.

[0492] Table III-1 HTRF inhibitory activity (IC 50 , μM)

[0493] In Table III-1, the symbols a1, a, b, c, d and e have the following meanings: 0<a1≤0.05μM, 0.05μM<a2≤0.1μM, 0.1μM<a≤0.5μM, 0.5μM<b≤1μM, 1μM<c≤1.5μM, 1.5μM<d<1.9μM, 1.9μM≤e≤10μM, 10μM<f.

[0494] The results in Table III-1 indicate that the compounds of the present invention (including but not limited to the compounds in Table 1 and the compounds in the Examples) have lower or equivalent IC values ​​compared to lenalidomide. 50 value, or has a higher inhibition rate, showing a stronger binding ability to CRBN.

[0495] IV. TNF-α Activity Inhibition Experiment

[0496] PBMCs were cultured at 37°C under 5% CO2 and then 1×10 7 Cells were seeded per well in a 96-well plate. Test compounds (including compounds in Table 1 and compounds from the Examples) were dissolved in DMSO and diluted to the appropriate concentration, such that the final DMSO concentration added to the cell culture did not exceed 0.5%. After incubation for 1 hour in medium containing or without the compound, cells were stimulated with lipopolysaccharide (LPS; 1 ng / ml) and cultured for an additional 18-20 hours. The supernatant was then collected, diluted with serum-free medium, and assayed for TNF-α levels using an ELISA kit. IC values ​​were then calculated using Graphpad Prism 7.0. 50 .

[0497] Down-regulation of TNF-α expression is an important factor in the anti-tumor effect of immunomodulators. After treatment with the compounds of the present invention, TNF-α levels are inhibited in a dose-dependent manner.

[0498] V. Pharmacokinetic Studies of the Disclosed Compounds

[0499] Conventional pharmacokinetic experimental methods were used to test the pharmacokinetic properties of the disclosed compounds.

[0500] The test compounds of the present disclosure (including the compounds in Table 1 and the Example compounds) were orally administered to experimental animals to evaluate the pharmacokinetic properties of the compounds of the present disclosure. The experimental animals used can be adult healthy rodents (e.g., mice, rats (e.g., Sprague-Dawley (SD) rats), guinea pigs) or non-rodents (rabbits, dogs, and monkeys) commonly used in pharmacokinetic experiments. The experimental animals used in the present disclosure are mice.

[0501] Experimental animals were divided into two groups: a control group (blank plasma collection) and an oral administration group (administered at a dose of 10 mg / kg). Blood samples were collected at predetermined sampling points after administration, for example, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, and 24 h after administration. Blank plasma was collected from the control group.

[0502] Plasma samples were pretreated prior to analysis by adding 10 μL of 50% acetonitrile and 200 μL of an internal standard solution (50 ng / mL dexamethasone in acetonitrile) to 10 μL of plasma sample. A blank control plasma sample was prepared without the internal standard and supplemented with an equal volume of acetonitrile. The pretreated samples were vortexed, centrifuged, and the supernatant was injected for LC-MS / MS analysis.

[0503] After preparing the standard curve and QC samples, the compound concentration in the test plasma samples was determined by LC-MS / MS analysis. Based on the plasma drug concentration data determined by LC-MS / MS analysis, the pharmacokinetic parameters of the test compound were calculated using the non-compartmental model of the pharmacokinetic calculation software WinNonlin v8.1.

[0504] The results showed that the disclosed compound administered via oral administration has good pharmacokinetic (DMPK) properties and can be used as a therapeutic drug for cancer patients.

[0505] VI. Effects of the Disclosed Compounds on Lipopolysaccharide- or Phytohemagglutinin-Induced Release of TNF-α, IL-10, IL-6, IL-1β, IFN-γ, GM-CSF, IL-2, and IL-12p40 from PBMC

[0506] The following materials were used in this study:

[0507] VI.1 Reagents and consumables

[0508] VI.2 Method

[0509] VI.2.1 Cell recovery and plating

[0510] Prepare complete culture medium and preheat at 37°C. Remove cells from the liquid nitrogen tank and use tweezers to grasp the cryotube just below the junction of the cap and the bottle. Immerse the cell suspension in 37°C warm water and shake occasionally to thaw it as quickly as possible. Aspirate the cell suspension and add it to a centrifuge tube containing 10 mL of complete culture medium. Mix thoroughly. Centrifuge at 400 g for 10 min at room temperature. Discard the supernatant, add complete culture medium, count and adjust the cell density, and inoculate 75 μL / well into a 96-well plate until the number of cells per well is 1 × 10. 5 , high humidity, 37℃, 5% CO2 incubator for 2h.

[0511] VI.2.2 Preparation of compounds and addition to cell plates

[0512] 1) Test compounds were prepared into 10 mM stock solutions in DMSO.

[0513] 2) The test compound was diluted 5-fold with DMSO at the highest concentration of 1 mM to obtain 9 concentration gradients of the compound.

[0514] 3) Dilute the test compound with culture medium to 5 times the final concentration of the corresponding effect.

[0515] 4) Add 25 μL / well of the diluted compound to the corresponding wells according to the following layout. The final concentration of the compound should start at 1 μM and be diluted 5-fold for a total of 9 concentration points.

[0516] 5) After 1 h, add LPS or PHA to the cell wells at 25 μL / well to a final concentration of LPS of 1 μg / mL (TNF-α, IL-10, IL-6, GM-CSF and IL-12p40), 5 μg / mL (IL-1β), 50 μg / mL (IFN-γ), and a final concentration of PHA of 1 μg / mL (IL-2).

[0517] 6) Place the cell plate in a high humidity, 37°C, 5% CO2 incubator and incubate for 24 hours.

[0518] Cell Plate Layout:

[0519] VI.2.3 Detection

[0520] (1) Centrifuge, aspirate the culture supernatant, and detect TNF-α, IL-10, IL-6, IL-1β, IFN-γ, GM-CSF, IL-2, and IL-12p40 cytokines in the culture supernatant according to the ELISA kit instructions.

[0521] The concentrations of TNF-α, IL-10, IL-6, IL-1β, IFN-γ, GM-CSF, IL-2, and IL-12p40 in the samples were calculated based on the standard curve. Inhibition rate (%) = [(Ac-As) / (Ac-Ab)] × 100%

[0522] As: OA of sample (cells + LPS / PHA + test compound)

[0523] Ac: OA of positive cell control (cells + LPS / PHA + DMSO)

[0524] Ab: blank control OA (cells + culture medium + DMSO)

[0525] (2) IC was calculated using the software Graphpad Prism 6 using the formula XY-analysis / Nonlinear regression (curvefit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters). 50 Curve fitting and calculation of IC 50 value.

[0526] The experimental results show that the compounds disclosed herein can regulate the production level of cytokines related to autoimmune diseases and can be used to treat autoimmune diseases.

[0527] VII. Pharmacological efficacy of the disclosed compounds on imiquimod-induced psoriasis-like lesions on the back of mice

[0528] The compounds of the present invention (test substances, including the compounds in Table 1 and the compounds in the Examples) were orally administered to imiquimod-induced mice once a day for 7 consecutive days to study the pharmacodynamic effects of the compounds of the present invention on psoriasis-like lesions on the back skin of imiquimod-induced mice.

[0529] Sixty C57BL / 6J female mice (purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd.) were divided into 6 groups according to their body weight, with 10 mice in each group:

[0530] Note: ig. oral gavage; sc. subcutaneous injection; qd. once a day.

[0531] After the experimental animals were grouped, the backs of all mice were shaved. Except for the control group, all other groups were topically treated with imiquimod cream once daily for 7 consecutive days. Simultaneously, each group was given a solvent control, a positive control drug, or the test substance once daily for 7 consecutive days, as described in the table above.

[0532] Observe all clinical symptoms of each animal at the beginning and during the experiment. Weigh the animals every two days and record their weight.

[0533] score

[0534] Gross skin lesion assessment (PASI): During the final three days of modeling and drug administration, mice in each group were observed once daily for changes in skin lesions. The PASI score was based on the degree of erythema, scaling, and thickening of the lesions, with the sum of these three scores forming a total score. PASI scoring criteria: 0, none; 1, mild; 2, moderate; 3, severe; 4, very severe.

[0535] During the last 3 days of modeling and drug administration, the skin lesions were photographed once a day.

[0536] At the end of the experiment, mice were euthanized by inhalation of an overdose of CO 2. Skin from three different locations on the back lesion was obtained using a 6 mm punch, weighed, and recorded to calculate the average weight.

[0537] Skin tissue homogenates from lesional areas were used to detect the levels of IL-23p19, IL-12p40, IL-17, and TNF-α.

[0538] The local skin lesions were fixed and stained with HE, and pathological scoring (epidermal thickness, degree of epidermal cell keratinization, basal cell thickness, and degree of dermal inflammatory cell infiltration) was performed. The scoring criteria were: 0, none; 1, mild; 2, moderate; 3, severe; 4, extremely severe.

[0539] The experimental data were expressed as Mean ± SD. The data between the two groups were analyzed using SPSS statistics, and p < 0.05 was considered to be a significant difference.

[0540] The experimental results show that the disclosed compound has an improving effect on imiquimod-induced psoriasis-like lesions on the back skin of mice and can be used to treat psoriasis.

[0541] VIII. Pharmacological efficacy of the disclosed compounds on type II collagen-induced CIA model rats

[0542] The compounds of the present invention (test substances, including compounds in Table 1 and example compounds) were orally administered to Wistar rats induced with bovine type II collagen (Chondrex) once a day for 21 consecutive days to study the pharmacological effects of the compounds of the present invention on the rat arthritis model (CIA).

[0543] Modeling agent preparation:

[0544] Dissolve 10 mg of CII (Immunization Grade Bovine Type II Collagen, purchased from Chondrex) in 5 mL of 0.05 M acetic acid until fully dissolved, to a 2 mg / mL solution. Store the solution at 4°C in the dark overnight. For the experiment, equal volumes of the 2 mg / mL CII solution and 4 mg / mL Complete Freund's Adjuvant (CFA, purchased from Chondrex) were mixed in an ice bath to form an emulsion.

[0545] On day 0, 10 Wistar rats (purchased from Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd.) were randomly selected as a blank control group and not immunized. The remaining 100 Wistar rats received a first immunization by intradermal injection of an emulsion prepared by mixing equal volumes of CII (2 mg / mL) and CFA (4 mg / mL) at the base of the tail. A second booster immunization was performed on day 7. On days 10-14, i.e., 3-7 days after the second booster immunization, when the Arthritis Index (AI) score on the affected foot was 1-2, 50 rats were selected from the model animals and divided into five groups of 10 rats each based on body weight, foot volume, and AI score:

[0546] Note: ig. Oral gavage; sc. Subcutaneous injection

[0547] 3 to 7 days after the second booster immunization, when the AI ​​score of the diseased foot reaches 1 to 2 points, each group of animals is given solvent control, positive control drug or test substance by oral gavage (or subcutaneous injection) according to the above table, once a day for 21 consecutive days.

[0548] Starting 3 days after the second booster immunization, the volume of the bilateral hind paws was measured and recorded twice a week.

[0549] Foot Volume Measurement: Before measurement, mark the rat's ankle with a marker. Add clean water to the instrument and reset the instrument to zero. Place the rat's hind limb in the water so that the marked ankle line is at the surface of the liquid. Press the pedal to read the foot volume. Once the measurement is complete, press the pedal again to reset the reading and prepare for the next measurement.

[0550] score

[0551] Arthritis index (AI): The paw volume was measured twice a week and the swelling of the four toes was scored, with each foot ranging from 0 to 4 points, and the highest score for each rat was 16 points.

[0552] Arthritis Index scoring criteria:

[0553] The start of drug administration was recorded as day 0. Five days after drug administration, that is, 2 hours after drug administration on the fifth day, blood was collected from the jugular vein of the experimental animals, allowed to stand for more than 30 minutes, centrifuged to separate the serum, and frozen at -80°C. Serum TNF-α, IL-1β, and IL-6 were detected by ELISA.

[0554] After the experiment, the animals were euthanized by inhalation of an overdose of CO2. The spleen and thymus of the animals were collected, weighed, and the organ coefficient was calculated.

[0555] Pathological examination: The foot joint tissue of one side was fixed in 10% neutral formalin solution, decalcified and embedded in paraffin for preparation of pathological sections and HE staining for pathological observation.

[0556] Observation indicators:

[0557] 1. Infiltration of synovial inflammatory cells (lymphocytes, plasma cells);

[0558] 2. Synovial tissue hyperplasia;

[0559] 3. Synovial pannus;

[0560] 4. Fibrinoid necrosis on the synovial surface.

[0561] Scoring method: 0, 1, 2, 3, 4 five levels: "0" not seen; "1" mild; "2" moderate; "3" severe; "4" extremely severe.

[0562] Experimental data are expressed as mean ± SEM. Data between the two groups were analyzed using Excel-T test, and p < 0.05 was considered to be significantly different. Scoring data were analyzed using SPSS nonparametric test Mann-Whitney U test, and p < 0.05 was considered to be significantly different.

[0563] The experimental results show that the disclosed compound can regulate the serum inflammatory factor levels of CIA model rats induced by bovine type II collagen, has a significant improvement effect on the swelling of the rat limbs, and can be used to treat arthritis.

[0564] IX. Pharmacological Efficacy Experiment of the Disclosed Compounds in Systemic Lupus Erythematosus Mouse Model

[0565] Conventional pharmacodynamic experimental methods were used to evaluate the pharmacodynamic effects of the disclosed compounds in treating systemic lupus erythematosus.

[0566] The compounds of the present invention (test substances, including the compounds in Table 1 and the compounds of the embodiments) were orally gavaged once or twice a day for 20 consecutive weeks to MRL / MpJ-Fas(1pr) spontaneous systemic lupus erythematosus (SLE) mice (purchased from Shanghai Slake Laboratory Animal Co., Ltd.) to study their pharmacodynamic effects on systemic lupus erythematosus mice. Methylprednisolone was also used as a positive control drug group, and MRL / MpJ mice were used as a non-disease control group. Weekly test indicators included urine protein content scores, skin lesion scores, lymph node scores, and body weight measurements. Serum was collected every two weeks to detect anti-double-stranded DNA antibodies (IgG). At the end of the experiment, the kidneys, spleen, and lymph nodes were collected and weighed, and formalin-fixed paraffin-embedded (FFPE) samples of the kidneys were prepared for HE staining and nephritis pathology scoring.

[0567] Experimental results show that the disclosed compound can significantly reduce the urine protein content score of MRL / MpJ-Fas(1pr) spontaneous systemic lupus erythematosus (SLE) mice, alleviate skin lesions, reduce lymph node lesion scores, significantly reduce the concentration of anti-double-stranded DNA antibodies in mouse serum, and significantly alleviate mouse kidney lesions, indicating that it can be used to treat systemic lupus erythematosus.

[0568] X. Pharmacological efficacy of the disclosed compounds on calcipotriol (MC903)-induced atopic dermatitis in mice

[0569] Conventional pharmacodynamic experimental methods were used to evaluate the pharmacodynamic effects of the disclosed compounds in treating atopic dermatitis.

[0570] CD-1 mice (purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.) were adapted to feeding for 1 week before modeling and administration began. On the 1st to 5th day of the experiment, MC903 (2nmol) solution was used to smear the mouse ears for sensitization once a day. Starting from the 5th day of the experiment, the disclosed compounds (test substances, including the compounds in Table 1 and the compounds in the examples) were orally gavaged to the mice 1 or 2 times a day for 12 consecutive days. On the 12th day of the experiment, MC903 (2nmol) solution was used to smear the mouse ears for re-sensitization, and the ear tissue, serum and spleen of the mice were collected 2-5h after smearing the MC903 solution. Dexamethasone was also set as a positive control drug group, as well as a vehicle-administered control group and a normal mouse control group that was not sensitized by MC903. The weight and ear thickness of the mice were measured on the 1st, 3rd, 5th, 8th, 10th and 12th days of the experiment; the concentrations of inflammatory factors including IL4, IL6, IL19, IL33, IFN-γ, etc. in the mouse ear tissue were detected; the concentrations of inflammatory factors including IL4, IL6, IL19, IL33, IFN-γ, etc. in the serum were detected; and the mouse ear tissue was pathologically tested.

[0571] The experimental results show that the disclosed compound can significantly reduce the ear thickness of MC903-sensitized model mice, inhibit the release of inflammatory factors in the ears of model mice, reduce the concentration of inflammatory factors in the serum, and improve the ear lesions of model mice, indicating that it can be used to treat atopic dermatitis.

[0572] XI. Pharmacological Efficacy of the Disclosed Compounds on Non-Obese Diabetic (NOD) Mouse Type I Diabetes Model

[0573] Conventional pharmacodynamic experimental methods were used to detect the pharmacodynamic effects of the disclosed compounds in treating type I diabetes.

[0574] Compounds of the present disclosure (test substances, including compounds in Table 1 and compounds in the Examples) were administered orally to NOD mice (purchased from Beijing Huafukang Biotechnology Co., Ltd.) once or twice daily for 30 consecutive weeks to study the pharmacodynamic effects of the compounds of the present disclosure on NOD mice, a model of type I diabetes. Teplizumab (teplizumab) was also used as a positive control, and a vehicle-administered control group was also included. The mice were weighed twice weekly, and their blood glucose levels were measured once a week in the fasting state; at the same time, their blood glucose levels were measured once a week in the non-fasting state. The incidence rate and onset time of the mice were recorded.

[0575] At the end of the experiment, the mice were weighed and their plasma, liver, and pancreatic tissues were collected for the following analyses:

[0576] (1) Detect blood glucose concentration;

[0577] (2) Perform blood biochemical tests, including HDL-c, LDL-c, TC, and c-peptide concentrations;

[0578] (3) Weigh the liver and test for glycogen;

[0579] (4) Perform pathological examination on pancreatic tissue.

[0580] The experimental results show that the disclosed compound can significantly reduce the blood glucose concentration of NOD mice, a type 1 diabetes model, improve pancreatic tissue lesions, delay the onset of type 1 diabetes, and reduce the morbidity and mortality of mice, indicating that it can be used to treat type 1 diabetes.

[0581] XII. Pharmacological efficacy of the disclosed compounds on TMA (Trimellitic anhydride)-induced urticaria mouse model

[0582] Conventional pharmacodynamic experimental methods were used to detect the pharmacodynamic effects of the disclosed compounds in treating urticaria.

[0583] Female BALB / C mice (purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.) were shaved on the back and 100 μL of a 500 mg / ml TMA solution (the solvent was acetone / olive oil (4:1, v / v)) was applied to sensitize the mice for the first time. On the 5th day after the first sensitization, 50 μL of a 250 mg / ml TMA solution was applied to the same position on the back of the mice for re-sensitization, and on the same day, 5% TMA was applied to both ears of the mice for sensitization. Then, on days 6-12, 2% TMA was applied to both ears of the mice. Starting from the 6th day after the first sensitization, the compounds of the present invention (test substances, including the compounds in Table 1 and the compounds of each example) were orally administered to TMA-induced urticaria model mice 1 or 2 times a day for 7 consecutive days. Dexamethasone was also set up as a positive control drug group, as well as a solvent-administered control group and a normal mouse control group that was not sensitized with TMA. After drug administration, the thickness of the mice's ears was measured daily, and dorsal lesion scores were performed. The number of times the mice scratched their ears every 15 minutes was recorded before and at 0, 1, 24, 48, 72, 96, and 112 hours after ear drug application. Following the experiment, tissue and serum samples were collected from the mice for the following analyses:

[0584] (1) Detect the concentrations of inflammatory factors in serum, including IL-1β, TNF-α, INF-γ, IL-4, IL-6, IL12, IL13, and IgE;

[0585] (2) Pathological examination and scoring were performed on the back skin and ears of the mice.

[0586] Experimental results demonstrated that the disclosed compounds significantly reduced ear thickness in TMA-induced urticaria model mice, improved the severity of back lesions, and reduced the frequency of ear scratching in the model mice. Pathological analysis revealed that the disclosed compounds significantly improved pathological change...

Claims

1. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, in R a1 , R a2 , R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 Alkoxy; Y represents CH or N; X represents N(R1), wherein R1 represents hydrogen or C 1-4 Alkyl, or X represents a bond; Ring A represents a 6- to 20-membered monocyclic, bicyclic or tricyclic divalent group having the following structural formula: wherein ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring, i.e., ring atom W represents C or N, the dotted line represents the presence or absence of ring C and / or ring D, when ring C is present, ring C represents an optionally substituted heteroaromatic ring or an optionally substituted heterocyclic ring, and when ring D is present, ring D represents an optionally substituted aromatic ring, provided that: when both ring C and ring D are present or not, ring B represents an optionally substituted benzene ring; and when ring A represents a bicyclic divalent group, ring D is absent, ring C represents an optionally substituted heteroaromatic ring or an optionally substituted heterocyclic ring, and W represents C or N; and the symbol * indicates the point of attachment of said ring A to X, and the symbol ** indicates the point of attachment of said ring A to R x The connection point; R x Indicates C(O)NH, NHC(O), -N(R2)-C 0-2 Alkylene-, -C 0-2 alkylene-N(R2)-, O, S, S(O), S(O)2, alkynylene, alkenylene, -C(R3R4)-, optionally substituted piperazinylene or optionally substituted piperidinylene, wherein each R2 independently represents hydrogen or C 1-4 Alkyl, each C 0-2 The alkylene group is optionally substituted, and R3 and R4 each independently represent hydrogen, halogen or hydroxy; LIN means Where R L1 Connect R x , R L2 Connect R w ; R L2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a5 ), where R a5 Indicates H or C 1-3 alkyl; Each ring A 1 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 independently optionally by a1 R y1 Group substitution, each R y1 Independently for deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, Halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20; Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, 2 represents an integer 0, 1, 2, or 3, (R y2 ) a2 Represents each ring A 2 independently optionally by a2 R y2 Group substitution, each R y2 Independently for deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20; Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 independently optionally by a3 R y3 Group substitution, each R y3 Independently for deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; R L1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: La , R Lb and any combination thereof, each group R La Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R La When substituted, each group R La are not directly connected to each other; each group R Lb are each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof; R w express: NR w1 R w2 、C(O)NR w3 R w4 、N(R w5 )C(O)R w6 、NHC(O)NR w7 R w8 , OR w9 , SR w10 、S(O)2NR w11 R w12 、N(R w13 )S(O)2R w14 、S(O)2R w15 or an optionally substituted straight or branched chain alkyl group, wherein R w1 , R w2 , R w3 , R w7 , R w9 , R w10 and R w11 Each independently represents H, an optionally substituted straight or branched alkyl group, -(CH2) m -cycloalkyl, -(CH2) m -Aryl, -(CH2) m -heterocyclic group or -(CH2) m -heteroaryl, wherein R w4 , R w6 , R w8 , R w12 , R w14 and R w15 Each independently represents an optionally substituted straight or branched alkyl group, -(CH2) m -cycloalkyl, -(CH2) m -Aryl, -(CH2) m -heterocyclic group or -(CH2) m -heteroaryl, and wherein R w5 and R w13 Each independently represents H or an optionally substituted straight-chain or branched alkyl group, or wherein R w3 and R w4 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, or wherein R w11 and R w12 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, wherein each -(CH2) m -, cycloalkyl, aryl, heterocyclyl or heteroaryl are each independently optionally substituted, and m represents an integer of 0, 1 or 2; or Ring A 4 represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, (R d1 ) n1 Represents Ring A 4 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer of 0-20; R e represents C(O)NH or NHC(O), or R e represents a key; and Ring A 5 represents a heterocyclic group, a cycloalkyl group, an aryl group or a heteroaryl group, m1 represents an integer of 0 or 1, (R d2 ) n2 Represents Ring A 5 Optionally n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer of 0-20.

2. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in claim 1, wherein (i) When both ring C and ring D are present, W represents C, ring B represents an optionally substituted benzene ring, ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring, and ring D represents an optionally substituted C 5-10 The aromatic ring, ie, ring A, represents a 10- to 25-membered tricyclic divalent group having the following structural formula: Preferably, ring A represents a divalent group of an 11- to 21-membered tricyclic ring having the following structural formula: wherein Ring B and Ring D each independently represent an optionally substituted benzene ring, and Ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring; and / or For example, ring A includes the following optionally further substituted groups: (ii) Ring A represents an 8- to 20-membered bicyclic divalent group having the following structural formula: wherein Ring C represents an optionally substituted 4- to 16-membered heteroaromatic ring or an optionally substituted 4- to 16-membered heterocyclic ring, and Ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring, i.e. W represents C or N; and / or For example, ring A includes the following optionally further substituted groups: Among them, each R c Each independently represents H or C 1-6 Alkyl; or (iii) Ring A represents the following optionally substituted phenylene: The symbol * indicates the connection point between the ring A and X, and the symbol ** indicates the connection point between the ring A and R x connection point.

3. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in claim 1, wherein (i) The structure of formula (I) is also the structure of the following formula (IA): in, Ring B represents an optionally substituted benzene ring, Ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring, and Ring D represents an optionally substituted C 5-10 Aromatic rings; Preferably, the structure of formula (I) is also the structure of the following formula (IA-1): wherein Ring B and Ring D each independently represent an optionally substituted benzene ring, and Ring C represents an optionally substituted 4- to 14-membered heteroaromatic ring or an optionally substituted 4- to 14-membered heterocyclic ring; or (ii) The structure of formula (I) is also the structure of the following formula (IB): wherein Ring C represents an optionally substituted 4- to 16-membered heteroaromatic ring or an optionally substituted 4- to 16-membered heterocyclic ring, and Ring B represents an optionally substituted benzene ring or an optionally substituted pyridine ring, i.e. W represents C or N; or (iii) The structure of formula (I) is also the structure of the following formula (IC): The phenylene group in the formula (IC) may be further substituted by 1, 2, 3 or 4 identical or different groups independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Substitution of the alkynyl group by a substituent, and Wherein R in the structures of Formula (IA), Formula (IA-1), Formula (IB) and Formula (IC) a1 , R a2 , R a3 , R a4 , X, Y, R x , LIN and R w As defined in claim 1.

4. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph as claimed in claim 1, which is also a structure of the following formula: Among them, (R) in the structures of Formula (IA-11), Formula (IA-12), Formula (IB-11), Formula (IB-12), Formula (IB-13), Formula (IB-14), Formula (IB-15), Formula (IB-16), Formula (IB-17), Formula (IC-11), Formula (IC-12) and Formula (IC-13) d ) n represents n substituents R d , wherein n represents an integer of 0, 1, 2 or 3, each substituent R d are the same or different and are each independently selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl, and R a1 , R a2 , R a3 , R a4 , R x , LIN and R w As defined in claim 1.

5. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 4, wherein (i)R a1 , R a2 , R a3 and R a4 Each independently represents H; and / or (ii) Y represents CH, and X represents N(R1), wherein R1 represents hydrogen or C 1-4 Alkyl, or X represents a bond; or Y represents N and X represents a bond; and / or (iii) R x represents C(O)NH, NHC(O), N(R2), -N(R2)-methylene-, -N(R2)-ethylene-, -methylene-N(R2)-, -ethylene-N(R2)-, O, S, S(O), S(O)2, C 2-6 Alkenylene, C 2-6 alkynylene, -C(R3R4)-, optionally substituted piperazinylene or optionally substituted piperidinylene, wherein each R2 independently represents hydrogen or C 1-4 alkyl, each methylene and ethylene are each independently optionally substituted, and R3 and R4 each independently represent hydrogen, halogen or hydroxy; for example R x Including C(O)NH, NHC(O), NH, N(CH3), -NHCH2-, -NHCH2CH2-, -N(CH3)CH2-, -N(CH3)CH2CH2-, -CH2NH-, -CH2CH2NH-, -CH2N(CH3)-, -CH2CH2N(CH3)-, O, S, S(O), S(O)2, C 2-4 Alkenylene, C 2-4 Alkyne, -CH2-, optionally substituted piperazinyl or optionally substituted piperidinyl; and / or (iv)LIN means: Where R L1 Connect R x , R L2 Connect R w ; R L2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a5 ), where R a5 Indicates H or C 1-3 alkyl; Each ring A 1 are the same or different and each independently represent a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably each ring A 1 Each independently includes a 4- to 20-membered heterocyclylene group, a C 3-20 Cycloalkylene, C 5-20 arylene or 5- to 20-membered heteroarylene; or, for example, 4- to 15-membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 Each independently optionally can be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20; Each ring A 2 are the same or different and each independently represent a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably each ring A 2 Each independently includes a 4- to 20-membered heterocyclylene group, a C 3-20 Cycloalkylene, C 5-20 arylene or 5- to 20-membered heteroarylene; or, for example, 4- to 15-membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 Each independently optionally is a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20; Each ring A 3 are the same or different and each independently represent a 4- to 30-membered heterocyclylene group, a C 3-30 Cycloalkyl, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably each ring A 3 Each independently includes a 4- to 20-membered heterocyclylene group, a C 3-20 Cycloalkylene, C 5-20 arylene or 5- to 20-membered heteroarylene; or, for example, 4- to 15-membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Each independently optionally is a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; R L1 represents a bond, or represents an optionally substituted straight or branched chain C 1-20 Alkylene, wherein the linear or branched C 1- 20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: La , R Lb and any combination thereof, each group R La Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R La When substituted, each group R La are not directly connected to each other; each group R L b are each independently selected from optionally substituted C 3-30 Cycloalkylene, optionally substituted C 5-30 arylene, an optionally substituted 4- to 30-membered heterocyclylene, an optionally substituted 5- to 30-membered heteroarylene, C 2-6 Alkenylene or C 2-6 Alkyne or any combination thereof (preferably each independently selected from optionally substituted C 3-20 Cycloalkylene, optionally substituted C 5-20 arylene, an optionally substituted 4- to 20-membered heterocyclylene, an optionally substituted 5- to 20-membered heteroarylene, C 2-4 Alkenylene or C 2-4 or any combination thereof; or for example, each independently selected from optionally substituted C 3-15 Cycloalkylene, optionally substituted C 5-15 arylene, an optionally substituted 4- to 15-membered heterocyclylene, an optionally substituted 5- to 15-membered heteroarylene, C 2-4 Alkenylene or C 2-4 alkynylene or any combination thereof); and / or (v)R w express: NR w1 R w2 、C(O)NR w3 R w4 、N(R w5 )C(O)R w6 、NHC(O)NR w7 R w8 , OR w9 , SR w10 、S(O)2NR w11 R w12 、N(R w13 )S(O)2R w14 or S(O)2R w15， Where R w1 , R w2 , R w3 , R w7 , R w9 , R w10 and R w11 Each independently represents H, an optionally substituted straight or branched chain C 1-10 Alkyl (eg, optionally substituted straight or branched chain C 1-6 Alkyl), -(CH2) m -C 3-30 Cycloalkyl (preferably -(CH2) m -C 3- 20 Cycloalkyl; for example -(CH2) m -C 3-15 Cycloalkyl), -(CH2) m -C 5-30 Aryl (preferably -(CH2) m -C 5- 20 Aryl; for example -(CH2) m -C 5-15 Aryl), -(CH2) m -4 to 30 membered heterocyclic group (preferably -(CH2) m -4 to 20 membered heterocyclic group; for example -(CH2) m -4 to 15 membered heterocyclic group) or -(CH2) m -5 to 30 membered heteroaryl (preferably -(CH2) m -5 to 20 membered heteroaryl; for example -(CH2) m -5 to 15 membered heteroaryl), wherein R w4 , R w6 , R w8 , R w12 , R w14 and R w15 Each independently represents an optionally substituted straight or branched chain C 1- 10 Alkyl (eg, optionally substituted straight or branched chain C 1-6 Alkyl), -(CH2) m -C 3-30 Cycloalkyl (preferably -(CH2) m -C 3-20 Cycloalkyl; for example -(CH2) m -C 3-15 Cycloalkyl), -(CH2) m -C 5-30 Aryl (preferably -(CH2) m -C 5-20 Aryl; for example -(CH2) m -C 5-15 Aryl), -(CH2) m -4 to 30 membered heterocyclic group (preferably -(CH2) m -4 to 20 membered heterocyclic group; for example -(CH2) m -4 to 15 membered heterocyclic group) or -(CH2) m -5 to 30 membered heteroaryl (preferably -(CH2) m -5 to 20 membered heteroaryl; for example -(CH2) m -5 to 15 membered heteroaryl), and wherein R w5 and R w13 Each independently represents H or an optionally substituted straight or branched chain C 1- 10 Alkyl (eg, optionally substituted straight or branched chain C 1-6 alkyl), or wherein R w3 and R w4 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, or wherein R w11 and R w12 Together with the nitrogen atom to which they are attached, they form an optionally substituted 4- to 20-membered nitrogen-containing heterocyclic group, wherein each -(CH2) m -, cycloalkyl, aryl, heterocyclyl or heteroaryl are each independently optionally substituted, m represents an integer 0, 1 or 2; or Optionally substituted straight or branched chain C 1-10 Alkyl (eg, optionally substituted straight or branched chain C 1-6 alkyl); or Ring A 4 represents a 4- to 30-membered heterocyclylene group (preferably, a 4- to 20-membered heterocyclylene group; for example, a 4- to 15-membered heterocyclylene group), C 3-30 Cycloalkylene (preferably, C 3-20 Cycloalkylene; for example, C 3-15 Cycloalkylene), C 5-30 Arylene (preferably C 5-20 Arylene; for example, C 5-15 arylene) or a 5- to 30-membered heteroarylene (preferably, a 5- to 20-membered heteroarylene; for example, a 5- to 15-membered heteroarylene), (R d1 ) n1 Represents Ring A 4 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, nitro, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer of 0-20; R e represents C(O)NH or NHC(O), or R e represents a key; and Ring A 5 represents a 4- to 30-membered heterocyclic group (preferably, a 4- to 20-membered heterocyclic group; for example, a 4- to 15-membered heterocyclic group), C 3-30 Cycloalkyl (preferably C 3-20 Cycloalkyl; for example, C 3-15 Cycloalkyl), C 5-30 Aryl (preferably C 5-20 Aryl; for example, C 5-15 aryl) or 5- to 30-membered heteroaryl (preferably, 5- to 20-membered heteroaryl; for example, 5- to 15-membered heteroaryl), m1 represents an integer of 0 or 1, (R d2 ) n2 Represents Ring A 5 Optionally n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, nitro, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer of 0-20.

6. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 4, wherein (i) Each ring A 1 , Ring A 2 and Ring A 3 Each independently represents: aziridinyl, oxadienyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, azooctanyl, dioxanyl, azohepanyl, azooctanyl, diazepanyl, diazepanyl, diazepanyl, 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[3.1.1]heptanyl bicyclo[2.2.1]heptanylene, 3,6-diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic radical, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydronaphthylene, Cyclopentadienyl, octahydro-1H-indenyl, 2,3-dihydro-1H-indenyl, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo or each ring A is, for example, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene ...1-b]thiazolylene; or each ring A is, for example, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo 1 , Ring A 2 and Ring A 3 Each independently represents: y1 represents an integer of 0, 1, 2 or 3, each ring A 1 Each independently optionally can be a1 R y1 Group substitution, each R y1 Independently for deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20; y2 represents an integer of 0, 1, 2 or 3, each ring A 2 Each independently optionally is a2 R y2 Group substitution, each R y2 Independently for deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20; or y3 represents an integer of 0, 1, 2 or 3, each ring A 3 Each independently optionally is a3 R y3 Group substitution, each R y3 Independently for deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; and / or (ii) R L1 represents a key, or R L1 express: -C 1-15 Alkylene-; -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 ))r2) s1 -(R La (C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R La (C(R Lc5 )(R Lc6 )) r3 ) s2 -(R L a (C(R Lc7 )(R Lc8 )) r4 ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -((C(R Lc5 )(R Lc6 )) r3 R La ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -((C(R Lc5 )(R Lc6 )) r3 R La ) s2 -((C(R Lc7 )(R Lc8 )) r4 R La ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R Lb (C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R Lb (C(R Lc5 )(R Lc6 )) r3 ) s2 -(R Lb (C(R Lc7 )(R Lc8 )) r4 ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -((C(R Lc5 )(R Lc6 )) r3 R Lb ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -((C(R Lc5 )(R Lc6 )) r3 R Lb ) s2 -((C(R Lc7 )(R Lc8 )) r4 R Lb ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R La -R Lb -(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R La (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R Lb (C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R Lb -R La -(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(R Lb (C(R Lc3 )(R Lc4 )) r2 ) s1 -(R La (C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -R La -R Lb ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R La ) s1 -((C(R Lc5 )(R Lc6 )) r3 R Lb ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -R Lb -R a ) s1 -#;or -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 R Lb ) s1 -((C(R Lc5 )(R Lc6 )) r3 R La ) s2 -#; in, Each group R La independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R La1 )、N(R La1 )S(O)2、C(O)N(R La1 )、N(R La1 )C(O), N(R La1 ) and N(R La1 )C(O)N(R La1 ), where each R La1 Each independently represents H or C 1-6 Alkyl; each group R Lb are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (eg, optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenyl (e.g. 2-6 The cycloalkylene, arylene, heterocyclylene and heteroarylene groups are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R Lc1 , R Lc2 , R Lc3 , R Lc4 , R Lc5 , R Lc6 , R Lc7 and R Lc8 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and r1, r2, r3, r4, s1, s2, s3 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; The symbol # indicates the same as R x connection points; and The C 1-15 The alkylene group is optionally substituted with one or more substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, haloC 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

7. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 4, wherein (i) Part of the LIN formula express: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Substitution of alkenyl groups by substituents; and / or (ii) R L1 Represents the following structure: -(C(R Lc1 )(R Lc2 )) r1 -(O(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(O(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O(C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(O(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O(C(R Lc5 )(R Lc6 )) r3 ) s2 -(O(C(R Lc7 )(R Lc8 )) r4 ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 O) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 O) s1 -((C(R Lc5 )(R Lc6 )) r3 O) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 O) s1 -((C(R Lc5 )(R Lc6 )) r3 O) s2 -((C(R Lc7 )(R Lc8 )) r4 O) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )(C(R Lc3 )(R Lc4 )) r2 ) s1 -(N(R La1 )(C(R Lc5 )(R L c6 )) r3 ) s2 -#; -(C(R Lc1 )(R L c2)) r1 -(N(R La1 )(C(R Lc3 )(R Lc4 )) r2 ) s1 -(N(R La1 )(C(R Lc5 )(R Lc6 )) r3 ) s2 -(N(R La1 )(C(R Lc7 )(R Lc8 )) r4 ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 N(R La1 )) s1 -#; -(C(R Lc1 )(R L c2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 N(R L a1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 N(R La1 )) s2 -#; -(C(R Lc1 )(R L c2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 N(R La1 )) s2 - ((C(R Lc7 )(R Lc8 )) r4 N(R La1 )) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(C(O)N(R La1 )-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(C(O)N(R La1 )-(C(R Lc5 )(R Lc6 )) r3 ) s2 -(C(O)N(R La1 )-(C(R Lc7 )(R Lc8 )) r4 ) s3 -#; -(C(R Lc1 )(R Lc2 )) rl -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 -C(O)N(R La1 )) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 -C(O)N(R La1 )) s2 -((C(R Lc7 )(R Lc8 )) r4 -C(O)N(R La1 )) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -(C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 -(O(C(R Lc5 )(R Lc6 )) r3 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )) s1 -((C(R Lc5 )(R Lc6 )) r3 O) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(C(R Lc3 )(R Lc4 )) r2 -C(O)N(R La1 )-((C(R Lc5 )(R Lc6 )) r3 O) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O-(C(R Lc5 )(R Lc6 ))) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(O-(C(R Lc5 )(R Lc6 )) r3 ) s2 -(O-(C(R Lc7 )(R Lc8 )) r4 ) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -N(R La1 )C(O)-(C(R Lc3 )(R Lc4 )) r2 -(O(C(R Lc5 )(R Lc6 )) r3 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -N(R La1 )C(O)N(R La1 )-(C(R Lc3 )(R Lc4 )) r2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -N(R La1 )C(O)) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -N(R La1 )C(O)) s1 -((C(R Lc5 )(R Lc6 ))) r3 -O) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -N(R La1 )C(O)) s1 -((C(R Lc5 )(R Lc6 )) r3 O) s2 -((C(R Lc7 )(R Lc8 )) r4 O) s3 -#; -(C(R Lc1 )(R Lc2 )) r1 -(C(R Lc3 )(R Lc4 )) r2 -N(R La1 )C(O)-((C(R Lc5 )(R Lc6 )) r3 O) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(arylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(arylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -arylene-(C(R Lc5 )(R Lc6 )) r3 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -arylene) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -arylene) s1 -(C(R Lc5 )(R Lc6 )) r3 -arylene-#; -(C(R Lc1 )(R Lc2 )) r1 -(Heterocyclylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(Heterocyclylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(Heterocyclylene-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heterocyclylene) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heterocyclylene) s1 -((C(R Lc5 )(R Lc6 )) r3 -heterocyclylene) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(heteroarylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(heteroarylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(heteroarylene-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heteroarylene) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -heteroarylene) s1 -((C(R Lc5 )(R Lc6 )) r3 -heteroarylene) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -(cycloalkylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -#; -(C(R Lc1 )(R Lc2 )) r1 -(cycloalkylene-(C(R Lc3 )(R Lc4 )) r2 ) s1 -(cycloalkylene-(C(R Lc5 )(R Lc6 )) r3 ) s2 -#; -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -cycloalkylene) s1 -#;or -(C(R Lc1 )(R Lc2 )) r1 -((C(R Lc3 )(R Lc4 )) r2 -cycloalkylene) s1 -((C(R Lc5 )(R Lc6 )) r3 -cycloalkylene) s2 -#; Among them, each R La1 Independently represents H or C 1-6 alkyl; The cycloalkylene group (e.g., C 3-20 Cycloalkylene), the arylene group (e.g. C 5-20 The heterocyclylene (e.g., 4- to 20-membered heterocyclylene) and the heteroarylene (e.g., 5- to 20-membered heteroarylene) are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R Lc1 , R Lc2 , R Lc3 , R Lc4 , R Lc5 , R L c6 , R Lc7 and R Lc8 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and r1, r2, r3, r4, s1, s2, s3 each independently represent an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and The symbol # indicates the same as R x connection point.

8. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 4, wherein (i)R L1 express: -CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-(CH2)7-、-(CH2)8-、-(CH2)9-、-(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -;-O-CH2-、-O-(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)5-、-O-(CH2)6-、-O-(CH2)7-、-O-(CH2)8-、-O-(CH2)9-、-O-(CH2) 10 -、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2) 10 -、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7- 、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、 -(CH2)5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、- (CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、- CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-CH(CH3)-O-(CH2)9-、-CH(CH3)-O-(CH2) 10 -、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(CH2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2 )2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2- (O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-C H2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、 -(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(C H2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2 )3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4- (O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-( CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2 )2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R、 La1 )-(CH2)1-、-(CH2)1-N(R La1 )-(CH2)2-、-(CH2)1-N(R La1 )-(CH2)3-、-(CH2)1-N(R La1 )-(CH2)4-、-(CH2)1-N(R La1 )-(CH2)5-、-(CH2)1-N(R La1 )-(CH2)6-、-(CH2)1-N(R La1 )-(CH2)7-、-(CH2)1-N(R La1 )-(CH2)8-、-(CH2)1-N(R La1 )-(CH2)9-、-(CH2)1-N(R La1 )-(CH2) 10 -、-N(R La1 )-(CH2)1-、-N(R La1 )-(CH2)2-、-N(R La1 )-(CH2)3-、-N(R La1 )-(CH2)4-、-N(R La1 )-(CH2)5-、-N(R La1 )-(CH2)6-、-N(R La1 )-(CH2)7-、-N(R La1 )-(CH2)8-、-N(R La1 )-(CH2)9-、-N(R La1 )-(CH2) 10 -、-(CH2)2-N(R La1 )-(CH2)1-、-(CH2)2-N(R La1 )-(CH2)2-、-(CH2)2-N(R La1 )-(CH2)3-、-(CH2)2-N(R La1 )-(CH2)4-、-(CH2)2-N(R La1 )-(CH2)5-、-(CH2)2-N(R La1 )-(CH2)6-、-(CH2)2-N(R La1 )-(CH2)7-、-(CH2)2-N(R La1 )-(CH2)8-、-(CH2)2-N(R La1 )-(CH2)9-、-(CH2)2-N(R La1 )-(CH2) 10 -、-(CH2)3-N(R La1 )-(CH2)1-、-(CH2)3-N(R La1 )-(CH2)2-、-(CH2)3-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)1-、-(CH2)4-N(R La1 )-(CH2)2-、-(CH2)4-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)1-、-(CH2)5-N(R La1 )-(CH2)2-、-(CH2)5-N(R La1 )-(CH2)3-、-(CH2)5-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)5-、-(CH2)6-N(R La1 )-(CH2)1-、-(CH2)6-N(R La1 )-(CH2)2-、-(CH2)6-N(R La1 )-(CH2)3-、-(CH2)7-N(R La1 )-(CH2)1-、-(CH2)7-N(R La1 )-(CH2)2-、-(CH2)7-N(R La1 )-(CH2)3-、-(CH2)8-N(R La1 )-(CH2)1-、-(CH2)8-N(R La1 )-(CH2)2-、-(CH2)8-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)1-、-CH(CH3)-N(R La1 )-(CH2)2-、-CH(CH3)-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)4-、-CH(CH3)-N(R La1 )-(CH2)5-、-CH(CH3)-N(R La1 )-(CH2)6-、-CH(CH3)-N(R La1 )-(CH2)7-、-CH(CH3)-N(R La1 )-(CH2)8-、-CH(CH3)-N(R La1 )-(CH2)9-、-CH(CH3)-N(R La1 )-(CH2) 10 -、-(CH2)1-N(R La1 )-、-(CH2)2-N(R La1 )-、-(CH2)3-N(R La1 )-、-(CH2)4-N(R La1 )-、-(CH2)5-N(R La1 )-、-(CH2)6-N(R La1 )-、-(CH2)7-N(R La1 )-、-(CH2)8-N(R La1 )-、-(CH2)9-N(R La1 )-、- (CH2) 10 -N(R La1 )-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)N H(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O )NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O) (CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)( CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC( O)(CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene -CH2-, -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-, -(CH2)2-phenylene-, -(CH2)3-phenylene-, -(CH2)4-phenylene-, -(CH2)5-phenylene-, -(CH2)6-phenylene-, -(CH2)7-phenylene-, -(CH2)8-phenylene-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-,-CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH 2) 3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene-(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5- , -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, -(CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6- Phenylene-(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-,-(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-, -(CH2)8-phenylene-(CH2)7-, -N(R, La1 )-CH2-phenylene-CH2-, -N(R La1 )-CH2-phenylene-(CH2)2-, -N(R La1 )-CH2-phenylene-(CH2)3-, -N(R La1 )-CH2-phenylene-(CH2)4-, -N(R La1 )-CH2-phenylene-(CH2)5-, -N(R L a1 )-CH2-phenylene-(CH2)6-, -N(R La1 )-CH2-phenylene-(CH2)7-, -N(R L a1 )-CH2-phenylene-(CH2)8-, -CH2-N(R La1 )-CH2-phenylene-CH2-, -CH2-N(R L a1 )-CH2-phenylene-(CH2)2-, -CH2-N(R La1 )-CH2-phenylene-(CH2)3-, -CH2-N(R La1 )-CH2-phenylene-(CH2)4-, -CH2-N(R La1 )-CH2-phenylene-(CH2)5-, -CH2-N(R La1 )- CH2-phenylene-(CH2)6-, -CH2-N(R La1 )-CH2-phenylene-(CH2)7-, -CH2-N(R La1 )-CH2-phenylene-(CH2)8-, -CH2-N(R La1 )-(CH2)2-phenylene-CH2-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)2-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)3-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)4-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)5-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)6-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)7-, -CH2-N(R La1 )-(CH2)2-phenylene-(CH2)8-, -(CH2)2-N(R La1 )-CH2-phenylene-CH2-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)4-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)5-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)6-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)7-, -(CH2)2-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)3-N(R La1 )-CH2-phenylene-CH2-, -(CH2)3-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)3-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)3-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)4-N(R La1 )-CH2-phenylene-CH2-, -(CH2)4-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)4-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)4-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)5-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)5-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)6-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)6-N(R La1 )-CH2-phenylene-(CH2)8-, -(CH2)7-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R La1 )-CH2-phenylene-CH2-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)2-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)4-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)5-, -(CH2)8-N(R La1 )-CH2-phenylene-(CH2)6-, -thiazolylene-CH2-, -thiazolylene-(CH2)2-, -thiazolylene-(CH2)3-, -thiazolylene-(CH2)4-, -thiazolylene-(CH2)5-, -thiazolylene-(CH2)6-, -thiazolylene-(CH2)7-, -thiazolylene-(CH2)8-, -CH2-thiazolylene-, -(CH2)2-thiazolylene-, -(CH2)3-thiazolylene-, -(CH2)4-thiazolylene-, -(CH2)5-thiazolylene-, -CH2-thiazolylene-CH2-, -CH2-thiazolylene-(CH2)2-, -CH2-thiazolylene-(CH2)3-, -CH2- Thiazolylene-(CH2)4-, -CH2-thiazolylene-(CH2)5-, -CH2-thiazolylene-(CH2)6-, -CH2-thiazolylene-(CH2)7-, -CH2-thiazolylene-(CH2)8-, -(CH2)2-thiazolylene-(CH2)1-, -(CH2)2-thiazolylene-(CH2)2-, -(CH2)2-thiazolylene-(CH2)3-, -(CH2)2-thiazolylene-(CH2)4-, -(CH2)2-thiazolylene-(CH2)5-, -(CH2)2-thiazolylene-(CH2)6-, -(CH2)2-thiazolylene-(CH2)7-, -(CH2)2-thiazolylene-(CH2) 8-, -(CH2)3-thiazolylene-CH2-, -(CH2)3-thiazolylene-(CH2)2-, -(CH2)3-thiazolylene-(CH2)3-, -(CH2)3-thiazolylene-(CH2)4-, -(CH2)3-thiazolylene-(CH2)5-, -(CH2)3-thiazolylene-(CH2)6-, -(CH2)3-thiazolylene-(CH2)7-, -(CH2)3-thiazolylene-(CH2)8-, -(CH2)4-thiazolylene-CH2-, -(CH2)4-thiazolylene-(CH2)2-, -(CH2)4-thiazolylene-(CH2)3-, -(CH2)4-thiazolylene-(CH2)4-, - (CH2)4-thiazolylene-(CH2)5-, -(CH2)4-thiazolylene-(CH2)6-, -(CH2)4-thiazolylene-(CH2)7-, -(CH2)4-thiazolylene-(CH2)8-, -(CH2)5-thiazolylene-(CH2)1-, -(CH2)5-thiazolylene-(CH2)2-, -(CH2)5-thiazolylene-(CH2)3-, -(CH2)5-thiazolylene-(CH2)4-, -(CH2)5-thiazolylene-(CH2)5-, -(CH2)5-thiazolylene-(CH2)6-, -(CH2)5-thiazolylene-(CH2)7-, -(CH2)5-thiazolylene-(CH2)8-,-(CH2)6-thiazolylene-(CH2)1-, -(CH2)6-thiazolylene-(CH2)2-, -(CH2)6-thiazolylene-(CH2)3-, -(CH2)6-thiazolylene-(CH2)4-, -(CH2)6-thiazolylene-(CH2)5-, -(CH2)6-thiazolylene-(CH2)6-, -(CH2)6-thiazolylene-(CH2)7-, -(CH2)6-thiazolylene-(CH2)8-, -(CH2)7-thiazolylene-(CH2)1-, -(CH2)7-thiazolylene-(CH2)2-, -(CH2)6-thiazolylene-(CH2)3-, -(CH2)6-thiazolylene-(CH2)4-, -(CH2)6-thiazolylene-(CH2)5-, -(CH2)6-thiazolylene-(CH2)6-, -(CH2)6-thiazolylene-(CH2)7-, -(CH2)6-thiazolylene-(CH2)8-, -(CH2)7-thiazolylene-(CH2)1-, -(CH2)7-thiazolylene-(CH2)2-, -( -(CH2)7-thiazolylene-(CH2)3-, -(CH2)7-thiazolylene-(CH2)4-, -(CH2)7-thiazolylene-(CH2)8-, -(CH2)8-thiazolylene-CH2-, -(CH2)8-thiazolylene-(CH2)2-, -(CH2)8-thiazolylene-(CH2)3-, -(CH2)8-thiazolylene-(CH2)4-, -(CH2)8-thiazolylene-(CH2)5-, -(CH2)8-thiazolylene-(CH2)6-, -(CH2)8-thiazolylene-(CH2)7-, -piperidinylene-, CH2-, -piperidinylene-(CH2)2-, -piperidinylene-(CH2)3-, -piperidinylene-(CH2)4-, -piperidinylene-(CH2)5-, -piperidinylene-(CH2)6-, -piperidinylene-(CH2)7-, -piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7-, -CH2-piperidinylene-(CH2)8-, -(CH2) 2) 2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH 2) 3-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-(CH2)6-, -(CH2)3-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2)4-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-(CH2) H2)5-piperidinylene-(CH2)1-, -(CH2)5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-(CH2)1-, -(CH2)6-piperidinylene-(CH2)2-, -(CH2)6-piperidinylene-(CH2)3-, -(CH2)6-piperidinylene-(CH2)4-,-(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene-(CH2)4-, - (CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R, La1 )-CH2-piperidinyl-CH2-, -N(R La1 )-CH2-piperidinyl-(CH2)2-, -N(R La1 )-CH2-piperidinyl-(CH2)3-, -N(R L a1 )-CH2-piperidinyl-(CH2)4-, -N(R La1 )-CH2-piperidinyl-(CH2)5-, -N(R La1 )-CH2-piperidinyl-(CH2)6-, -N(R La1 )-CH2-piperidinyl-(CH2)7-, -N(R La1 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R La1 )-CH2-piperidinyl-CH2-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)2-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)3-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)5-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)6-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)7-, -CH2-N(R La1 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R La1 )-(CH2)2-piperidinyl-CH2-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)2-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)3-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)4-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)5-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)6-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)7-, -CH2-N(R La1 )-(CH2)2-piperidinyl-(CH2)8-, -(CH2)2-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)4-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)5-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)6-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)7-, -(CH2)2-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)3-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)3-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)3-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)3-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)4-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)4-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)4-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)4-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)5- N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)5-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)6-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)6-N(R La1 )-CH2-piperidinyl-(CH2)8-, -(CH2)7-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R La1 )-CH2-piperidinyl-CH2-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)2-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)4-, -(CH2)8-N(R La1 )-CH2-piperidinyl-(CH2)5-, -(CH2)8-N(R La1) -CH2-Piperidinylene-(CH2)6-, -piperazinylene-CH2-, -piperazinylene-(CH2)2-, -piperazinylene-(CH2)3-, -piperazinylene-(CH2)4-, -piperazinylene-(CH2)5-, -piperazinylene-(CH2)6-, -piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7- , -(CH2)2-piperazinyl-(CH2)8-, -(CH2)2-piperazinyl-(CH2)1-, -(CH2)2-piperazinyl-(CH2)2-, -(CH2)2-piperazinyl-(CH2)3-, -(CH2)2-piperazinyl-(CH2)4-, -(CH2)2-piperazinyl-(CH2)5-, -(CH2)2-piperazinyl-(CH2)6-, -(CH2)2-piperazinyl-(CH2)7-, -(CH2)2-piperazinyl-(CH2)8-, -(CH2)3-piperazinyl-CH2-, -(CH2)3-piperazinyl-(CH2)2-, -(CH2)3-piperazinyl-(CH2)3-, -( -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-(CH2)6-, -(CH2)3-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene -(CH2)4-piperazinylene-(CH2)8-, -(CH2)5-piperazinylene-(CH2)1-, -(CH2)5-piperazinylene-(CH2)2-, -(CH2)5-piperazinylene-(CH2)3-, -(CH2)5-piperazinylene-(CH2)4-, -(CH2)5-piperazinylene-(CH2)5-, -(CH2)5-piperazinylene-(CH2)6-, -(CH2)5-piperazinylene-(CH2)7-, -(CH2)5-piperazinylene-(CH2)8-, -(CH2)6-piperazinylene-(CH2)1-, -(CH2)6-piperazinylene-(CH2)2-, -(CH2)6-piperazinylene-(CH2)3-,-(CH2)6-piperazinylene-(CH2)4-, -(CH2)6-piperazinylene-(CH2)5-, -(CH2)6-piperazinylene-(CH2)6-, -(CH2)6-piperazinylene-(CH2)7-, -(CH2)6-piperazinylene-(CH2)8-, -(CH2)7-piperazinylene-(CH2)1-, -(CH2)7-piperazinylene-(CH2)2-, -(CH2)7-piperazinylene -(CH2)3-, -(CH2)7-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-(CH2)5-, or -(CH2)8-piperazinylene-(CH2)6-; Among them, each R La1 Independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl or isopropyl); The phenylene and thiazolylene groups are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted with cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; and The piperazinyl and piperidinyl groups are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; or (ii)LIN means: a key, C(O), C(O)NH, NHC(O), NH, -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -, -(CH2) 11 -, -(CH2) 12 -, -(CH2) 13 -, -(CH2) 14 -, -(CH2) 15 -; -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-、-O-(CH2)9-、-O-(CH2) 10 -、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-( CH2)1-O-(CH2)8-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2 )5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(C H2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、- (CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O -(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5 -、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、 -CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-CH2-(O(CH2)2)6-OCH 2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(C H2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2- (O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-CH2-O-(CH2)2-O -(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 La1 )-(CH2)1-、-(CH2)1-N(R La1 )-(CH2)2-、-(CH2)1-N(R La1 )-(CH2)3-、-(CH2)1-N(R La1 )-(CH2)4-、-(CH2)1-N(R La1 )-(CH2)5-、-(CH2)1-N(R La1 )-(CH2)6-、-N(R La1 )-(CH2)1-、-N(R La1 )-(CH2)2-、-N(R La1 )-(CH2)3-、-N(R La1 )-(CH2)4-、-N(R La1 )-(CH2)5-、-N(R La1 )-(CH2)6-、-(CH2)2-N(R La1 )-(CH2)1-、-(CH2)2-N(R La1 )-(CH2)2-、-(CH2)2-N(R La1 )-(CH2)3-、-(CH2)2-N(R La1 )-(CH2)4-、-(CH2)2-N(R La1 )-(CH2)5-、-(CH2)2-N(R La1 )-(CH2)6-、-(CH2)3-N(R La1 )-(CH2)1-、-(CH2)3-N(R La1 )-(CH2)2-、-(CH2)3-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)1-、-(CH2)4-N(R La1 )-(CH2)2-、-(CH2)4-N(R La1 )-(CH2)3-、-(CH2)4-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)1-、-(CH2)5-N(R La1 )-(CH2)2-、-(CH2)5-N(R La1 )-(CH2)3-、-(CH2)5-N(R La1 )-(CH2)4-、-(CH2)5-N(R La1 )-(CH2)5-、-(CH2)6-N(R La1 )-(CH2)1-、-(CH2)6-N(R La1 )-(CH2)2-、-(CH2)6-N(R La1 )-(CH2)3-、-(CH2)7-N(R La1 )-(CH2)1-、-(CH2)7-N(R La1 )-(CH2)2-、-(CH2)7-N(R La1 )-(CH2)3-、-(CH2)8-N(R La1 )-(CH2)1-、-(CH2)8-N(R La1 )-(CH2)2-、-(CH2)8-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)1-、-CH(CH3)-N(R La1 )- (CH2)2-、-CH(CH3)-N(R La1 )-(CH2)3-、-CH(CH3)-N(R La1 )-(CH2)4-、-CH(CH3)-N(R La1 )-(CH2)5-、-CH(CH3)-N(R La1 )-(CH2)6-、-(CH2)1-N(R La1 )-、-(CH2)2-N(R La1 )-、-(CH2)3-N(R La1 )-、-(CH2)4-N(R La1 )-、-(CH2)5-N(R La1 )-、-(CH2)6-N(R La1 )-、-(CH2)7-N(R La1 )-、-(CH2)8-N(R La1 )-、-(CH2)9-N(R La1 )-、-(CH2) 10 -N(R La1 )-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O) NH(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH 2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH 2)4-、-(CH2)4NHC(O)(CH2)4-、-(CH2)5NHC(O)(CH2)5-、-(CH2)2NHC(O)(CH2)2-O-(CH2)2-、-(CH2)4NHC(O)CH2-、-phenylene-CH2-、-phenylene-(CH2)2-、-phenylene-(CH2)3-、-phenylene-(CH2)4-、-phenylene-(CH2)5-、-phenylene-(CH2)6-、-phenylene-(CH2)7-、-phenylene-(CH2)8-、-CH2-phenylene-、-(CH2)2-phenylene-、-(CH2)3-phenylene-、-(CH2)4-phenylene-、-(C H2)5-phenylene-, -(CH2)6-phenylene-, -(CH2)7-phenylene-, -(CH2)8-phenylene-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-,-(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -thiazolylene-CH2-, -thiazolylene-(CH2)2-, -thiazolylene-(CH2)3-, -thiazolylene-(CH2)4-, -thiazolylene-(CH2)5-, -thiazolylene-(CH2)6-, -thiazolylene-(CH2)7-, -thiazolylene-(CH2)8-, -CH2-thiazolylene-, -(CH2)2-thiazolylene-, -(CH2)3-thiazolylene-, -(CH2)4-thiazolylene-, -(CH2)5-thiazolylene-, -CH2-thiazolylene-CH2-, -CH2-thiazolylene-(CH2)2-, -CH2-thiazolylene-(CH2)3-, -CH2-thiazolylene-(CH2)4-, -CH2-thiazolylene-(CH2)5-, -CH2-thiazolylene-(CH2)6-, -CH2-thiazolylene-(CH2)7-, - CH2-thiazolylene-(CH2)8-, -(CH2)2-thiazolylene-(CH2)1-, -(CH2)2-thiazolylene-(CH2)2-, -(CH2)2-thiazolylene-(CH2)3-, -(CH2)2-thiazolylene-(CH2)4-, -(CH2)2-thiazolylene-(CH2)5-, -(CH2)2-thiazolylene-(CH2)6-, -(CH2)2-thiazolylene-(CH2)7-, -(CH2)2-thiazolylene-(CH2)8-, -(CH2)3-thiazolylene-CH2-, -(CH2)3-thiazolylene-(CH2)2-, -(CH2)3-thiazolylene-(CH2)3-, -( -(CH2)3-thiazolylene-(CH2)4-, -(CH2)3-thiazolylene-(CH2)5-, -(CH2)3-thiazolylene-(CH2)6-, -(CH2)3-thiazolylene-(CH2)7-, -(CH2)3-thiazolylene-(CH2)8-, -(CH2)4-thiazolylene-CH2-, -(CH2)4-thiazolylene-(CH2)2-, -(CH2)4-thiazolylene-(CH2)3-, -(CH2)4-thiazolylene-(CH2)4-, -(CH2)4-thiazolylene-(CH2)5-, -(CH2)4-thiazolylene-(CH2)6-, -(CH2)4-thiazolylene-(CH2)7-,-(CH2)4-thiazolylene-(CH2)8-, -(CH2)5-thiazolylene-(CH2)1-, -(CH2)5-thiazolylene-(CH2)2-, -(CH2)5-thiazolylene-(CH2)3-, -(CH2)5-thiazolylene-(CH2)4-, -(CH2)5-thiazolylene-(CH2)5-, -(CH2)5-thiazolylene-(CH2)6-, -(CH2)5-thiazolylene-(CH2)7-, -(CH2)5-thiazolylene-(CH2)8-, -(CH2)6-thiazolylene-(CH2)1-, -(CH2)6-thiazolylene-(CH2)2-, -(CH2)6-thiazolylene-(CH2)3-, -(CH2)6-thiazolylene-(CH2)4-, -(CH2)6-thiazolylene-(CH2)5-, -(CH2)6-thiazolylene-(CH2)6-, -(CH2)6-thiazolylene-(CH2)7-, -(CH2)6-thiazolylene-(CH2)8-, -(CH2)7-thiazolylene-(CH2)1-, -(CH2)7-thiazolylene-(CH2)2-, -(CH2)7-thiazolylene-(CH2)3-, -(CH2)7-thiazolylene-(CH2)4-, -(CH2)7-thiazolylene-(CH2) -(CH2)8-thiazolylene-CH2-, -(CH2)8-thiazolylene-(CH2)2-, -(CH2)8-thiazolylene-(CH2)3-, -(CH2)8-thiazolylene-(CH2)4-, -(CH2)8-thiazolylene-(CH2)5-, -(CH2)8-thiazolylene-(CH2)6-, -(CH2)8-thiazolylene-(CH2)7-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene Piperidinyl-(CH2)6-, -(CH2)2-piperidinyl-(CH2)1-, -(CH2)2-piperidinyl-(CH2)2-, -(CH2)2-piperidinyl-(CH2)3-, -(CH2)2-piperidinyl-(CH2)4-, -(CH2)2-piperidinyl-(CH2)5-, -(CH2)3-piperidinyl-CH2-, -(CH2)3-piperidinyl-(CH2)2-, -(CH2)3-piperidinyl-(CH2)3-, -(CH2)3-piperidinyl-(CH2)4-, -(CH2)3-piperidinyl-(CH2)5-, -CH2-piperazinyl-CH2-, -CH2-piperazinyl-(CH2) H2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-,-(CH2)3-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, or -(CH2)8-piperazinylene-(CH2)5-; Among them, each R La1 Each independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl or isopropyl); The phenylene and thiazolylene groups are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; The piperazinyl and piperidinyl groups are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; or LIN means: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

9. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 4, wherein (i)R w1 , R w2 , R w3 , R w7 , R w9 , R w10 and R w11 Each independently represents: H or an optionally substituted straight or branched chain C 1-10 alkyl; -(CH2) m -cyclopropyl, -(CH2) m -cyclobutyl, -(CH2) m -cyclopentyl, -(CH2) m -cyclopentenyl, -(CH2) m -cyclohexyl, -(CH2) m -cyclohexenyl, -(CH2) m -cycloheptyl, -(CH2) m -cyclooctyl, -(CH2) m -decalin, -(CH2) m -octahydrocyclopentadienyl, -(CH2) m -octahydro-1H-indenyl, -(CH2) m -spirocycloalkyl (e.g. -(CH 2)m -C5-C 20 Spirocyclic groups, such as -(CH2) m -spiro[3.3]heptyl, -(CH2) m -spiro[2.5]octyl, -(CH2) m -Spiro[3.5]nonyl, -(CH2) m -spiro[4.4]nonyl, -(CH2) m -spiro[4.5]decyl, -(CH2) m -spiro[5.5]undecyl), -(CH2) m -p-Menthyl, -(CH2) m -m-menthanyl, or -(CH2) m -bridged cycloalkyl (e.g. -(CH2) m -C6-C 20 Bridged ring groups, such as -(CH2) m -Adamantyl, -(CH2) m -Noradamantyl, -(CH2) m -Bornyl, -(CH2) m -Norbornyl, -(CH2) m -bicyclo[2.2.1]heptyl, -(CH2) m -2-Oxobicyclo[ 2.2.1] Heptyl or -(CH2) m -bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; -(CH2) m -azetidinyl, -(CH2) m -Oxetane, -(CH2) m -pyrrolidinyl, -(CH2) m -imidazolidinyl, -(CH2) m -pyrazolidinyl, -(CH2) m -tetrahydrofuranyl, -(CH2) m -tetrahydropyranyl, -(CH2) m -tetrahydrothienyl, -(CH2) m -tetrahydrothiopyranyl, -(CH2) m -oxazolidinyl, -(CH2) m -thiazolidinyl, -(CH2) m -piperidinyl, -(CH2) m -piperazinyl, -(CH2) m -tetrahydropyridinyl, -(CH2) m -dihydroxypiperidinyl, -(CH2) m -difluoropiperidinyl, -(CH2) m -morpholinyl, -(CH2) m -Thiomorpholinyl, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -dioxane, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -diazepanyl (e.g. -(CH2) m -1,4-diazepanyl, -(CH2) m -4,5-diazepanyl, -(CH2) m -1,3-diazepanyl), -(CH2) m -diazooctanyl, -(CH2) m -bridged heterocyclic group (e.g. -(CH2) m -6 to 20 membered bridged heterocyclic group, for example -(CH2) m -6-azabicyclo[3.1.1]heptyl, -(CH2) m - 2,5-diazabicyclo[2.2.1]heptyl, -(CH2) m -3,6-diazabicyclo[3.1.1]heptyl, -(CH2) m -3-Azabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -2,5-diazabicyclo[2.2.2]octyl and -(CH2) m -quinuclidine), and -(CH2) m -azaspirocyclic group (e.g. -(CH2) m -5 to 20 membered azaspirocyclic group, such as -(CH2) m -2,6-diazaspiro[3.3]heptyl, -(CH2) m -2,7-diazaspiro[3.5]nonane, -(CH2) m -2,8-diazaspiro[4.5]decyl, -(CH2) m -3,9-diazaspiro[5.5]undecyl, -(CH2) m -3-azaspiro[5.5]undecyl and -(CH2) m -7-azaspiro[3.5]nonyl), or -(CH2) m -octahydropyrrolo[3,4-c]pyrrolyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents; -(CH2) m -phenyl or -(CH2) m -naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1- 6-alkyl, amino-substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; or -(CH2) m -furanyl, -(CH2) m -oxazolyl, -(CH2) m -isoxazolyl, -(CH2) m -oxadiazolyl, -(CH2) m -thienyl, -(CH2) m -thiazolyl, -(CH2) m -isothiazolyl, -(CH2) m -thiadiazole, -(CH2) m -pyrrolyl, -(CH2) m -Imidazolyl, -(CH2) m -pyrazolyl, -(CH2) m -triazolyl, -(CH2) m -pyridyl, -(CH2) m -pyrimidinyl, -(CH2) m -pyridazinyl, -(CH2) m -pyrazinyl, -(CH2) m -Triazine, -(CH2) m -Indolyl, -(CH2) m -isoindolyl, -(CH2) m -Indolinyl, -(CH2) m -Benzofuryl, -(CH2) m -chromanyl, -(CH2) m -isobenzofuranyl, -(CH2) m -Benzothienyl, -(CH2) m -Indazolyl, -(CH2) m -Benzimidazolyl, -(CH2) m -Benzoxazolyl, -(CH2) m -Benzisoxazolyl, -(CH2) m -Benzothiazolyl, -(CH2) m -Benzisothiazolyl, -(CH2) m -Benzotriazolyl, -(CH2) m -Benzo[2,1,3]oxadiazolyl, -(CH2) m -Benzo[2,1,3]thiadiazolyl, -(CH2) m -Benzo[1,2,3]thiadiazolyl, -(CH2) m -2-Oxo-2,3-dihydro-1H-benzo[d]imidazolyl, -(CH2) m -Benzo[b][1,4]oxazinyl, -(CH2) m -3,4-dihydro-2H-benzo[b][1,4]oxazinyl, -(CH2) m -Quinolinyl, -(CH2) m -isoquinolyl, -(CH2) m -1,2,3,4-tetrahydroquinolinyl, -(CH2) m -Naphthyridinyl, -(CH2) m -cinnolinyl, -(CH2) m -quinazolinyl, -(CH2) m -quinoxalinyl, -(CH2) m -1,2,3,4-tetrahydroquinoxalinyl, -(CH2) m -Phthalocyanyl, -(CH2) m -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, -(CH2) m -4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, -(CH2) m -5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, -(CH2) m -thieno[2,3-d]pyrimidinyl, -(CH2) m -thieno[3,2-d]pyrimidinyl, -(CH2) m -isoxazolo[4,5-c]pyridinyl, -(CH2) m -isoxazolo[4,5-c]pyrimidinyl, -(CH2) m -isoxazolo[4,5-d]pyrimidinyl, -(CH2) m -pyrazolo[1,5-a]pyridinyl, -(CH2) m -pyrazolo[1,5-a]pyrimidinyl, -(CH2) m -imidazo[1,2-a]pyridinyl, -(CH2) m -1H-pyrrolo[3,2-b]pyridinyl, -(CH2) m -1H-pyrrolo[2,3-b]pyridinyl, -(CH2) m -pyrrolo[2,1-b]thiazolyl, -(CH2) m -imidazo[2,1-b]thiazolyl, -(CH2) m -5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or -(CH2) m -6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; and / or (ii) R w4 , R w6 , R w8 , R w12 , R w14 and R w15 Each independently represents: Optionally substituted straight or branched chain C 1-10 alkyl; -(CH2) m -cyclopropyl, -(CH2) m -cyclobutyl, -(CH2) m -cyclopentyl, -(CH2) m -cyclopentenyl, -(CH2) m -cyclohexyl, -(CH2) m -cyclohexenyl, -(CH2) m -cycloheptyl, -(CH2) m -cyclooctyl, -(CH2) m -decalin, -(CH2) m -octahydrocyclopentadienyl, -(CH2) m -octahydro-1H-indenyl, -(CH2) m -spirocycloalkyl (e.g. -(CH2) m -C5-C 20 Spirocyclic groups, such as -(CH2) m -spiro[3.3]heptyl, -(CH2) m -spiro[2.5]octyl, -(CH2) m -Spiro[3.5]nonyl, -(CH2) m -spiro[4.4]nonyl, -(CH2) m -spiro[4.5]decyl, -(CH2) m -spiro[5.5]undecyl), -(CH2) m -p-Menthyl, -(CH2) m -m-menthanyl, or -(CH2) m -bridged cycloalkyl (e.g. -(CH2) m -C6-C 20 Bridged ring groups, such as -(CH2) m -Adamantyl, -(CH2) m -Noradamantyl, -(CH2) m -Bornyl, -(CH2) m -Norbornyl, -(CH2) m -bicyclo[2.2.1]heptyl, -(CH2) m -2-Oxobicyclo[ 2.2.1] Heptyl or -(CH2) m -bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; -(CH2) m -azetidinyl, -(CH2) m -Oxetane, -(CH2) m -pyrrolidinyl, -(CH2) m -imidazolidinyl, -(CH2) m -pyrazolidinyl, -(CH2) m -tetrahydrofuranyl, -(CH2) m -tetrahydropyranyl, -(CH2) m -tetrahydrothienyl, -(CH2) m -tetrahydrothiopyranyl, -(CH2) m -oxazolidinyl, -(CH2) m -thiazolidinyl, -(CH2) m -piperidinyl, -(CH2) m -piperazinyl, -(CH2) m -tetrahydropyridinyl, -(CH2) m -dihydroxypiperidinyl, -(CH2) m -difluoropiperidinyl, -(CH2) m -morpholinyl, -(CH2) m -Thiomorpholinyl, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -dioxane, -(CH2) m -azepanyl, -(CH2) m -Azoline, -(CH2) m -diazepanyl (e.g. -(CH2) m -1,4-diazepanyl, -(CH2) m -4,5-diazepanyl, -(CH2) m -1,3-diazepanyl), -(CH2) m -diazooctanyl, -(CH2) m -bridged heterocyclic group (e.g. -(CH2) m -6 to 20 membered bridged heterocyclic group, for example -(CH2) m -6-azabicyclo[3.1.1]heptyl, -(CH2) m -2,5-diazabicyclo[2.2.1]heptyl, -(CH2) m -3,6-diazabicyclo[3.1.1]heptyl, -(CH2) m -3-Azabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -3,8-diazabicyclo[3.2.1]octyl, -(CH2) m -2,5-diazabicyclo[2.2.2]octyl and -(CH2) m -quinuclidine), and -(CH2) m -azaspirocyclic group (e.g. -(CH2) m -5 to 20 membered azaspirocyclic group, such as -(CH2) m -2,6-diazaspiro[3.3]heptyl, -(CH2) m -2,7-diazaspiro[3.5]nonane, -(CH2) m -2,8-diazaspiro[4.5]decyl, -(CH2) m -3,9-diazaspiro[5.5]undecyl, -(CH2) m -3-azaspiro[5.5]undecyl and -(CH2) m -7-azaspiro[3.5]nonyl), or -(CH2) m -octahydropyrrolo[3,4-c]pyrrolyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; -(CH2) m -phenyl or -(CH2) m -naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1- 6-alkyl, amino-substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; or -(CH2) m -furanyl, -(CH2) m -oxazolyl, -(CH2) m -isoxazolyl, -(CH2) m -oxadiazolyl, -(CH2) m -thienyl, -(CH2) m -thiazolyl, -(CH2) m -isothiazolyl, -(CH2) m -Thiadiazolyl, -(CH2) m -pyrrolyl, -(CH2) m -Imidazolyl, -(CH2) m -pyrazolyl, -(CH2) m -triazolyl, -(CH2) m -pyridyl, -(CH2) m -pyrimidinyl, -(CH2) m -pyridazinyl, pyrazinyl, triazinyl, -(CH2) m -Indolyl, -(CH2) m -isoindolyl, -(CH2) m -Indolinyl, -(CH2) m -Benzofuryl, -(CH2) m -chromanyl, -(CH2) m -isobenzofuranyl, -(CH2) m -Benzothienyl, -(CH2) m -Indazolyl, -(CH2) m -Benzimidazolyl, -(CH2) m -Benzoxazolyl, -(CH2) m -Benzisoxazolyl, -(CH2) m -Benzothiazolyl, -(CH2) m -Benzisothiazolyl, -(CH2) m -Benzotriazolyl, -(CH2) m -Benzo[2,1,3]oxadiazolyl, -(CH2) m -Benzo[2,1,3]thiadiazolyl, -(CH2) m -Benzo[1,2,3]thiadiazolyl, -(CH2) m -2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, -(CH2) m -Benzo[b][1,4]oxazinyl, -(CH2) m -3,4-dihydro-2H-benzo[b][1,4]oxazinyl, -(CH2) m -Quinolinyl, -(CH2) m -isoquinolyl, -(CH2) m -1,2,3,4-tetrahydroquinolinyl, -(CH2) m -Naphthyridinyl, -(CH2) m -cinnolinyl, -(CH2) m -quinazolinyl, -(CH2) m -quinoxalinyl, -(CH2) m -1,2,3,4-tetrahydroquinoxalinyl, -(CH2) m -Phthalocyanyl, -(CH2) m -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, -(CH2) m -4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, -(CH2) m -5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, -(CH2) m -thieno[2,3-d]pyrimidinyl, -(CH2) m -thieno[3,2-d]pyrimidinyl, -(CH2) m -isoxazolo[4,5-c]pyridinyl, -(CH2) m -isoxazolo[4,5-c]pyrimidinyl, -(CH2) m -isoxazolo[4,5-d]pyrimidinyl, -(CH2) m -pyrazolo[1,5-a]pyridinyl, -(CH2) m -pyrazolo[1,5-a]pyrimidinyl, -(CH2) m -imidazo[1,2-a]pyridinyl, -(CH2) m -1H-pyrrolo[3,2-b]pyridinyl, -(CH2) m -1H-pyrrolo[2,3-b]pyridinyl, -(CH2) m -pyrrolo[2,1-b]thiazolyl, -(CH2) m -imidazo[2,1-b]thiazolyl, -(CH2) m -5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or -(CH2) m -6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; and / or (iii) R w3 and R w4 Together with the nitrogen atoms to which they are attached they form: azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazepanyl, diazaoctanyl, nitrogen-bridged heterocyclic radicals (e.g., 6- to 20-membered nitrogen-bridged heterocyclic radicals, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[3.1.2]heptanyl, 3-azabicyclo[3.1.3]heptanyl, 3-azabicyclo[3.1.4]heptanyl, 3-azabicyclo[3.1.5]heptanyl, 3-azabicyclo[3.1.6]heptanyl, 3-azabicyclo[3.1.7]heptanyl, 3-azabicyclo[3.1.8]heptanyl, 3-azabicyclo[3.1.9]heptanyl, 3-azabicyclo[3.20]heptanyl, 3-azabicyclo[3.21]heptanyl, 3-azabicyclo[3.22]heptanyl, 3-azabicyclo[3.23]heptanyl, 3-azabicyclo[3.24]heptanyl, 3-azabicyclo[3.25]heptanyl, 3-azabicyclo[3.26]heptanyl, 3-azabicyclo[3.27]heptanyl, 3-azabicyclo[3.28]heptanyl, 3-azabicyclo[3.29]heptanyl, 3-azabicyclo[3.30]heptanyl, 6-azabicyclo[3.1.1]heptyl, 2-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), or nitrogen-containing spiro heterocyclic group (e.g., a 5- to 20-membered nitrogen-containing spiroheterocyclyl group, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or an octahydropyrrolo[3,4-c]pyrrolyl group, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; and / or (iv) R w11 and R w12 Together with the nitrogen atoms to which they are attached they form: azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazacycloheptyl, diazacyclooctanyl, nitrogen-bridged heterocyclic radicals (e.g., 6- to 20-membered nitrogen-bridged heterocyclic radicals, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.2]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3 -azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), or a nitrogen-containing spiro heterocyclic group (e.g., a 5- to 20-membered nitrogen-containing spiro heterocyclic group, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or an octahydropyrrolo[3,4-c]pyrrolyl group, which is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; and / or (v) Ring A 4 express: Cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, spirocycloalkylene (e.g. C5-C 20 spirocycloalkylene (e.g., spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, spiro[5.5]undecanylene), para-menthanylene, meta-menthanylene, or bridged cycloalkylene (e.g., C6-C 20 adamantylene, noradamantylene, bornylene, norbornylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[ 2.2.1] heptane or bicyclo[2.2.1] heptene), which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; or Azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, tetrahydropyridinylene, dihydroxypiperidinylene, difluoropiperidinylene, morpholinylene, thiomorpholinylene, azepanylene, azocyclooctanylene, dioxanylene, azepanylene, azocyclooctanylene, diazepanylene (e.g., 1,4-diazo heterocycloheptanyl, 4,5-diazacycloheptanyl, 1,3-diazacycloheptanyl), diazacyclooctanyl, subbridged heterocyclic groups (e.g., 6- to 20-membered subbridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2 .1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene and quinuclidinyl), azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptaneylidene, 2,7-diazaspiro[3.5]nonaneylidene subunit, 2,8-diazaspiro[4.5]decane subunit, 3,9-diazaspiro[5.5]undecane subunit, 3-azaspiro[5.5]undecane subunit and 7-azaspiro[3.5]nonane subunit), or octahydropyrrolo[3,4-c]pyrrole subunit, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1- 6-alkyl, amino-substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; Phenylene or naphthylene, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2- 6-alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; or furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, triazinylene, indolylene, isoindolylene, indolinylene, benzofuranylene, chromanylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzo isoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolylidene, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolylene, isoquinolylene, 1,2,3,4-tetrahydroquinoline subunit, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl , isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2- 6-alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; and / or (vi) Ring A 5 express: Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 spirocyclic groups, such as spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or bridged cycloalkyl groups (e.g., C6-C 20 bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy 、氘代C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基磺酰基、二(C1-6烷基)膦酰基、C1-6烷基磺酰氧基、C1-3烷氧基羰基、卤代C2-4烯基、C2-6烯基、C2-6炔基和其任意组合的取代基取代；或 azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazepanyl, bridged heterocyclic radical (e.g., 6- to 20-membered bridged heterocyclic radicals such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazepanyl, 3,6-diazepanyl, 3 5- to 20-membered azaspirocyclyl, for example 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy 、卤代C1-6烷氧基、C1-6烷基磺酰基、二(C1-6烷基)膦酰基、C1-6烷基磺酰氧基、C1-3烷氧基羰基、卤代C2-4烯基、C2-6烯基、C2-6炔基和其任意组合的取代基取代； Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino Substituted C 1-6 Alkyl, C 1-6 Alkoxy 、氘代C1-6烷氧基、卤代C1-6烷氧基、C1-6烷基磺酰基、二(C1-6烷基)膦酰基、C1-6烷基磺酰氧基、C1-3烷氧基羰基、卤代C2-4烯基、C2-6烯基、C2-6炔基和其任意组合的取代基取代；或 furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[ 4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 1-6 Alkylsulfonyl, di(C 1-6 Alkyl)phosphonyl, C 1-6 Alkylsulfonyloxy, C 1-3 Alkoxycarbonyl, halocarbonyl 2-4 Alkenyl, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination of substituents thereof; wherein m in (i) and (ii) each independently represents an integer of 0, 1 or 2.

10. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in claim 1, wherein (i)R w represents: piperidine-1-carbonyl, N,N-diisopropylcarbamoyl, NHC(O)CH3, OH, adamantyl-O-, norbornyl-O-, 1,7,7-trimethyl-bicyclo[2.2.1]heptanyl-O-, 2-isopropyl-5-methylcyclohexyl-O-, SH, adamantyl-NHC(O)-, 3,5-dimethyladamantan-1-yl-NHC(O)-, cyclopropyl, cyclobutyl, 3,3-difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptan-2-yl, adamantyl, 2,3-dihydro-1H-indenyl, 4-cyano-2,3-dihydro-1H-indenyl, 3,5-dimethyladamantan-1-yl, 1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl, phenyl, 4-fluorophenyl, 4-chlorophenyl, 3,5-difluorophenyl, 4-(bromomethyl)-2-fluorophenyl, 3,4,5-trifluorophenyl, (2-bromovinyl)phenyl, morpholinyl, piperidinyl, 2-oxopiperidin-1-yl, piperazinyl, N-methylpiperazinyl, 4-(methylsulfonyl)piperazin-1-yl, 4-(ethylsulfonyl)piperazin-1-yl, 3,5-dimethylpiperazinyl, 1,4-diazepan-1-yl, 4-methyl-1,4-diazepan-1-yl, 1-methyl-1,4-diazepan-1-yl, 8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl, 1,4-diazabicyclo[3.2.1]octan-3-yl, 2-(trifluoromethyl)pyrrolidin-1-yl, 2,6-dioxopiperidin-3-yl, 4,4-dimethylpiperidin-1-yl, 3,5-dimethylpiperidin-2-yl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 3-fluoro-4-hydroxypyrrolidin-1-yl, 3-methyl-4-(trifluoromethyl)pyrrolidin-1-yl, 2,6-dioxopiperidin-3-yl, 4,4-dimethylpiperidin-1-yl, 3,5-dimethyl piperidin-1-yl, 4,4-difluoropiperidinyl, 4-methylpiperazin-1-yl, tetrahydro-2H-pyran-2-yl, pyrrolidinyl, 3-cyanoazetidinyl, 3-hydroxyazetidinyl, 3-hydroxy-3-methylazetidinyl, 3-hydroxy-2-methylazetidin-1-yl, 3-(trifluoromethoxy)azetidin-1-yl, azepan-1-yl, azooctan-1-yl, 7-fluoro-5-azaspiro[2.4]heptane-5-yl, 1,1-difluoro-5-azaspiro[2.4]heptane-5-yl, 1,1-difluoro-6-azaspiro[2.5]octane-6-yl, 6-azaspiro[2.5]octane-6-yl, 2-oxa-7-azaspiro[3.5]nonane-7-yl, 3-azabicyclo[3.1.0]hexane-3-yl, 6-(difluoromethyl)-3-azabicyclo[4.1.0]heptane-3-yl, pyridyl, pyrimidinyl, thiazolyl, quinolyl, 6, 7-difluoroquinazolin-4-yl, 3-cyano-quinolinyl, indolyl, isoindol-2-yl, 1-methyl-1H-indol-7-yl, benzothienyl, benzofuranyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, 3-fluoro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl, 3-(trifluoromethyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl or thiomorpholino; or, for example, R w express: (ii) R w Indicates NR w1 R w2 , where R w1 represents H, methyl, ethyl, isopropyl, cyclohexyl or phenyl, and R w2 represents methyl, ethyl, isopropyl, tert-butyl, 2,4-dimethylpentan-3-yl, dicyclopropylmethyl, 1-cyclopropylethyl, 2,6-dichloro-3-fluorophenylethyl, 2,4-dimethylpentan-3-yl, pyrimidinyl, pyridinyl, quinazolinyl, 6,7-difluoroquinazolin-4-yl, indolyl, 1-methyl-1H-indol-7-yl, benzothienyl, benzofuranyl, 3-cyano-quinolin-4-yl , quinolyl, thiazolyl, oxazolyl, 2,3-dihydro-1H-indenyl, 5-methyloxazol-2-yl, 4-cyano-2,3-dihydro-1H-inden-1-yl, phenyl, 3-chloro-4-methylphenyl, 4-fluorophenyl, 3,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-(dimethylphosphonyl)phenyl, 2-(isopropylsulfonyl)phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, dimethylcyclo hexyl, 4,4-dimethylcyclohexyl, adamantyl, 3,5-dimethyladamantyl, 3-hydroxyadamantyl, 3-chloroadamantane-1-yl, 4-chloroadamantane-1-yl, 2-chloroadamantane-1-yl, spiro[5.5]undecane-3-yl, spiro[3.3]heptyl, noradamantyl, norbornyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.2]octanyl, 4,4-dimethylcyclohexyl , 1,7,7-trimethylbicyclo[2.2.1]heptyl, 7,7-dimethylbicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptyl, 2-methoxycyclopropyl, 3-fluorocyclobutyl, 3,3-difluorocyclobutyl, 3,3-difluorocyclopentyl, 3-hydroxycyclohexyl, 3-cyano-bicyclo[1.1.1]pentan-1-yl, bicyclo[2.2.2]octan-1-yl, 4-hydroxybicyclo[ 2.2.2] octan-1-yl, 2-isopropyl-5-methylcyclohexyl, quinuclidine-3-yl, 7,7-dimethyl-2-oxobicyclo[ 2.2.1]heptane-1-yl, hexahydro-2,5-methanocyclopentadien-3a(1H)-yl, bicyclo[2.2.1]heptane, pyrrolidinyl, azepanyl, azocanyl, piperidinyl, dimethylpiperidinyl, oxetanyl or quinuclidinyl; or for example R w Represents: NHCH3, N(CH3)2, N(CH2CH3)2, N(CH(CH3)2)2, (iii) R w NHC(O)NR w7 R w8 , where R w7 represents H, and R w8 represents adamantyl, 3,5-dimethyladamantan-1-yl, phenyl or 3-chloro-4-methylphenyl; or (iv) R w represents optionally substituted by one or more independently selected from halogen, amino, hydroxy, mercapto, cyano, oxo, nitro and C 3-6 The cycloalkyl substituents are substituted with straight or branched C 1-10 Alkyl; for example, R w It represents CF2CF3, CF3, dicyclopropylmethyl or cyclopropylethyl.

11. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in claim 1, selected from: 3-(4-((8-morpholinooctyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((8-morpholinooctyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-8-morpholinooctylamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-8-morpholinooctylamide; 1-(4-((8-morpholinooctyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((8-morpholinooctyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-8-morpholinooctaneamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-8-morpholinooctaneamide; 3-((4-((8-morpholinooctyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((8-morpholinooctyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-8-morpholinooctylamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-8-morpholinooctylamide; 3-(1-methyl-7-((8-morpholinooctyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-8-morpholinooctylamide; 3-(3-methyl-4-((8-morpholinooctyl)amino)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-8-morpholinooctylamide; 3-(3-methyl-4-((methyl(7-morpholinoheptyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-2,6- 二酮； N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-7-morpholinoheptylamide; 3-(5-((8-morpholinooctyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-8-morpholinooctylamide; 3-(5-(9-morpholinonan-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-((methyl(7-morpholinoheptyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-7-morpholinoheptylamide; 3-(6-((8-morpholinooctyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-8-morpholinooctylamide; 3-(4-((8-(diethylamino)octyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((8-(diethylamino)octyl)amino)phenyl)piperidine-2,6-dione; 8-(Diethylamino)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)octanamide; 8-(Diethylamino)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)octanamide; 1-(4-((8-(diethylamino)octyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((8-(diethylamino)octyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 8-(Diethylamino)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)octanamide; 8-(Diethylamino)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)octanamide; 3-((4-((8-(diethylamino)octyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((8-(diethylamino)octyl)amino)phenyl)amino)piperidine-2,6-dione; 8-(Diethylamino)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)octanamide; 8-(Diethylamino)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)octanamide; 3-(7-((8-(diethylamino)octyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 8-(Diethylamino)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)octanamide; 3-(4-((8-(diethylamino)octyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 8-(Diethylamino)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)octanamide; 3-(4-(((7-(diethylamino)heptyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-(Diethylamino)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)heptylamide; 3-(5-((8-(diethylamino)octyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 8-(Diethylamino)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)octanamide; 3-(5-(9-(diethylamino)non-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((7-(diethylamino)heptyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-(Diethylamino)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)heptylamide; 3-(6-((8-(diethylamino)octyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 8-(Diethylamino)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)octanamide; 3-(4-((8-(piperidin-1-yl)octyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((8-(piperidin-1-yl)octyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-8-(piperidin-1-yl)octanamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-8-(piperidin-1-yl)octanamide; 1-(4-((8-(piperidin-1-yl)octyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((8-(piperidin-1-yl)octyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-8-(piperidin-1-yl)octanamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-8-(piperidin-1-yl)octanamide; 3-((4-((8-(piperidin-1-yl)octyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((8-(piperidin-1-yl)octyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-8-(piperidin-1-yl)octanamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-8-(piperidin-1-yl)octanamide; 3-(1-methyl-7-((8-(piperidin-1-yl)octyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-8-(piperidin-1-yl)octanamide; 3-(3-methyl-2-oxo-4-((8-(piperidin-1-yl)octyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-8-(piperidin-1-yl)octanamide; 3-(3-methyl-4-((methyl(7-(piperidin-1-yl)heptyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-7-(piperidin-1-yl)heptylamide; 3-(5-((8-(piperidin-1-yl)octyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-8-(piperidin-1-yl)octanamide; 3-(5-(9-(piperidin-1-yl)non-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-((methyl(7-(piperidin-1-yl)heptyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-7-(piperidin-1-yl)heptylamide; 3-(2-oxo-6-((8-(piperidin-1-yl)octyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-8-(piperidin-1-yl)octanamide; 3-(4-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)phenyl)piperidine-2,6-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)octanamide; 8-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)octanamide; 1-(4-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)octanamide; 8-(4,4-difluoropiperidin-1-yl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)octanamide; 3-((4-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)phenyl)amino)piperidine-2,6-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)octanamide; 8-(4,4-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)octanamide; 3-(7-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)octanamide; 3-(4-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)octanamide; 3-(4-(((7-(4,4-difluoropiperidin-1-yl)heptyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)heptylamide; 3-(5-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)octanamide; 3-(5-(9-(4,4-difluoropiperidin-1-yl)non-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((7-(4,4-difluoropiperidin-1-yl)heptyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)heptylamide; 3-(6-((8-(4,4-difluoropiperidin-1-yl)octyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 8-(4,4-difluoropiperidin-1-yl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)octanamide; 3-(4-((7-oxo-7-(piperidin-1-yl)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-oxo-7-(piperidin-1-yl)heptyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-7-oxo-7-(piperidin-1-yl)heptylamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-7-oxo-7-(piperidin-1-yl)heptylamide; 1-(4-((7-oxo-7-(piperidin-1-yl)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-oxo-7-(piperidin-1-yl)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-oxo-7-(piperidin-1-yl)heptylamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-oxo-7-(piperidin-1-yl)heptylamide; 3-((4-((7-oxo-7-(piperidin-1-yl)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-oxo-7-(piperidin-1-yl)heptyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-oxo-7-(piperidin-1-yl)heptylamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-oxo-7-(piperidin-1-yl)heptylamide; 3-(1-methyl-7-((7-oxo-7-(piperidin-1-yl)heptyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-7-oxo-7-(piperidin-1-yl)heptylamide; 3-(3-methyl-2-oxo-4-((7-oxo-7-(piperidin-1-yl)heptyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-7-oxo-7-(piperidin-1-yl)heptylamide; 3-(3-methyl-4-((methyl(6-oxo-6-(piperidin-1-yl)hexyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-6-oxo-6-(piperidin-1-yl)hexanamide; 3-(5-((7-oxo-7-(piperidin-1-yl)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-7-oxo-7-(piperidin-1-yl)heptylamide; 3-(5-(8-oxo-8-(piperidin-1-yl)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-((methyl(6-oxo-6-(piperidin-1-yl)hexyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-6-oxo-6-(piperidin-1-yl)hexanamide; 3-(2-oxo-6-((7-oxo-7-(piperidin-1-yl)heptyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-7-oxo-7-(piperidin-1-yl)heptylamide; 3-(4-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)phenyl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-7-oxoheptylamide; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-7-oxoheptylamide; 1-(4-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-oxoheptylamide; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-oxoheptylamide; 3-((4-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)phenyl)amino)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-oxoheptylamide; 7-(4,4-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-oxoheptylamide; 3-(7-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-7-oxoheptylamide; 3-(4-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-7-oxoheptylamide; 3-(4-(((6-(4,4-difluoropiperidin-1-yl)-6-oxohexyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 6-(4,4-difluoropiperidin-1-yl)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-6-oxohexanamide; 3-(5-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-7-oxoheptylamide; 3-(5-(8-(4,4-difluoropiperidin-1-yl)-8-oxooct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((6-(4,4-difluoropiperidin-1-yl)-6-oxohexyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 6-(4,4-difluoropiperidin-1-yl)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-6-oxohexanamide; 3-(6-((7-(4,4-difluoropiperidin-1-yl)-7-oxoheptyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-7-oxoheptylamide; 7-((4-(2,6-dioxopiperidin-3-yl)phenyl)amino)-N,N-diisopropylheptylamide; 7-((3-(2,6-dioxopiperidin-3-yl)phenyl)amino)-N,N-diisopropylheptylamide; N1-(4-(2,6-dioxopiperidin-3-yl)phenyl)-N7,N7-diisopropylpiperidinamide; N1-(3-(2,6-dioxopiperidin-3-yl)phenyl)-N7,N7-diisopropylpiperidinamide; 7-((4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)amino)-N,N-diisopropylheptylamide; 7-((3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)amino)-N,N-diisopropylheptylamide; N1-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-N7,N7-diisopropylpimelamide; N1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-N7,N7-diisopropylpimelamide; 7-((4-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-N,N-diisopropylheptylamide; 7-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-N,N-diisopropylheptylamide; N1-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-N7,N7-diisopropylpiperamide; N1-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-N7,N7-diisopropylpiperidinamide; 7-((3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)amino)-N,N-diisopropylheptylamide; N1-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-N7,N7-diisopropylpiperamide; 7-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)amino)-N,N-diisopropylheptylamide; N1-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-N7,N7-diisopropylpiperamide; 6-(((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)(methyl)amino N,N-diisopropylhexanoamide; N1-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-N6,N6-diisopropyladipamide; 7-((3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)amino)-N,N-diisopropylheptylamide; N1-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-N7,N7-diisopropylpiperamide; 8-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-N,N-diisopropyloctan-7-ynamide; 6-(((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)(methyl)amino)-N,N-diisopropylhexanamide; N1-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-N6,N6-diisopropyladipamide; 7-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)amino)-N,N-diisopropylheptylamide; N1-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-N7,N7-diisopropylpimelic acid amide; 3-(4-((7-((adamantan-1-yl)amino)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-((adamantan-1-yl)amino)heptyl)amino)phenyl)piperidine-2,6-dione; 7-((adamantan-1-yl)amino)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 7-((adamantan-1-yl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 1-(4-((7-((adamantan-1-yl)amino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-((adamantan-1-yl)amino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 7-((adamantan-1-yl)amino)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 7-((adamantan-1-yl)amino)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 3-((4-((7-((adamantan-1-yl)amino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-((adamantan-1-yl)amino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 7-((adamantan-1-yl)amino)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 7-((adamantan-1-yl)amino)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 3-(7-((7-((adamantan-1-yl)amino)heptyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)heptylamide; 3-(4-((7-((adamantan-1-yl)amino)heptyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)amino)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)heptylamide; 3-(4-(((6-((adamantan-1-yl)amino)hexyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 6-((adamantan-1-yl)amino)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)hexanamide; 3-(5-((7-((adamantan-1-yl)amino)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)heptylamide; 3-(5-(8-((adamantan-1-yl)amino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((6-((adamantan-1-yl)amino)hexyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 6-((adamantan-1-yl)amino)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenz[cd]indol-6-yl)methyl)hexanamide; 3-(6-((7-((adamantan-1-yl)amino)heptyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)amino)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)heptylamide; 3-(4-((4-((adamantan-1-yl)amino)butyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-((adamantan-1-yl)amino)butyl)amino)phenyl)piperidine-2,6-dione; 4-((adamantan-1-yl)amino)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)butanamide; 4-((adamantan-1-yl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)butanamide; 1-(4-((4-((adamantan-1-yl)amino)butyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-((adamantan-1-yl)amino)butyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 4-((adamantan-1-yl)amino)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)butanamide; 4-((adamantan-1-yl)amino)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)butanamide; 3-((4-((4-((adamantan-1-yl)amino)butyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-((adamantan-1-yl)amino)butyl)amino)phenyl)amino)piperidine-2,6-dione; 4-((adamantan-1-yl)amino)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)butanamide; 4-((adamantan-1-yl)amino)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)butanamide; 3-(7-((4-((adamantan-1-yl)amino)butyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 4-((adamantan-1-yl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)butanamide; 3-(4-((4-((adamantan-1-yl)amino)butyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 4-((adamantan-1-yl)amino)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)butanamide; 3-(4-(((3-((adamantan-1-yl)amino)propyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-((adamantan-1-yl)amino)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)propanamide; 3-(5-((4-((adamantan-1-yl)amino)butyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 4-((adamantan-1-yl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)butanamide; 3-(6-(((3-((adamantan-1-yl)amino)propyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-((adamantan-1-yl)amino)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenz[cd]indol-6-yl)methyl)propanamide; 3-(6-((4-((adamantan-1-yl)amino)butyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 4-((adamantan-1-yl)amino)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)butanamide; 3-(4-((4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-4-(piperidin-1-ylmethyl)benzamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-4-(piperidin-1-ylmethyl)benzamide; 1-(4-((4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-4-(piperidin-1-ylmethyl)benzamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-4-(piperidin-1-ylmethyl)benzamide; 3-((4-((4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-4-(piperidin-1-ylmethyl)benzamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-4-(piperidin-1-ylmethyl)benzamide; 3-(1-methyl-7-((4-(piperidin-1-ylmethyl)benzyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-4-(piperidin-1-ylmethyl)benzamide; 3-(3-methyl-2-oxo-4-((4-(piperidin-1-ylmethyl)benzyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-4-(piperidin-1-ylmethyl)benzamide; 3-(3-methyl-4-((methyl(4-(piperidin-1-ylmethyl)phenyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((4-(piperidin-1-ylmethyl)benzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-4-(piperidin-1-ylmethyl)benzamide; 3-(6-((methyl(4-(piperidin-1-ylmethyl)phenyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(2-oxo-6-((4-(piperidin-1-ylmethyl)benzyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-(piperidin-1-ylmethyl)benzamide; 3-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)phenyl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)benzamide; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)benzamide; 1-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)benzamide; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)benzamide; 3-((4-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)benzamide; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)benzamide; 3-(7-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)benzamide; 3-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)benzamide; 3-(4-(((4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)benzamide; 3-(6-(((4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(6-((4-((4,4-difluoropiperidin-1-yl)methyl)benzyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzamide; 3-(4-((7-(cyclohexylamino)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-(cyclohexylamino)heptyl)amino)phenyl)piperidine-2,6-dione; 7-(Cyclohexylamino)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 7-(Cyclohexylamino)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 1-(4-((7-(cyclohexylamino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-(cyclohexylamino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 7-(Cyclohexylamino)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 7-(Cyclohexylamino)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 3-((4-((7-(cyclohexylamino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-(cyclohexylamino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 7-(Cyclohexylamino)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 7-(Cyclohexylamino)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 3-(7-((7-(cyclohexylamino)heptyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 7-(Cyclohexylamino)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)heptylamide; 3-(4-((7-(cyclohexylamino)heptyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-(Cyclohexylamino)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)heptylamide; 3-(4-(((6-(cyclohexylamino)hexyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 6-(Cyclohexylamino)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)hexanamide; 3-(5-((7-(cyclohexylamino)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 7-(Cyclohexylamino)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)heptylamide; 3-(5-(8-(cyclohexylamino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((6-(cyclohexylamino)hexyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 6-(Cyclohexylamino)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)hexanamide; 3-(6-((7-(cyclohexylamino)heptyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-(Cyclohexylamino)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)heptylamide; 3-(4-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)phenyl)piperidine-2,6-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 7-((adamantan-1-yl)(methyl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 1-(4-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 7-((adamantan-1-yl)(methyl)amino)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 3-((4-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 7-((adamantan-1-yl)(methyl)amino)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 3-(7-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)heptylamide; 3-(4-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)heptylamide; 3-(4-(((6-((adamantan-1-yl)(methyl)amino)hexyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 6-((adamantan-1-yl)(methyl)amino)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)hexanamide; 3-(5-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)heptylamide; 3-(5-(8-((adamantan-1-yl)(methyl)amino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((6-((adamantan-1-yl)(methyl)amino)hexyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 6-((adamantan-1-yl)(methyl)amino)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)hexanamide; 3-(6-((7-((adamantan-1-yl)(methyl)amino)heptyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-((adamantan-1-yl)(methyl)amino)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)heptylamide; 3-(4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; 1-(4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; 3-((4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino 1-(2-amino-4-nitropropene)heptylamide; 3-(1-methyl-7-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; 3-(3-methyl-2-oxo-4-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; 3-(3-methyl-4-((methyl(6-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)hexyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-6-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)hexanamide; 3-(5-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; 3-(5-(8-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-((methyl(6-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)hexyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-6-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)hexanamide; 3-(2-oxo-6-((7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)heptyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-7-(((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)heptylamide; 3-(4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; 1-(4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; 3-((4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; 3-(1-methyl-7-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; 3-(3-methyl-2-oxo-4-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; 3-(3-methyl-4-((methyl(4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)phenyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide; 3-(6-((methyl(4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)phenyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(2-oxo-6-((4-((((1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl)amino)methyl)benzyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-((((1R,2S,4R)-1,7,7-trimethylol (4-(2-( ...4-(2-(4-(4-(2-(4-(4-(2-bicyclo[2.2.1]heptane-2-yl)amino)methyl)benzamide); 3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)phenyl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)benzamide; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)benzamide; 1-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)benzamide; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)benzamide; 3-((4-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)benzamide; 4-(((adamantan-1-yl)amino)methyl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)benzamide; 3-(7-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)benzamide; 3-(4-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)benzamide; 3-(4-(((4-(((adamantan-1-yl)amino)methyl)phenyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)benzamide; 3-(6-(((4-(((adamantan-1-yl)amino)methyl)phenyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(6-((4-(((adamantan-1-yl)amino)methyl)benzyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzamide; 3-(4-((7-(spiro[3.3]heptan-2-ylamino)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-(Spiro[3.3]heptan-2-ylamino)heptyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; 1-(4-((7-(Spiro[3.3]heptan-2-ylamino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-(Spiro[3.3]heptan-2-ylamino)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-(spiro[3.3]heptane-2-ylamino)heptylamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-(spiro[3.3]heptane-2-ylamino)heptylamide; 3-((4-((7-(spiro[3.3]heptan-2-ylamino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-(Spiro[3.3]heptan-2-ylamino)heptyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; 3-(1-methyl-7-((7-(spiro[3.3]heptan-2-ylamino)heptyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; 3-(3-methyl-2-oxo-4-((7-(spiro[3.3]heptane-2-ylamino)heptyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-7-(spiro[3.3]heptane-2-ylamino)heptylamide; 3-(3-methyl-4-((methyl(6-(spiro[3.3]heptan-2-ylamino)hexyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-6-(spiro[3.3]heptan-2-ylamino)hexanamide; 3-(5-((7-(spiro[3.3]heptane-2-ylamino)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; 3-(5-(8-(spiro[3.3]heptane-2-ylamino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-((methyl(6-(spiro[3.3]heptane-2-ylamino)hexyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidin-2,6- 二酮； N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenz[cd]indol-6-yl)methyl)-6-(spiro[3.3]heptan-2-ylamino)hexanamide; 3-(2-oxo-6-((7-(spiro[3.3]heptan-2-ylamino)heptyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-7-(spiro[3.3]heptan-2-ylamino)heptylamide; 3-(4-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 1-(4-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 3-((4-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 3-(7-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 3-(4-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 3-(4-(((3-fluoro-4-(piperidin-1-ylmethyl)phenyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 3-(6-(((3-fluoro-4-(piperidin-1-ylmethyl)phenyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(6-((3-fluoro-4-(piperidin-1-ylmethyl)benzyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-fluoro-4-(piperidin-1-ylmethyl)benzamide; 3-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)phenyl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-3-fluorobenzamide; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-3-fluorobenzamide; 1-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-3-fluorobenzamide; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-3-fluorobenzamide; 3-((4-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)phenyl)amino)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-3-fluorobenzamide; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-3-fluorobenzamide; 3-(7-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-3-fluorobenzamide; 3-(4-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d] Imidazol-4-yl)-3-fluorobenzamide; 3-(4-(((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorophenyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-3-fluorobenzamide; 3-(6-(((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorophenyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(6-((4-((4,4-difluoropiperidin-1-yl)methyl)-3-fluorobenzyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 4-((4,4-difluoropiperidin-1-yl)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-fluorobenzamide; 3-(4-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)piperidine-2,6-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)benzamide; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)benzamide; 1-(4-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)benzamide; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)benzamide; 3-((4-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)amino)piperidine-2,6-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)benzamide; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)benzamide; 3-(7-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)benzamide; 3-(4-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)benzamide; 3-(4-(((4-(2-((adamantan-1-yl)amino)ethyl)phenyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)benzamide; 3-(6-(((4-(2-((adamantan-1-yl)amino)ethyl)phenyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(6-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 4-(2-((adamantan-1-yl)amino)ethyl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)benzamide; 3-(4-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((4-(2-((adamantan-1-yl)amino)ethyl)benzyl)amino)phenyl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)thiazole-2-carboxamide; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)thiazole-2-carboxamide; 1-(4-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)thiazole-2-carboxamide; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)thiazole-2-carboxamide; 3-((4-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)phenyl)amino)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)thiazole-2-carboxamide; 4-(((adamantan-1-yl)amino)methyl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)thiazole-2-carboxamide; 3-(7-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)thiazole-2-carboxamide; 3-(4-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)thiazole-2-carboxamide; 3-(4-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 3-(5-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)thiazole-2-carboxamide; 3-(6-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 3-(6-(((4-(((adamantan-1-yl)amino)methyl)thiazol-2-yl)methyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 4-(((adamantan-1-yl)amino)methyl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)thiazole-2-carboxamide; 3-(4-((7-(piperidin-1-yl)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-(piperidin-1-yl)heptyl)amino)phenyl)piperidine-2,6-dione; N-(4-(2,6-dioxopiperidin-3-yl)phenyl)-7-(piperidin-1-yl)heptylamide; N-(3-(2,6-dioxopiperidin-3-yl)phenyl)-7-(piperidin-1-yl)heptylamide; 1-(4-((7-(piperidin-1-yl)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-(piperidin-1-yl)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-(piperidin-1-yl)heptylamide; N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)-7-(piperidin-1-yl)heptylamide; 3-((4-((7-(piperidin-1-yl)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-(piperidin-1-yl)heptyl)amino)phenyl)amino)piperidine-2,6-dione; N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-(piperidin-1-yl)heptylamide; N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-7-(piperidin-1-yl)heptylamide; 3-(1-methyl-7-((7-(piperidin-1-yl)heptyl)amino)-1H-indazol-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)-7-(piperidin-1-yl)heptylamide; 3-(3-methyl-2-oxo-4-((7-(piperidin-1-yl)heptyl)amino)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-7-(piperidin-1-yl)heptylamide; 3-(3-methyl-4-((methyl(6-(piperidin-1-yl)hexyl)amino)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-7-(piperidin-1-yl)heptylamide; 3-(5-((7-(piperidin-1-yl)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)-7-(piperidin-1-yl)heptylamide; 3-(5-(8-(piperidin-1-yl)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-((methyl(6-(piperidin-1-yl)hexyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)-6-(piperidin-1-yl)hexanamide; 3-(2-oxo-6-((7-(piperidin-1-yl)heptyl)amino)benzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-7-(piperidin-1-yl)heptylamide; 3-(4-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)phenyl)piperidine-2,6-dione; 3-(3-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)phenyl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(4-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)phenyl)heptylamide; 1-(4-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(3-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)phenyl)dihydropyrimidine-2,4(1H,3H)-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)heptylamide; 3-((4-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 3-((3-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)phenyl)amino)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 7-(4,4-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)heptylamide; 3-(7-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)heptylamide; 3-(4-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)heptylamide; 3-(4-(((6-(4,4-difluoropiperidin-1-yl)hexyl)(methyl)amino)methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione; 6-(4,4-difluoropiperidin-1-yl)-N-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)hexanamide; 3-(5-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)benzofuran-3-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(3-(2,6-dioxopiperidin-3-yl)benzofuran-5-yl)heptylamide; 3-(5-(8-(4,4-difluoropiperidin-1-yl)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(6-(((6-(4,4-difluoropiperidin-1-yl)hexyl)(methyl)amino)methyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 6-(4,4-difluoropiperidin-1-yl)-N-((1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)methyl)hexanamide; 3-(6-((7-(4,4-difluoropiperidin-1-yl)heptyl)amino)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione; 7-(4,4-difluoropiperidin-1-yl)-N-(1-(2,6-dioxopiperidin-3-yl)-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)heptylamide; 3-(5-(3-((adamantan-1-yl)amino)prop-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(5-((adamantan-1-yl)amino)pent-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(7-((adamantan-1-yl)amino)hept-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(7-((adamantan-1-yl)(methyl)amino)hept-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(8-((adamantan-1-yl)amino)oct-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(7-((adamantan-1-yl)amino)heptyl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(7-((3-hydroxyadamantan-1-yl)amino)hept-1-yn-1-yl)benzofuran-3-yl)piperidine-2,6-dione; 3-(5-(7-((3-hydroxyadamantan-1-yl)amino)heptyl)benzofuran-3-yl)piperidine-2,6-dione; 1-(6-(5-((adamantan-1-yl)amino)pent-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(6-(7-((adamantan-1-yl)amino)hept-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(6-(7-((adamantan-1-yl)(methyl)amino)hept-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine- 2,4(1H,3H)-dione; 1-(6-(8-((adamantan-1-yl)amino)oct-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(6-(8-((adamantan-1-yl)amino)octyl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione; and 1-(6-(7-(4-(adamantan-1-yl)piperazin-1-yl)hept-1-yn-1-yl)imidazo[1,2-a]pyridin-3-yl)dihydropyrimidine-2,4(1H,3H)-dione.

12. A compound of formula (I) or a salt thereof, enantiomer, stereoisomer, solvate, polymorph thereof as claimed in any one of claims 1 to 11, which is a hydrohalide salt (including hydrochloride, hydrobromide), sulfate, maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2- dichloroacetate, trimethylacetate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecylenate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthalenecarboxylate, 1-hydroxy-2-naphthalenecarboxylate, 2-naphthalenesulfonate, trifluoroacetate, glycolate or p-toluenesulfonate.

13. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 12, and at least one pharmaceutically acceptable carrier or excipient.

14. The pharmaceutical composition of claim 13, further comprising a second therapeutic agent, such as an anticancer agent.

15. A compound of formula (I) or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 12, for use in preventing or treating a disease or condition selected from the following: tumors or cancer, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

16. The compound of formula (I) according to claim 15, or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic Myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell Lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory Primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; brain glioma; astrocytoblastoma; ovarian cancer; bronchial cancer; prostate cancer; breast cancer, including triple-negative breast cancer, sporadic breast cancer, ductal carcinoma and Cowden's disease patients; pancreatic cancer; central nervous system cancer; neuroblastoma; glioma; Peripheral neuroepithelial tumor; Extramedullary plasmacytoma; Plasmacytoma; Gastric cancer; Gastrointestinal stromal tumor; Esophageal cancer; Colorectal adenocarcinoma; Esophageal squamous cell carcinoma; Liver cancer; Renal cell carcinoma; Bladder cancer; Endometrial cancer; Uterine cancer; Head and neck cancer; Brain cancer; Oral cancer; Sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; Urothelial carcinoma; Basal cell carcinoma; Oral squamous cell carcinoma; Cholangiocarcinoma; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, Including viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

17. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 12 or a pharmaceutical composition as described in claim 13 or 14, for preparing a medicament for preventing or treating a disease or condition selected from the following: tumor or cancer, infectious disease, inflammatory disease, autoimmune disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

18. A method for treating or preventing a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 13 or 14, wherein the disease or condition is selected from the group consisting of: tumor or cancer, infectious disease, inflammatory disease, autoimmune disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

19. The use of claim 17 or the method of claim 18, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; Transplant-related cancers; Neutropenia; Leukemias, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; Lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; glioblastoma; ovarian cancer; bronchial cancer; prostate cancer; breast cancer, including triple-negative breast cancer, sporadic breast cancer, ductal carcinoma and patients with Cowden's disease; pancreatic cancer; central nervous system cancer; neuroblastoma; glioma; Peripheral neuroepithelial tumor; Extramedullary plasmacytoma; Plasmacytoma; Gastric cancer; Gastrointestinal stromal tumor; Esophageal cancer; Colorectal adenocarcinoma; Esophageal squamous cell carcinoma; Liver cancer; Renal cell carcinoma; Bladder cancer; Endometrial cancer; Uterine cancer; Head and neck cancer; Brain cancer; Oral cancer; Sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; Urothelial carcinoma; Basal cell carcinoma; Oral squamous cell carcinoma; Cholangiocarcinoma; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, Including viral pneumonia, AIDS, COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

Images